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ABSTRACT

Humans Serum Albumin (HSA) or an HSA fusion protein is
expressed in plant plastids. A plastid transformation vector is
made which contains an expression cassette that contains
regulatory sequences, the coding region for HSA or an HSA
fusion protein and a selectable marker coding sequence. The
vector is used to transform a plant where the plant expresses
the HSA or HSA fusion protein. HSA is isolated and purified
from the plant. A preferred plant is tobacco.
8 Claims, 20 Drawing Sheets
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EXPRESSION OF HUMAN SERUM ALBUMIN
INPLASTIDS

accumulation of recombinant proteins up to 30% of the total
cellular protein (McBride et al., 1994 ).
The aforementioned approaches (except chloroplast transformation) are limited to eukaryotic gene expression because
prokaryotic genes are expressed poorly in nuclear compartment. However, several pharmacologically important proteins (such as insulin, human serum albumin, antibodies,
enzymes etc.) are currently produced in prokaryotic systems
(such as E. coli.) via fermentation.
Chloroplasts are prokaryotic compartments inside eukaryotic cells. Since the transcriptional and translational machineryofthechloroplastis similartoE. coli. (Brixey eta!., 1997),
it is possible to express prokaryotic genes at very high levels
in plant chloroplasts than in the nucleus. In addition, plant cell
contain up to 50,000 compies of the circular plastid genome
(Bendich 1987) which may amplify the foreign gene like a
"plasmid in the plant cell," thereby enabling higher levels of
expression. Therefore, chloroplasts are an ideal choice for
expression of recombinant proteins that are currently
expressed inE. Coli (such as insulin, human serum albumin,
vaccines, antibodies, etc.). We exploited the chloroplast transformation approach to express a pharmacological protein that
is of no value to the plant to demonstrate this concept,
GVGVP (SEQ ID NO 20) gene has been synthesized with a
codon preferred for prokaryotic (EG121) or eukaryotic
(TG131) expression. Based on transcript levels, chloroplast
expression of this polymer was a hundred-fold higher than
nuclear expression in transgenic plants (Guda et al., 1999)
Recently, we observed 16.966-fold more tps 1 transcripts in
chloroplast transfomants than the highly expressing nuclear
transgenic plants (Lee et al. 200, in review).
Research on human proteins in the past years has revolutionized the use of these therapeutically valuable proteins in a
variety of clinical situations. Since the demand for these
proteins is expected to increase considerably in the coming
years, it would be wise to ensure that in the future they will be
available in significantly larger amounts, preferably on a costeffective basis. Because most genes can be expressed in many
different systems, it is essential to determine which system
offers the most advantages for the manufacture of the recombinant protein. An ideal expression system would be one that
produces a maximum amount of safe, biologically active
material at a minimum cost. The use of modified manimalian
cells with recombinant DNA techniques has the advantage of
resulting in products, which are closely related to those of
natural origin. However, culturing these cells is intricate and
can only be carried out on limited scale.
The use of microorganisms such as bacteria permits manufacture on a larger scale, but introduces the disadvantage of
producing products, which differ appreciably from the products of natural origin. for example, proteins that are usually
glycosylated in humans are not glycosylated by bacteria.
Furthermore, human proteins that are expressed at high levels
in E. coli frequently acquire an unnatural conformation,
accompanied by intracellular precipitation due to lack of
proper folding and disulfide bridges. Production ofrecombinant proteins in plants has many potential advantages for
generating biopharmaceuticals relevant to clinical medicine.
These include the following: (i) plant systems are more economical than industrial facilities using fermentation systems;
(ii) technology is available for harvesting and processing
plant/plant products on a large scale; (iii) elimination of the
purification requirement when the plant tissue containing the
recombinant protein is used as a food (edible vaccines); (iv)
plants can be directed to target proteins into stable, intracellular compartments as chloroplasts, or expressed directly in
chloroplasts; (v) the amount of recombinant product that can

CROSS-REFERENCE TO RELATED
APPLICATIONS
This application is a continuation-in-part U.S. Ser. No.
11/230,299 filed Sep. 19, 2005 now abandoned; which is a
continuation ofU.S. Ser. No. 09/807,742, filedApr. 18, 2001
now abandoned, which claims priority to U.S. Ser. No.
60/185,987, filed Mar. 1, 2000, U.S. Ser. No. 60/263,473,
filed Jan. 23, 2001 and U.S. Ser. No. 60/263,668, filed Jan. 23,
2001. This application is also a continuation-in-part U.S. Ser.
No. 09/079,610 filed May 15, 1998 now U.S. Pat. No. 7,129,
391; which claims priority to U.S. Ser. No. 60/055,314, filed
Aug. 7, 1997 and U.S. Ser. No. 60/079,042, filed Mar. 23,
1998. All of those applications are incorporated herein by
reference in their entirety including any figures, tables, or
drawings.
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BACKGROUND
Research efforts have been made to synthesize high value
pharmacologically active recombinant proteins in plants.
Recombinant proteins such as vaccines, monoclonal antibodies, hormones, growth factors, neuropeptides, cytotoxins,
serum proteins an enzymes have been expressed in nuclear
transgenic plants (May et al., 1996). It has been estimated that
one tobacco plant should be able to produce more recombinant protein than a 300-liter fermenter of E. coli. In addition,
a tobacco plant produces a million seeds, thereby facilitating
large-scale production. Tobacco is also an ideal choice
because of its relative ease of genetic manipulation and an
impending need to explore alternate uses for this hazardous
crop.
A primary reason for the high cost of production via fermentation is the cost of carbon source co-substances as well
as maintenance of a large fermentation facility. In contrast,
most estimates of plant production are a thousand-fold less
expensive than fermentation. Tissue specific expression of
high value proteins in leaves can enable the use of crop plants
as renewable resources. Harvesting the cobs, tubers, seeds or
fruits for food and feed and leaves for value added products
should results in further economy with no additional investment.
However, one of the major limitations in producing pharmaceutical proteins in plants is their low level of foreign
protein expression, despite reports of higher levee expression
of enzymes and certain proteins. May et al. (1998) discuss this
problem using the following examples. Although plant
derived recombinant hepatitis B surface antigen was as effective as a commercial recombinant vaccine, the levels of
expression in transgenic tobacco were low (0.01 % of total
soluble protein). Even though Norwalk virus capsid protein
expressed in potatoes caused oral immunization when consumed as food (edible vaccine), expression levels were low
(0.3% of total soluble protein). A synthetic gene coding for
the human epidermal growth factor was expressed only up to
0.001 % of total soluble protein in transgenic tobacco. Human
serum albumin has been expressed only up to 0.02% of the
total soluble protein in transgenic plants.
Therefore, it is important to increase levels of expression of
recombinant proteins in plants to exploit plant production of
pharmacologically important proteins. An alternate approach
is to express foreign proteins in chloroplasts of higher plant.
Foreign genes (up to 10,000 copies per cell) have been incorporated into the tobacco chloroplast genome resulting in
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be produced approaches industrial-scale levels; and (vi)
health risks due to contamination with potential human
pathogens/toxins are minimized.
It has been estimated that one tobacco plant should be able
to produce more recombinant protein than a 300-liter fermenterofE.coli (Crop Tech, VA). In addition, a tobacco plant
can produce a million seeds, facilitating large-scale production. Tobacco is also an ideal choice because of its relative
ease of genetic manipulation and an impending need to
explore alternate uses for this hazardous crop. However, with
the exception of enzymes (e.g. phytase), levels of foreign
proteins produced in nuclear transgenic plants are generally
low, mostly less than 1% of the total soluble protein (Kusnadi
et al. 1997). (Cholera Toxin Subunit B filing) Protein accumulation levels of recombinant enzymes, like phytase and
xylase were high in nuclear transgenic plants (14% and 4.1 %
of total soluble tobacco leaf protein respectively). This may
be because their enzymatic nature made them more resistant
to proteolytic degradation. May et al. (1996) discuss this
problem using the following examples. Although plant
derived recombinant hepatitis B surface antigen was as effective as a commercial recombinant vaccine, the levels of
expression in transgenic tobacco were low (0.0066% of total
soluble protein). Even though Norwald virus capsid protein
expressed in potatoes caused oral immunization when consumed as food (edible vaccine), expression levels were low
(0.3% of total soluble protein).
In particular, expression of human proteins in nuclear
transgenic plants has been disappointingly low: e.g. human
Interferon-~0.000017% of fresh weight, human serum albumin 0.02% and erythropoietin 0.0026% of total soluble protein (see table 1 in Kusnadi et al. 1997). A synthetic gene
coding for the human epidermal growth factor as expressed
only up to 0.001 % of total soluble protein in transgenic
tobacco (May et al. 1996). The cost of producing recombinant
proteins in alfalfa leaves was estimated to be 12-fold lower
than in potato tubers and comparable with seeds (Kusnadi et
al 1997). However, tobacco leaves are much larger and have
much higher biomass than alfalfa. Planet Biotechnology has
recently estimated that at 50 mg/liter of mammalian cell
culture or transgenic goat's milk or 50 mg/kg of tobacco leaf
expression, the cost of purified IgA will be $10,000, 1000 and
50/g, respectively (Daniell et al. 2000). the cost of production
of recombinant proteins will be 50-fold lower than that of E.
coli fermentation (with 20% of 5% of biomass doubled the
cost of production of E. coli (Petri dis et al. 1995). Expression
level less than 1% of total soluble protein in plants has been
found to be not commercially feasible (Kusnadi et al. 1997).
Therefore, it is important to increase levels of expression of
recombinant proteins in plants to exploit plant production of
pharmacologically important proteins.
An alternate approach is to express foreign proteins in
chloroplasts of higher plants. We have recently integrated
foreign genes (up to 10,000 copies per cell) into the tobacco
chloroplast genome resulting in accumulation of recombinant proteins up to 46% of the total soluble protein (De Casa
et al, 2001 ). Chloroplast transformation utilizes two flanking
sequences that, through homologous recombinant, insert foreign DNA into the spacer region between the functional genes
of the chloroplast genome, thereby targeting the foreign
genes to a precise location. This eliminates the position effect
and gene silencing frequently observed in nuclear transgenic
plants. Chloroplast genetic engineering is an environmentally
friendly approach, minimizing concerns of out-cross of introduced traits via pollen to weeds or other crops (Bock and
Hagemann 200, Heifetz 2000). Also, the concerns of insects
developing resistance to biopesticides are minimized by

hyper-expression of single insecticidal proteins (high dosage)
or expression of different types of insecticides in a single
transformation event (gene pyramiding). Concerns of insecticidal proteins on non-target insects are minimized by lack of
expression in transgenic pollen (De Casa et al. 2001).
Importantly, a significant advantage in the production of
pharmaceutical proteins in chloroplasts is their ability to process eukaryotic proteins, including folding and formation of
disulfide bridges (Drescher et al. 1998). Chaperonin proteins
are present in chloroplasts (Roy, 1989; Veirling, 1991) that
function in folding and assembly of prokaryotic/eukaryotic
proteins. Also, proteins are activated by disulfide bond oxido/
reduction cycles using the chloroplast thioredoxin system
(Reulland and Miginiac-Maslow, 1999) or chloroplast protein disulfide isomersase (Kim and Mayfield, 1997). Accumulation of fully assembled, disulfide bonded form of human
somatotropin via chloroplast transformation (Staub et al.
2000), oligomeric form of CTB (Henriques and Daneill,
2000) and the assembly of heavy/light chains of humanized
Guy's 13 antibody in transgenic chloroplasts (Panchal et al.
2000) provide strong evidence for successful processing of
pharmaceutical proteins inside chloroplasts. Such folding
and assembly should eliminate the need for highly expensive
in vitro processing of pharmaceutical proteins. For example,
60% of the total operating cost in the production of human
insulin is associated with in vitro processing (formation of
disulfide bridges and cleavage of methionine, Petri dis et al.
1995).
Another major cost of insulin production is purification.
Chromatography accounts for 30% of operating expenses and
70% of equipment in production of insulin (Petridis et al.
1995). Therefore, new approaches are needed to minimize or
eliminate chromatography in insulin production. One such
approach is the use ofGVGVP (SEQ ID NO. 20) as a fusion
protein to facilitate single step purification without the use of
chromatography. GVGVP (SEQ ID NO. 20) is a Protein
Based Polymer (PBP) made form synthetic genes. At lower
temperatures this polymer exists as more extended folds into
dynamic structures called .beta.-spirals that further aggregate
by hydrophobic association to form twisted filaments Urry,
1991; Urry et al., 1994 ). Inverse temperature transition offers
several advantages. It facilitates scale up of purification from
grams to kilograms. Milder purification condition requires
only a modest change in temperature and ionic strength. This
should also facilitate higher recovery, faster purification and
high volume processing. Protein purification is generally the
slow step (bottleneck) in pharmaceutical product development. Though exploitation of this reversible inverse temperature transition properly, simple and inexpensive extraction
and purification may be performed. The temperature at which
the aggregation takes place can be manipulated by engineering biopolymers containing varying numbers of repeats and
changing salt concentration in solution (McPherson et al.,
1996). Chloroplast mediated expression of insulin-polymer
fusion protein should eliminate the need for the expensive
fermentation process as well as reagents needed for recombinant protein purification and downstream processing.
Oral delivery of insulin is yet another powerful approach
that can eliminate up to 97% of the production cost of insulin
(Petridis et al., 1995). For example, Sun et al. (1994) have
shown that feeding a small dose of antigens conjugated to the
receptor binding non-toxic B subunit moiety of the cholera
toxin (CTB) suppressed systemic T cell-mediated inflammatory reactions in animals. Oral administration of a myelin
antigen conjugated to CTB has been shown to protect animals
against encephalomyelitis, even when given after disease
induction (Sun et al., 1996). Bergerot et al. (1997) reported
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that feeding small amounts of human insulin conjugated to
CTB suppressed beta cell destruction and clinical diabetes in
adult non-obese diabetic (NOD) mice. The protective effect
could be transferred by T cells from CTB-insulin treated
animals and was associated with reduced insulitis. These
results demonstrate that protection against autoimmune diabetes can indeed be achieved by feeding small amounts of a
pancreas islet cell auto antigen linked to CTB (Bergerot et al.
1997). Conjugation with CTB facilitates antigen delivery and
presentation to the Gut Associated Lymphoid Tissues
(GALT) due to its affinity for the cell surface receptor GM 1 ganglioside located on GALT cells, for increased uptake and
immunologic recognition (Arakawa et al. 1998). Transgenic
potato tubers expressed up to 0.1 % CTB-insulin fusion protein of total soluble protein, which retained GM 1 -ganglioside
binding affinity and native autogenicity for both CTB and
insulin. NOD mice fed with transgenic potato tubers containing micro gram quantities of CTB-insulin fusion protein
showed a substantial reduction in insulitis and a delay in the
progression of diabetes (Arkawa et al., 1998). However, for
commercial exploitation, the levels of expression should be
increased in transgenic plants. Therefore, we propose here
expression of CTB-insulin fusion in transgenic chloroplasts
of nicotine free edible tobacco to increase levels of expression
adequate for animal testing.
Taken together, low levels of expression of human proteins
in E. coli should make chloroplasts an alternate compartment
for expression of these proteins. Production of human proteins in transgenic chloroplasts should also dramatically
lower the production cost. Large-scale production of insulin
in tobacco in conjunction with an oral delivery system can be
a powerful approach to provide treatment to diabetes patients
at an affordable cost and provide tobacco farmers alternate
uses for this hazardous crop. Therefore, it is first advantageous to use poly(GVGVP) (SEQ ID NO. 20) as a fusion
protein to enable hyper-expression of insulin and accomplish
rapid one step purification of the fusion peptide utilizing the
inverse temperature transition properties of this polymer. It is
further advantageous to develop insulin-CTB fusion protein
for oral delivery in nicotine free edible tobacco (LAMD 605).

fused to either enhanced mucosa! immunity or to induce oral
tolerance of the products of these peptides.
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This invention synthesizes high value pharmaceutical proteins in transgenic plants by chloroplast expression for pharmaceutical protein production. Chloroplasts are suitable for
this purpose because of their ability to process eukaryotic
proteins, including folding and formation of disulfide
bridges, thereby eliminating the need of expensive post-purification processing. Tobacco is an ideal choice for this purpose because of its large biomass, ease of scale-up (million
seeds per plant) and genetic manipulation. We use poly
(GVGVP) (SEQ ID No. 20) as a fusion protein to enable
hyper-expression of insulin and accomplish rapid one step
purification of fusion peptides utilizing the inverse temperature transition properties of this polymer. We also use insulinCTB fusion protein in chloroplasts of nicotine free edible
tobacco (LAMD 605) for oral delivery to NOD mice.
(Cholera Toxin Subunit B filing) This invention includes
expression of native cholera toxin B subunit gene as oligomers in transgenic tobacco chloroplasts which may be utilized in connection with large-scale production of purified
CTB, as well as an edible vaccine if expressed in an edible
plant or as a transmucosal carrier of peptides to which it is
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FIG. 1 shows analysis of Biopolymer-Proinsulin Fusion
Protein Expression.
FIG. 2 shows confirmation of chloroplast integration by
PCR of polymer-proinsulin fusion gene.
FIG. 3 shows CTB gene expression in E. Coli and chloroplast integration.
FIG. 4 shows graphs ofCry2A protein concentration determined by ELISA in transgenic leaves.
FIG. 5 is an inmunogold labeled electron microscopy of a
mature transgenic tobacco leaf.
FIG. 6 contains photographs ofleaves infected with 10 µI
of8xl0 5 , 8xl04 , 8xl03 , and 8xl0 2 cells of P. syringae five
days after inoculation.
FIG. 7 is a graph of total plant protein mixed with 5 µI of
mid-log phase bacteria from overnight culture, incubated for
two hours at 25° C. at 125 rpm and grown in LB broth
overnight.
FIG. SA CTB ELISA quantification: Absorbance of CTBantibody complex in known concentrations of total soluble
plant protein was compared to absorbance of known concentration of bacterial CTB-antibody complex and the amount of
CTB was expressed as percentage of the total soluble plant
protein. Total soluble plant protein from young, mature and
old leaves of transgenic lines 3 and 7 was quantified.
FIG. SB CTBGM 1 Ganglioside binding ELISA assays:
Plates coated first with GM 1 gangliosides and BSA respectively, were plated with total soluble plant protein from lines
3 and 7, untransformed plant total soluble protein and purified
bacterial CTB and the absorbance of the GM 1 gangliosideCTB-antibody complex in each case was measured is a graph
of CTB ELISA quantification shown as a percentage of total
soluble plant protein is a graph of CTB-GMl Ganglioside
binding ELISA assays.
FIG. 9 is a 12% reducing PAGE using Chemiluminescent
detection of CTB oligomer with rabbit anti-cholera serum
(1°) and AP labeled mouse anti-rabbit IgG (2°) antibodies.
FIGS. 10 A and B show reducing gels of expression and
assembly of disulfide bonded Guy's 13 monoclonal antibody.
FIG. 10 C shows a non-reducing gel of expression and
assembly of disulfide bonded Guy's 13 monoclonal antibody.
FIGS. 11 A-F show photographs comparing betaine aldehyde and spectinomycin selection.
FIGS. 12 A and B show biopolymer-proinsulin fusion protein expression in E. Coli.
FIG. 13 A shows western blots of biopolymer-proinsulin
fusion protein after single step purification in E. Coli.
FIG. 13 B shows western blots of another biopolymerproinsulin fusion protein after single step purification in E.
Coli.
FIG. 13 C shows western blots of yet another biopolymerproinsulin fusion protein after single step purification in
transgenic chloroplasts.
FIG. 14 shows biopolymer-proinsulin fusion gene integration into the chloroplast genome confirmed by Southern blot
analysis.
FIG. 15 A-Care a Western Blot Analysis of heavy and light
chains of Guy's 13 monoclonal antibody from plant chloroplasts.
FIG. 16 is a Western Blot of transgenic potato tubers, cv
Desiree expressing HSA.
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FIG. 17 is a frequency histogram including percentage
Kennebec and Desiree transgenic plants expressing different
HAS levels.
FIG. 18 is a Western Blot of HAS Expression in E. coli.
FIG. 19 shows the Western Blot of tobacco protein extracts
showing expression of HSA via the chloroplast genome.
FIG. 20 shows the PCR analysis oftransformants to determine integration of HSA gene into the chloroplast genome.
FIG. 21 pLD-LH-CTB vector and PCR analysis of control
and chloroplast transformants. A. The perpendicular dotted
line shows the vector sequences that are homologous to native
chloroplast DNA, resulting in homologous recombination
and site specific integration of the gene cassette into the
chloroplast genome. Primer landing sites are also shown. B.
PCR analysis: 0.8% agarose gel of PCR products using total
plant DNA as template. 1 kb ladder (lane 1); Untransformed
plant (lane 2); PCR products with DNA template from transgenic lines 1-10 (lanes 3-12).
FIG. 22 Southern blot analysis of T 0 and T 1 plants. A.
Untransformed and transformed chloroplast genome: Transformed and untransformed plant DNA was digested with
BglII and hybridized with 0.81 kb probe that contained the
chloroplast flanking sequences used for homologous recombination. Southern Blot results of To lines (B) Untransformed
plant DNA (lane 1); Transformed lines DNA (lanes 2-4) and
T 1 lines (C) Transformed plant DNA (lanes 1-4) and Untransformed plant DNA (lane 5).
FIG. 23 Western blot analysis ofCTB expression inE. coli
and chloroplasts. Blots were detected using rabbit anti-cholera serum as primary antibody and alkaline phosphates
labeled mouse anti-rabbit IgG as secondary antibody. A. E.
coli protein analysis: Purified bacterial CTB, boiled (lane 1);
Unboiled 24 hand 48 h transformed (lanes 2 &4) and untransformed (lanes 3 &5)E. coli ell extracts. Plant protein analysis:
B. Color Development detection: Boiled, untransformed protein (lane 1); Boiled, purified CTB antigen (lane 2): Boiled,
protein from 4 different transgenic lines (lanes 3-6). C.
Chemiluminescent detection: Plant protein-Untransformed,
unboiled (lane 1); Untransformed, boiled (lane 2); Transgenic
lines 3 & 7, boiled (lanes 3 & 5), Transgenic line 3, unboiled
(lane 4 ); Purified CTB antigen boiled (lane 6), unboiled (lane
7); Marker (lane 8).
FIG. 24 Plant phenotypes; 1: Confirmed transgenic line 7;
2: Untransformed plant B. 10-day-old seedlings of T 1 transformed (1, 2 & 3) and untransformed plant (4) plated on 500
mg/L spectinomycin selection medium.
FIG. 25 shows the cloning of the psbA 5' untranslated
region (5'UTR) from the chloroplast genome.
FIG. 26 shows the SOEing of the 5'UTR to the CTB-human
proinsulin sequence.
FIG. 27 shows a comparison of the DNA sequences of
native human proinsulin and plastid modified proinsulin.
FIG. 28 shows recursive PCR to synthesize the chloroplast
modified proinsulin (Ptpris).
FIG. 29 shows SOEing of the 5'UTR, CTB and plastid
modified proinsulin, which results in the fusion of all three
sequences denoted as 5CPTP.
FIG. 30 shows the PCR products to confirm construct
integration into the chloroplast genome using two primers, 3P
and 3M.
FIG. 31 shows Southern Blot of HSA chloroplast transgenic plants. Untransformed tobacco DNA vs. transgenic
tobacco DNA digested with EcoRI.
FIG. 32 shows Northern Blot of HSA chloroplast transgenic plants using HSA probe (1.8 kb).
FIG. 33 shows ELISA ofHSA transgenic plants.

FIG. 34A shows IGF-I native sequence coding for the
mature protein
FIG. 34B shows IGF-I optimized sequence according to
chloroplast preferred codon usage.
FIG. 34C shows IGF-I synthetic gene after recursive PCR
FIG. 35 shows a map of the tobacco chloroplast genome.
The thick lines in the genome map represent the inverted
repeat regions of the chloroplast genome. The arrows labeled
"W" represent the insertion sequences for the preferred
embodiment of the universal integration and expression vector (UV); the arrow labelled "TV" represents the insertion
sequence for the tobacco vector (TV).
FIG. 36 shows the universal chloroplast expression and
integration vector (UV), pSBL-RD-EPSPS for expression of
herbicide resistance.
FIGS. 37A-C show construction of the vector pSBL-Ct
border.
FIG. 38 shows transformed and untransformed tobacco
plants growing in the presence of spectinomycin indicating
non-lethal selection on the medium (500yg/ml). Note growth
of transformed (bleached) and untransformed leaves (green).
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A remarkable feature of chloroplast genetic engineering is
the observation of exceptionally large accumulation of foreign proteins in transgenic plants. This can be as much as 46%
of CRY protein in total soluble protein, even in bleached old
leaves (DeCosa et al. 2001 ). Stable expression of a pharmaceutical protein in chloroplasts was first reported for GVGVP
(SEQ ID NO. 20), a protein based polymer with varied medical applications (such as the prevention of post-surgical adhesions and scars, wound coverings, artificial pericardia, tissue
reconstruction and programmed drug delivery) (Guda et al.
2000). Subsequently, expression of the human somatotropin
via the tobacco chloroplast genome (Staub et al. 2000) to high
levels (7% of total soluble protein) was observed. The following investigations that are in progress illustrate the power of
this technology to express small peptides, entire operons,
vaccines that require oligomeric proteins with stable disulfide
bridges and monoclonals that require assembly of heavy/light
chains via chaperoning. It is essential to develop a selection
system free of antibiotic resistant genes for the edible insulin
approach to be successful. One such marker free chloroplast
transformation system has been accomplished (Daniell et al.
2000). Experiments are in progress to develop chloroplast
transformation of edible leaves (alfalfa and lettuce) for the
practical applications of this approach.
In our research, we use insulin as a model protein to demonstrate its production as a value added trait in transgenic
tobacco. Most importantly, a significant advantage in the
production of pharmaceutical proteins in chloroplasts is their
ability to process eukaryotic protein, including folding and
formation of disulfide bridges (Dreshcher et al., 1998). Chaperonin proteins are present in chloroplasts (Verling 1991; Roy
1989) that function in folding and assembly of prokaryotic/
eukaryotic proteins. Also, proteins are activated by disulfide
bond oxido/reduction cycles using the chloroplast inicredoxin system (Reulland and Mirginiac-Maslow, 1999) or
chloroplast protein disulfide isomerase (Kim and Mayfield,
1997). Accumulation of fully assembled, disulfide bonded
form of antibody inside chloroplasts, even though plastics
were not transformed (During et al. 1990), provides strong
evidence for(Panchal eta!. 2000, in review). Such folding and
assembly eliminates the need for post-purification processing
of pharmaceutical proteins. Chloroplasts may also be isolated
from crude homogenates by centrifugation (1500xg). This
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fraction is free of other cellular proteins. Isolated chloroplasts
are burst open by osmotic shock to release foreign proteins
that are compartmentalized in this organelle along with few
other native soluble proteins (Daniel and McFadden, 1987).
GVGVP (SEQ ID NO. 20) is a PBP made from synthetic
genes. At lower temperatures the polymers exist as more
extended molecules which, on raising the temperature above
the transition range, hydrophobically fold into dynamic structures called .beta.-spirals that further aggregate by hydrophobic association to form twisted filaments (Urry, 1991; Urry, et
al., 1994). Inverse temperature transition offers several
advantages. Expense associated with chromatographic resins
and equipment are eliminated. It also facilitates scale up of
purification from grams to kilograms. Milder purification
conditions use only a modest change in temperature and ionic
strength. This also facilitates higher recovery, faster purification and high volume processing. Protein purification is generally the slow step (bottleneck) in pharmaceutical product
development. Though exploitation of this reversible inverse
temperature transition property, simple and inexpensive
extraction and purification is performed. The temperature at
which the aggregation takes place can be manipulated by
engineering biopolymers containing varying numbers of
repeats and changing salt concentration in solution (McPherson et al., 1996). Chloroplast mediated expression of insulinpolymer fusion protein eliminates the need for the expensive
fermentation process as well as reagents needed for recombinant protein purification and downstream processing.
Large-scale production of insulin in plants in conjunction
with an oral delivery system is a powerful approach to provide
insulin to diabetes patients at an affordable cost and provide
tobacco farmers alternate uses for this hazardous crop. For
example, Sun et al. (1994) showed that feeding a small dose
of antigens conjugated to the receptor binding non-toxic B
subunit moiety of the cholera toxin (CTB) suppressed systemic T cell-mediated inflammatory reactions in animals.
Oral administration of a myelin antigen conjugated to CTB
has been shown to protect animals against encephalomyelitis,
even when given after disease induction (Sun et al. 1996).
Bergerot et al. (1997) reported that feeding small amounts of
human insulin conjugated to CTB suppressed beta cell
destruction and clinical diabetes in adult non-obese diabetic
(NOD) mice. The protective effect could be transferred by T
cells from CTB-insulin treated animals and was associated
with reduced insulitis. These results demonstrate that protection against autoimmune diabetes can indeed be achieved by
feeding small amounts of pancreas islet cell auto antigen
linked to CTB (Bergerot, et al. 1997). Conjugation with CTB
facilitates antigen delivery and presentation to the Gut Associated Lymphoid Tissues (GALT) due to its affinity for the
cell surface receptor GM-ganglioside located on GALT cells,
for increased uptake and immunologic recognition (Arakawa
et al. 1998). Transgenic potato tubers expressed up to 0.1%
CTB-insulin fusion protein of total soluble protein, which
retained GM-ganglioside binding affinity and native autogenicty for both CTB and insulin. NOD mice fed with transgenic potato tubers containing microgram quantities ofCTBinsulin fusion protein showed a substantial reduction in
insulitis and a delay in the progression of diabetes (Arkawa et
al., 1998). However, for commercial exploitation, the levels
of expression need to be increased in transgenic plants. Therefore, we undertook the expression of CTB-insulin fusion in
transgenic chloroplasts of nicotine free edible tobacco to
increase levels of expression adequate for animal testing.
In accordance with one advantageous feature of this invention, we use poly(GVGVP) (SEQ ID NO. 20) as a fusion
protein to enable hyper-expression of insulin and accomplish

rapid one step purification of fusion peptides utilizing the
inverse temperature transition properties of this polymer. In
another advantageous feature of this invention, we develop
insulin-CTB fusion protein for oral delivery in nicotine free
edible tobacco (LAMD 605). Both features are accomplished
as follows: a) Develop recombinant DNA vectors for
enhanced expression of Proinsulin as fusion proteins with
GVGVP (SEQ ID NO. 20 or CTB via chloroplast genomes of
tobacco, b) Obtain transgenic tobacco (Petit Havana &
LAMD 605) plants, c) Characterize transgenic expression of
proinsulin polymer or CTB fusion proteins using molecular
and biochemical methods in chloroplasts, d) Employ existing
or modified methods of polymer purification from transgenic
leaves, e) Analyze Mendelian or maternal inheritance of
transgenic plants, f) Larch scale purification of insulin and
comparison of current insulin purification methods with polymer-based purification method in E. coli and tobacco, g)
Compare natural refolding chloroplasts with in vitro processing, h) Characterization (yield and purity) of proinsulin produced inE. coli and transgenic tobacco, and i) Assessment of
diabetic symptoms in mice fed with edible tobacco expressing CTB-insulin fusion protein.
Diabetes and Insulin: Insulin lowers blood glucose (Oakly
et al. 1973). This is a result of its immediate effect in increasing glucose uptake in tissues. In muscle, under the action of
insulin, glucose is more readily taken up and either converted
to glycogen and lactic acid or oxidized to carbon dioxide.
Insulin also affects a number of important enzymes concerned with cellular metabolism. It increases the activity of
glucokinase, which phosphoryiates glucose, thereby increasing the rate of glucose metabolism in the liver. Insulin also
suppresses gluconeogenesis by depressing the function of
liver enzymes, which operate the reverse pathway from proteins to glucose. Lack of insulin can restrict the transport of
glucose into muscle and adipose tissue. This results in
increases in blood glucose levels (hyperglycemia). In addition, the breakdown of natural fat to free fatty acids and
glycerol is increased and there is a rise in the fatty acid content
in the blood. Increased catabolism of fatty acids by the liver
results in greater production of ketone bodies. They diffuse
from the liver and pass to the muscles for further oxidation.
Soon, ketone body production rate exceeds oxidation rate and
ketosis results. Fewer amino acids are taken up by the tissues
and protein degradation results. At the same time, gluconeogenesis is stimulated and protein is used to produce glucose.
Obviously, lack of insulin has serious consequences.
Diabetes is classified into types I and II. Type I is also
known as insulin dependent diabetes mellitus (IDDM). Usually this is caused by a cell-mediated autoimmune destruction
of the pancreatic ~-cells (Davidson, 1998). Those suffering
from this type are dependent on external sources of insulin.
Type II is known as noninsulin-dependent diabetes mellitus
(NIDDM). This usually involved resistance to insulin in combination with its underproduction. These prominent diseases
have led to extensive research into microbial production of
recombinant human insulin (rHI).
Expression of Recombinant Human Insulin in E. coli: In
1978, two thousand kilograms of insulin were used in the
world each year; half of this was used in the United States
(Steiner et al., 1978). At that time, the number of diabetics in
the US were increasing 6% every year (Gunby, 1978). In
1997-98, 10% increase in sales of diabetes care products and
19% increase in insulin products have been reported by Novo
Nordisk (world's leading supplier of insulin), making it a 7 .8
billion dollar industry. Annually, 160,000 Americans are
killed by diabetes, making it the fourth leading cause of death.
Many methods of production of rHI have been developed.
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Insulin genes were first chemically synthesized for expression in Escherichia coli (Crea et al., 1978). These genes
encoded separate insulin A and B chains. The genes were each
expressed in E. coli as fusion proteins with the ~-galactosi
dase (Goedde! et al., 1979). The first documented production
of rHI using this system was reported by David Goedde! from
Genentech (Hall, 1988). For reasons explained later, the
genes were fused to the Trp synthase gene. This fusion protein
was approved for commercial production by Eli Lilly in 1982
(Chance and Frank, 1993) with a product name ofHumulin.
As of 1986, Humulin was produced from proinsulin genes.
Proinsulin contains both insulin chains and the C-peptide that
connects them. Data concerning commercial production of
Humulin and other insulin products is now considered proprietary information and is not available to the public.
Delivery of Human Insulin: Insulin has been delivered
intravenously in the past several years. However, more
recently, alternate methods such as nasal spray are also available. Oral delivery of insulin is yet another new approach
(Mathiowitz et al., 1997). Engineered polymer microspheres
made of biologically erodable polymers, which display
strong interactions with gastrointestinal mucus and cellular
linings, can traverse both mucosa! absorptive epithelium and
the follicle-associated epithelium, covering the lymphoid tissue of Peyer' s patches. Polymers maintain contact with intestinal epithelium for extended periods of time and actually
penetrate through and between cells. Animals fed with the
poly(FA:PLGA)-encapsulated insulin preparation were able
to regulate the glucose load better than controls, confirming
that insulin crossed the intestinal barrier and was released
from the microspheres in a biologically active form (Mathiowitz et al, 1997).
Protein Based Polymers (PBP): The synthetic gene that
codes for a bioelastic PBP was designed after repeated amino
acid sequences GVGVP, observed in all sequenced mammalian elastin proteins (Yeh et al. 1987). Elastin is one of the
strongest known natural fibers and is present in skin, ligaments, and arterial walls. Bioelastic PBPs containing multiple repeats of this pentamer have remarkable elastic properties, enabling several medical and non-medical applications
(Urry et al. 1993, Urry 1995, Daniell 1995). GVGVP (SEQ
ID NO. 20) polymers prevent adhesions following surgery,
aid in reconstructing tissues and delivering drugs to the body
over an extended period of time. North American Science
Associates, Inc. reported that GVGVP (SEQ ID NO. 20)
polymer is non-toxic in mice, non-sensitizing and non-antigenic in guinea pigs, andnon-pyrogenic in rabbits (Urry et al.
1993 ). Researchers have also observed that inserting sheets of
GVGVP (SEQ ID NO. 20) at the sites of contaminated
wounds in rats reduces the number of adhesions that form as
the wounds heal (Urry et al. 1993). In a similar manner, using
the GVGVP (SEQ ID NO. 20) to encase muscles that are cut
during eye surgery in rabbits prevents scarring following the
operation (Urry et al. 1993, Urry 1995). Other medical applications ofbioelastic PBPs include tissue reconstruction (synthetic ligaments and arteries, bones), wound coverings, artificial pericardia, catheters and programmed drug delivery
(Urry, 1995; Urry et al., 1993, 1996).
We have expressed the elastic PBP (GVGVP) 121 (SEQ ID
NO. 21) inE. coli (Guda et al. 1995, Brixey et al. 1997), in the
fungus Aspergillus nidulans (Herzog et al. 1997), in cultured
tobacco cells (Zhang et al. 1995), and in transgenic tobacco
plants (Zhang et al. 1996). In particular, (GVGVP) 121 (SEQ
ID NO. 21) has been expressed to such high levels in E. coli
that polymer inclusion bodies occupied up to about 90% of
the cell volume. Also, inclusion bodies have been observed in
chloroplasts of transgenic tobacco plants (see attached

article, Daniell and Guda, 1997). Recently, we reported stable
transformation of the tobacco chloroplasts by integration and
expression the biopolymer gene (EG121), into the Large
Single Copy region (5,000 copies per cell) or the Inverted
Repeat region (10,000 copies per cell) of the chloroplast
genome (Guda et al., 1999).
PBP as Fusion Proteins: Several systems are now available
to simplify protein purification including the maltose binding
protein (Marina et al. 1988), glutethione S-transferase (Smith
and Johnson 1988), biotinylated (Tsao et al. 1996), thioredoxin (Smith et al. 1998) and cellulose binding (Ong et al.
1989) proteins. Recombinant DNA vectors for fusion with
short peptides are now available to effectively utilize aforementioned fusion proteins in the purification process (Smith
et al. 1998; Kim and Raines, 1993; Su et al. 1992). Recombinant proteins are generally purified by affinity chromatography, using ligands specific to carrier proteins (Nilsson et al.
1997). While these are useful techniques for laboratory scale
purification, affinity chromatography for large-scale purification is time consuming and cost prohibitive. Therefore, economical and non-chromatographic techniques are highly
desirable. In addition, a common solution to N-terminal degradation of small peptides is to fuse foreign peptides to endogenous E.coli proteins. Early in the development of this technique, ~-galactosidase (~-gal) was used as a fusion protein
(Goldberg and Goff, 1986). A drawback of this method was
that the ~-gal protein is of relatively high molecular weight
(MW 100,000). Therefore, theproportionofthepeptideproduct in the total protein is low. Another problem associated
with the large (~-gal fusion is early termination of translation
(Burnett, 1983; Hall, 1988). This occurred when (~-gal was
used to produce human insulin peptides because the fusion
was detached from the ribosome during translation thus
yielding incomplete peptides. Other proteins of lower
molecular weight proteins have been used as fusion proteins
to increase the peptide production. For example, better yields
were obtained with the tryptophan synthase (190aa) fusion
proteins (Hall, 1988; Burnett, 1983).
Accordingly, one achievement according to this invention
is to use poly(GVGVP) (SEQ. ID NO. 20 as a fusion protein
to enable hyper-expression of insulin and accomplish rapid
one step purification of the fusion peptide. At lower temperature the polymers exist as more extended molecules which, on
raising the temperature above the transition range, hydrophobically fold into dynamic structures called (~-spirals that
further aggregate by hydrophobic association to form twisted
filaments (Urry, 1991 ). Through exploitation of this reversible property, simple and inexpensive extraction and purification is performed. The temperature at which aggregation
takes place (T 1 ) is manipulated by engineering biopolymers
containing varying numbers ofrepeats or changing salt concentration (McPherson et al., 1996). Another group has
recently demonstrated purification of recombinant proteins
by fusion with thermally responsive polypeptides (Meyer and
Chilkoti, 1999). Polymers of different sizes have been synthesized and expressed in E. coli. This approach also eliminates the need for expensive reagents, equipment and time
required for purification.
Cholera Toxin ~ subunit as a fusion protein: Vibrio cholerae causes diarrhea by colonizing the small intestine and
producing enterotoxins, of which the cholera toxin (CT) is
considered the main cause of toxicity. CT is a hexameric AB 5
protein having one 27 Kda A subunit which has toxic ADPribosyl transferase activity and a non-toxic pentamer of 11.6
kDa B subunits that are non-covalently linked into a very
stable doughnut like structure into which the toxic active (A)
subunit is inserted. The A subunit of CT consists of two
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fragments -Al andA2 which are linked by a disulfide bond.
The enzymatic activity of CT is located solely on the Al
fragment (Gill, 1976). TheA2 fragment of the A subunit links
Al fragment and the B pentamer. CT binds via specific interactions of the B subunit pentamer with GMl ganglioside, the
membrane receptor, present on the intestinal epithelial cell
surface of the host. TheA subunit is then translocated into the
cell where it ADP-ribosylates the Gs subunit of adenylate
cyclase bringing about the increased levels of cyclic AMP in
affected cells that is associated with the electrolyte and fluid
loss of clinical cholera (Lebens et al. 1994). For optimal
enzymatic activity, the Al fragment needs to be separated
from the A2 fragment by proteolytic cleavage of the main
chain and by reduction of the disulfide bond linking them
(Mekalanos et al., 1979).
The Expression and assembly of CTB in transgenic potato
tubers has been reported (Arakawa et al. 1997). The CTB
gene including the leader peptide was fused to an endoplasmic reticulum retention signal (SEKDEL) (SEQ ID NO. 2) at
the 3' end to sequester the CTB protein within the lumen of the
ER. The DNA fragment encoding the 21-amino acid leader
peptide of the CTB protein was retained to direct the newly
synthesized CTB protein into the lumen of the ER. Immunoblot analysis indicated that the plant derived CTB protein was
antigenically indistinguishable from the bacterial CTB protein and that oligomeric CTB molecules (Mr-50 kDa) were
the dominant molecular species isolated from transgenic
potato leaf and tuber tissues. Similar to bacterial CTB, plant
derived CTB dissociated into monomers (Mr-45 kDa) during
heat acid treatment.
Enzyme linked immunosorbent assay methods indicated
that plant synthesized CTB protein bound specifically to
GMl gangliosides, the natural membrane receptors of Cholera Toxin. The maximum amount of CTB protein detected in
auxin induced transgenic potato leaf and tuber issues was
approximately 0.3% of the total soluble protein. The oral
immunization of CD-1 mice with transgenic potato tissues
transformed with the CTB gene (administered at weekly
intervals for a month with a final booster feeding on day 65)
has also been reported. The levels of serum and mucosa!
anti-cholera toxin antibodies in mice were found to generate
protective immunity against the cytopathic effects of CT
holotoxin.
Following intraileal injection with CT, the plant immunized mice showed up to a 60% reduction in diarrheal fluid
accumulation in the small intestine. Systemic and mucosa!
CTB-specific antibody titers were determined in both serum
and feces collected from immunized mice by the class-specific chemiluminescent ELISA method and the endpoint
titers for the three antibody isotypes (IgM, IgG and IgA) were
determined.
The extent of CT neutralization in both Vero cell and ilea!
loop experiments suggested that anti-CTB antibodies prevent
CT binding to cellular GMl-gangliosides. Also, mice fed
with 3 g of transgenic potato exhibited similar intestinal protection as mice gavaged with 30 g of bacterial CTB. Recombinant LTB [rLTB] (the heat labile enterotoxin produced by
Enterotoxigenic E. coli) which is structurally, functionally
and immunologically similar to CTB was expressed in transgenic tobacco (Arntzen et al. 1998; Haq et al., 1995). They
have reported that the rLTB retained its antigenicity as shown
by immunoprecipitation of rLTB with antibodies raised to
rLTB from E. coli. The rLTB protein was of the right molecular weight and aggregated to form the pentamer as confirmed
by gel permeation chromatography.
CTB has also been demonstrated to be an effective carrier
molecule for induction of mucosa! immunity to polypeptides

to which it is chemically or genetically conjugated (McKenzie et al, 1984; Dertzbaugh et al, 1993). The production of
immunomodulatory transmucosal carrier molecules, such as
CTB, in plants may greatly improve the efficacy of edible
plant vaccines (Haq et al, 1995; Thanavala et al, 1995; Mason
et al, 1996) and may also provide novel oral tolerance agents
for prevention of such autoimmune diseases as Type 1 diabetes (Zhang et al, 1991 ), Rheumatoid arthritis (Trentham et al,
1993), multiple sclerosis (Khoury et al, 1990; Miller et al,
1992; Weiner et al, 1993) as well as the prevention of allergic
and allograft rejection reactions (Savegh et al, 1992; Hancock
et al, 1993 ).
CTB, when administered orally (Lebens and Holmgren,
1994 ), is a potent mucosa! immunogen, which can neutralize
the toxicity of the CT holotoxin by preventing it from binding
to the intestinal cells (Mor et al. 1998). This is believed to be
a result of binding to eukaryotic cell surfaces via the GMI
gangliosides, receptors present on the intestinal epithelial
surface, thus eliciting a mucosa! immune response to pathogens (Lipscombe et al. 1991) and enhancing the immune
response when chemically coupled to other antigens
(Dertzbaugh and Elson, 1993; Holmgren et al. 1993; Nashar
et al. 1993; Sun et al. 1994).
Therefore, expressing a CTB-proinsulin fusion is an ideal
approach for oral delivery of insulin.
Chloroplast Genetic Engineering: Several enviromnental
problems related to plant genetic engineering now prohibit
advancement of this technology and prevent realization of its
full potential. One such common concern is the demonstrated
escape of foreign genes through pollen dispersal from transgenic crop plants to their weedy relatives creating super
weeds or causing gene pollution among other crops or toxicity of transgenic pollen to non-target insects such as butterflies. The high rates of gene flow from crops to wild relatives
(as high as 38% in sunflower and 50% in strawberries) are
certainly a serious concern. Clearly, maternal inheritance
(lack of chloroplast DNA in pollen) of the herbicide resistance gene via chloroplast genetic engineering has been
shown to be a practical solution to these problems (Daniell et
al, 1998). Another common concern is the sub-optimal production of Bacillus thuringiensis (B.t.) insecticidal protein or
reliance on a single (or similar) B.t. protein in commercial
transgenic crops resulting in B.t. resistance among target
pests. Clearly, different insecticidal proteins should be produced in lethal quantities to decrease the development of
resistance. Such hyper-expression of a novel B.t. protein in
chloroplasts has resulted in 100% mortality of insects that are
up to 40,000-fold resistant to other B.t. proteins (Kata et al.
1999). Therefore, chloroplast genome is an attractive target
for expression of foreign genes due to its ability to express
extraordinarily high levels of foreign proteins and efficient
contaimnent of foreign genes through maternal inheritance.
When we developed the concept of chloroplast genetic
engineering (Daniell and McFadden, 1988 U.S. Patents;
Daniell, World Patent, 1999). It was possible to introduce
isolated intact chloroplasts into protoplasts and regenerate
transgenic plants (Carlson, 1973). Therefore, early investigations on chloroplast transformation focused on the development of in organelle systems using intact chloroplasts capable
of efficient and prolonged transcription and translation
(Daniell and Rebeiz, 1982; Daniell et al., 1983, 1986) and
expression of foreign genes in isolated chloroplasts (Daniell
and McFadden, 1987). However, after the discovery of the
gene gun as a transformation device (Daniell, 1993), it was
possible to transform plant chloroplasts without the use of
isolated plastids and protoplasts. Chloroplast genetic engineering was accomplished in several phases. Transient
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expression of foreign genes in plastids of dicots (Daniell et
al., 1990; Ye et al., 1990) was followed by such studies in
monocots (Daniell et al., 1991). Unique to the chloroplast
genetic engineering is the development of a foreign gene
expression system using autonomously replicating chloroplast expression vectors (Daniell et al., 1990). Stable integration of a selectable marker gene into the tobacco chloroplast
genome (Svab and Maliga, 1993) was also accomplished
using the gene gun. However, useful genes conferring valuable traits via chloroplast genetic engineering have been demonstrated only recently. For example, plants resistant to B.t.
sensitive insects were obtained by integrating the cry!Ac gene
into the tobacco chloroplast genome (McBride et al., 1995).
Plants resistant to B.t. resistant insects (up to 40,000 fold)
were obtained by hyper-expression of the cryi!A gene within
the tobacco chloroplast genome (Kata et al., 1999). Plants
have also been genetically engineered via the chloroplast
genome to confer herbicide resistance and the introduced
foreign genes were maternally inherited, overcoming the
problem of cut-cross with weeds (Daniell et al., 1998). Chloroplast genetic engineering has also been used to produce
pharmaceutical products that are not used by plants (Guda et
al., 2000). Chloroplast genetic engineering technology is currently being applied to otheruseful crops (Sidorov et al. 1999;
Daniell. 1999).
Most transformation techniques co-introduce a gene that
confers antibiotic resistance, along with the gene ofinterest to
impart a desired trait. Regenerating transformed cells in antibiotic containing growth media permits selection of only
those cells that have incorporated the foreign genes. Once
transgenic plants are regenerated, antibiotic resistance genes
serve no useful purpose but they continue to produce their
gene products. One among the primary concerns of genetically modified (GM) crops is the presence of clinically important antibiotic resistance gene products in transgenic plants
that could inactivate oral doses of the antibiotic (reviewed by
Puchta 2000; Daniell 1999A). Alternatively, the antibiotic
resistant genes could be transferred to pathogenic microbes in
the gastrointestinal tract or soil rendering them resistant to
treatment with such antibiotics. Antibiotic resistant bacteria
are one of the major challenges of modern medicine. In Germany, GM crops containing antibiotic resistant genes have
been banned from release (Peerenboom 2000).
Chloroplast genetic engineering offers several advantages
over nuclear transformation including high levels of gene
expression and gene containment but utilizes thousands of
copies of the most commonly used antibiotic resistance
genes. Engineering genetically modified (GM) crops without
the use of antibiotic resistance genes should eliminate potential risk of their transfer to the environment or gut microbes.
Therefore, betaine aldehyde dehydrogenase (BADH) gene
from spinach is used herein as a selectable marker (Daniell et
al. 2000). The selection process involves conversion of toxic
betaine aldehyde (BA) by the chloroplast BADH enzyme to
nontoxic glycine betaine, which also serves as an osmoprotectant. Chloroplast transformation efficiency was 25 fold
higher in BA selection than spectinomycin, in addition to
rapid regeneration (Table 1). Transgenic shoots appeared
within 12 days in 80% ofleaf discs (up to 23 shoots per disc)
in BA selection compared to 45 days in 15% of discs (1 or 2
shoots per disc) on spectinomycin selection as show in FIG.
11. Southern blots confirm stable integration of foreign genes
into all of the chloroplast genomes (-10,000 copies per cell)
resulting in homoplasmy. Transgenic tobacco plants showed
1527-1816% higher BADH activity at different developmenta! stages than untransformed controls. Transgenic plants
were morpho-logically indistinguishable from untrans-

formed plants and the introduced trait was stably inherited in
the subsequent generation. This is the first report of genetic
engineering of the chloroplast genome without the use of
antibiotic selection. Use of genes that are naturally present in
spinach for selection, in addition to gene containment, should
ease public concerns or perception of GM crops. Also, this
should be very helpful in the development of edible insulin.
Polymer-proinsulin Recombinant DNA Vectors: First we
developed independent chloroplast vectors for expression of
insulin chains A and B as polymer fusion peptides, as it has
been produced in E. coli for commercial purposes in the past.
The disadvantage of this method is that E. coli does not form
disulfide bridges in the cell unless the protein is targeted to the
periplasm. Expensive in vitro assembly after purification is
necessary for this approach. Therefore, a better approach is to
express the human proinsulin as a polymer fusion protein.
This method is better because chloroplasts are capable of
forming disulfide bridges. Using a single gene, as opposed to
the individual chains, eliminates the necessity of conducting
two parallel vector construction processes, as is needed for
individual chains. In addition, the need for individual fermentations and purification procedures is eliminated by the single
gene method. Further, proinsulin products require less processing following, extraction. Another benefit of using the
proinsulin is that the C-peptide, which is an essential part the
proinsulin protein, has recently been show to play a positive
role in diabetic patients (Ido et al, 1997).
Recently, the human pre-proinsulin gene was obtained
from Genentech, Inc. First, thepre-proinsulin was sub-cloned
into pUCl 9 to facilitate further manipulations. The next step
was to design primers to make chloroplast expression vectors.
Since we are interested in proinsulin expression, the 5' primer
was designed to land on the proinsulin sequence. This FW
primer eluded the 69 bases or 23 coded amino acids of the
leader or pre-sequence of preproinsulin. Also, the forward
primer included the enzymatic cleavage site for the protease
factor Xa to avoid the use of cyanogen bromide. Besides the
Xa-factor, a Smal site was introduced to facilitate subsequent
subcloning. The order of the FW primer sequence is SmalXa-factor-Proinsulin gene. The reverse primer includes
BamHI and Xbal sites, plus a short sequence with homology
with the p UC! 9 sequence following the proinsulin gene. The
297 bp PCR product (Xa Pris) includes three restriction sites,
which are the Smal site at the 5'-end and Xbal/BamHI sites at
the 3' end of the proinsulin gene. The Xa-Pris was cloned into
pCR2.1 resulting in pCR2.l-Xa-Pris (4.2 kb). Insertion of
Xa-Pris into the multiple cloning site of pCR2.1, resulted in
additional flanking restriction enzyme sites that will be used
in subsequent sub-cloning steps. A GVGVP (SEQ ID NO. 20)
50-mer was generated as described previously (Daniell et al.
1997). The ribo some binding sequence was introduced by
digesting pUCs-10, which contains the RBS sequence
GAAGGAG (SEQ ID NO. 23), with Nool and Hind III flanking sites. The plasmid pUC19-50 was also digested with the
same enzymes. The 50 mer gene was eluted from the gel and
ligated to pUCs-10 to produce pUCs-10-50 mer. The ligation
step inserted into the 50 mer gene a RBS sequence and a Smal
site outside the gene to facilitate subsequent fusion to proinsulin.
Another Smal partial digestion was performed to eliminate
the stop codon of the biopolymer, transform the 50 mer to a 40
mer, and fuse the 40 mer to the Xa-proinsulin sequence. The
conditions for this partial digestion needed a decrease inDNA
concentration and the 1: 15 dilution ofSmal. Once the correct
fragment was obtained by the partial digestion ofSmal (eliminating the stop codon but include the RBS site), it was ligated
to the Xa-proinsulin fusion gene resulting in the construct
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pCR2.l-40-XaPris. Finally, the biopolymer (40 mer)-proinsulin fusion gene was subcloned into pSBL-CtV2. and the
final vector was called pSBL-OC-XaPris. The orientation of
the insert was checked with Nool: one the five colonies chosen had the correct orientation of the gene. The fusion gene
was also subcloned into pLD-CtV vector and the orientation
was checked with EooRl and Pvuil. One of the four colonies
had the correct orientation of the insert. This vector was called
pLD-OC-XaPris (FIG. 2A).
Both chloroplast vectors contain the 16S rNA promoter
(Prm) driving the selectable marker gene aadA (aminoglycoside adenyl transferase conferring resistance to spectinomycin) followed by the psbA 3' region (the terminator from a
gene coding for photosystem II reaction center components)
from the tobacco chloroplast genome. The only difference
between these two chloroplast vectors (pSBL and pLD) is the
origin of DNA fragments. Both pSBL and pLD are universal
chloroplast expression/integration vectors and can be used to
transform chloroplast genomes of several other plant species
(Daniell et al. 1998) because these flanking sequences are
highly conserved among higher plants. The universal vector
uses trnA and trnl genes (chloroplast transfer RNAs coding
for Alanine and Isoleucine) from the inverted repeat region of
the tobacco chloroplast genome as flanking sequences for
homologous recombination as shown in FIGS. 2A and 3B.
Because the universal vector integrates foreign genes within
the Inverted Repeat region of the chloroplast genome, it
should double the copy numberofinsulin genes (from 5000 to
10,000 copies per cell in tobacco). Furthermore, it has been
demonstrated that homoplasmy is achieved even in the first
round of selection in tobacco probably because of the presence of a chloroplast origin of replication within the flanking
sequence in the universal vector (thereby providing more
templates for integration). Because of these and several other
reasons, foreign gene expression was shown to be much
higher when the universal vector was used instead of the
tobacco specific vector (Guda et al., 2000).
DNA sequence of the polymer-proinsulin fusion was determined to confirm the correct orientation of genes, in frame
fusion and lack of stop codons in the recombinant DNA
constructs. DNA sequencing was performed using a Perkin
Elmer AB! prism 373 DNA sequencing system using a ABI
Prism Dye Termination Cycle Sequencing Kit. The kit uses
AmpliTaq DNA polymerase. Insertion sites at both ends were
sequenced using primers for each strand. Expression of all
chloroplast vectors was first tested in E. coli before their use
in tobacco transformation because of the similarity of protein
synthetic machinery (Brisey et al. 1997). For Escherichia coli
expression XL-1 Blue strain was used. E. coli was transformed by standard CaC1 2 transformation procedures.
Expression and Purification of the Biopolymer-proinsulin
fusion protein: Terrific broth growth medium was inoculated
with 40 µl of Ampicillin (100 mg/ml) and 40 µl of the XL-1
Blue MRF To strain of E. coli containing pSBL-OC-XaPris
plasmid. Similar inoculations were made for pLD-OCXaPris and the negative controls, which included both plasmids containing the gene in the reverse orientation and the E.
coli strain without any plasmid. Then, 24 hr cultures were
centrifuged at 13,000 rpm for 3 min. The pellets were resuspended in 500 µl of autoclaved dH 2 0 and transferred to 6 ml
Falcon tubes. The resuspended pellet was sonicated, using a
High Intensity Ultrasonic processor, for 15 sec at an amplitude of 40 and then 15 sec on ice to extract the fusion protein
from cells. This sonication cycle was repeated 15 times. The
sonicated samples were transferred to microcentrifuge tubes
and centrifuged at 4° C. at 10,000 g for 10 min to purify the
fusion protein. After centrifugation, the supernatant were

transferred to microcentrifudge tubes and an equal volume of
2xTN buffer (100 mM Tris HCI, pH 8, 100 mM NaCl) was
added. Tubes were warmed at 42° C. for 25 min to induce
biopolymer aggregation. Then the fusion protein was recovered by centrifuging at 2,500 rpm at 42° C. for 3 min. The
recovered fusion protein was resuspended in 100 µl of cold
water. The purification process was repeated twice. Also, the
fusion protein was recovered by using 6M Guanidine hydrochloride phosphate buffer, pH 7 .0 (instead of water), to facilitate stability of insulin. New cultures were incubated for this
step following the same procedure as described above, except
that the pSBL-OC-XaPris expressing cells were incubated for
24, 48, and 72 hrs. Cultures were centrifuged at 4,000 rpm for
12 min and the pellet was resuspended in 6M Guanidine
hydrochloride phosphate buffer, pH 7 .0, and then sonicated as
described above. After sonication, samples were run in a
16.5% Tricine gel, transferred to the nitrocellulose membrane, and immunoblotting was performed the following day.
A 15% glycine gel was run for 6 hat recommended voltage
as shown in FIG. 1. Two different methods of extraction were
used. It was observed that when the sonic extract is in 6M
Guanicine Hydrochloride Phosphate Buffer, pH 7 .0, the
molecular weight changes from its original and correct MW
24 kD to ahigher MW of approximately 30kDa (FIG. lC. I).
This is probably due to the conformation that the biopolymer
takes under this kind of buffer, which is used to maximize the
extraction of proinsulin.
The gel was first stained with 0.3M CuC1 2 and then the
same gel was stained with Commassie R-250 Staining Solution for an hour and then destained for 15 min first, and then
overnight. CuC1 2 creates a negative stain (Lee et al. 1987).
Polymer proteins (without fusion) appear as clear bands
against a blue background in color or dark against a light
semiopaque background (FIG. lA). This stain was used
because other protein stains such as Coomassie Blue R250
does not stain the polymer protein due to the lack of aromatic
side chains (McPherson et al. 1992). Therefore, the observation of the 24 kDa protein in the R250 stained gel (FIG. lB)
is due to the insulin fusion with the polymer. This observation
was further confirmed by probing these blots with the antihuman proinsulin antibody. As anticipated, the polymer insulin fusion protein was observed in western blots as shown in
FIG. lC, even though the binding of antibody was less efficient (probably due to concealment of insulin epitopes by the
polymer). Larger proteins observed as showninFIG. lC II are
tetramer and hexamer complexes of proinsulin.
It is evident that the insulin-polymer fusion proteins are
stable in E. coli. Confirming this observation, recently
another lab has shown that the PBP polymer protein conjugates (with thioredoxin and tendamistat) undergo thermally
reversible phase transition, retaining the transition behavior
of the free polymer (Meyer and Chikoti, 1999). These results
clearly demonstrate that insulin fusion has not affected the
inverse temperature transition property of the polymer. One
of the concerns is the stability of insulin at temperatures used
for thermally reversible purification. Temperature induced
production of human insulin has been in commercial use
(Schmidt et al. 1999). Also, the temperature transition can be
lowered by increasing the ionic strength of the solution during
purification of this PSP (McPherson et al, 1996). Thus,
GVGVP-fusion could be used to purify a multitude of economically important proteins in a simple inexpensive step.
XL-1 Blue strain ofE. coli containing pLD-OC-XaPris and
the negative controls, which included a plasmid containing
the gene in the reverse orientation and the E. coli strain
without any plasmid were grown in TB broth. Cell pellets
were resuspended in 500 µl of aytoclaved dH 2 0 or 6M Guani-
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dine hydrochloride phosphate buffer, pH 7 .0 were sonicated
and centrifuged at 4° C. at 10,000 g for 10 min. After centrifugation, the supernatants were mixed with and equal volume of 2xTN buffer (100 mM Tris-HCI, pH 8, 100 mM
NaCl). Tubes were warmed at 42° C. for 25 min to induce
biopolymer aggregation. Then fusion protein was recovered
by centrifuging at 2,500 rpm at 42° C. for 3 min. Samples
were run in a 16.5% Tricine gel, transferred to the nitrocellulose membrane, and immunoblotting was performed. When
the sonic extract is in 6M Guanidine Hydrochloride Phosphate Buffer, pH 7 .0, the molecular weight changes from its
original and correct MW to a higher MW of approximately 30
kDa as shown in FIGS. 12A and B. This probably due to the
conformation of the biopolymer in this buffer.
The gel was first stained with 0.3M CuCl 2 and then the
same gel was stained with Commassie R-250 Staining Solution for an hour and then destained for 15 min first, and then
overnight. CuCl 2 creates a negative stain (Lee et al. 1987).
Polymer proteins (without fusion) appear as clear banks
against a blue background in color or dark against a light
semi opaque background as shown in FIG. 12A. The stain was
used because other protein stains such as Coomassie Blue
R250 does not stain the polymer protein due to the lack of
aromatic side chains (McPherson et al., 1992). Therefore, the
observation of the 24 kDa protein in R250 stained gel as
shown in FIG. 12B is due to the insulin fusion with the
polymer. This observation was further confirmed by probing
these blots with the anti-human proinsulin antibody. As
anticipated, the polymer insulin fusion protein was observed
in western blots as shown in FIGS. 13A and B. Larger proteins observed in FIGS. 13A-C are tetramer and hexamer
complexes of proinsulin. It is evident that the insulin-polymer
fusion proteins are stable inE. coli. Confirming this observati on, recently others have shown that the PBP polymer protein
conjugates (with thioredoxin and tendamistat) undergo thermally reversible phase transition, retaining the transition
behavior of the free polymer (Meyer and Chilkoti, 1999).
These results clearly demonstrate that insulin fusion has not
affected the inverse temperature transition property of the
polymer. One of the concerns is the stability of insulin at
temperatures used for thermally reversible purification. Ternperature induced production of human insulin has been in
commercial use (Schmidt et al. 1999). Also, the temperature
transition can be lowered by increasing the ionic strength of
the solution during purification ofthis PBP (McPherson et al.
1996). Thus, GVGVP-fusion could be used to purify a mu!titude of economically important proteins in a simple inexpensive step.
Biopolymer-proinsulin fusion gene expression in chloroplast: As described in section d, pSBL-OC-R40XaPris vector
and pLD-OC-R40XaPris vectors were bombarded into the
tobacco chloroplasts genome via particle bombardment
(Daniell, 1997). PCR was performed to confirm biopolymerproinsulin fusion gene integration into chloroplast genome.
The PCR products were examined in 0.8% agarose gels. FIG.
2A shows primers landing sites and expected PCR products.
FIG. 2B shows the 1.6 kbp PCR product, confirming integrati on of the aadA gene into the chloroplast genome. This 1.6 kb
product is seen in all clones except L9, which is a mutant. We
used primers 2P and 2M to confirm integration of both the
aadA and biopolymer-proinsulin fusion gene. The 1.3 kbp
product corresponds to the native chloroplast fragment and
the 3.5 kbp product corresponds to the chloroplast genome
that has integrated all three genes as shown in FIGS. 2C and
D. All the clones examined at this time show heteroplasmy,
exce[t c;pmes :8d om Fog/2C, and S41 bin FIG. 2D, which
show almost homoplasmy.

As described in section d, chloroplast-vector was bombarded into the tobacco chloroplast genome via particle bombardment (Daniell, 1997). PCR and Southern Blots were
performed to confirm biopolymer-proinsulin fusion gene
integration into chloroplast genome. Southern blots show
homoplasmy in most T 0 lines but a few showed some heteroplasmy as shown in FIG. 14. Western blots show the expression of polymer proinsulin fusion protein in all transgenic
lines in FIG. 13C. Quantification is by ELISA.
Protease Xa Digestion of the Biopolymer-proinsulin
fusion protein and Purification of Proinsulin: Factor Xa was
purchased from New England Biolabs at a concentration of
1.0 mg/ml. The Factor Xa is supplied in 20 mM HEPES, 500
mM, NaCl, 2 mM CaCl 2 , 50% glycerol, (pH 8.0). The reaction was carried out in a 1: 1 ratio of fusion protein to reaction
buffer. The reaction buffer was made with 20 mM Tris-HCI,
100 mM NaCl, 2 mM CaC!sub 2 , (pH 8.0). The enzymatic
cleavage of the fusion protein to release the proinsulin protein
from the (GVGVP) 40 (SEQ ID NO. 24) was initiated by
adding the protease to the purified fusion protein at a ration
(ww) of approximately 1,500. This digestion was continued
for 5 days with mild stirring at 4.degree. C. Cleavage of the
fusion protein was monitored by SDS-PAGE analysis. After
the cleavage, the same conditions are used for purification of
the proinsulin protein. The purification steps are the same as
for the purification of the fusion protein, expect that instead of
recovering the pellet, the supernatant is saved. We detected
cleaved proinsulin in the extracts isolated in 6M guanidine
hydrochloride buffer as shown in FIG. lC 11. Conditions can
beestimizedforcompletecleavage. TheXa protease has been
successfully used to cleave (GVGVP) 20 (SEQ ID NO. 25)GST fusion (McPherson et al. 1992). Therefore, cleavage of
proinsulin from GVGVP using the Xa protease does not pose
problems.
The enzymatic cleavage of the fusion protein to release the
proinsulin protein from the (GVGVP)40 (SEQ ID NO. 24)
was initiated by adding the factor 1OA protease to the purified
fusion at a ratio (w/w) of approximately 1:500. Cleavage of
the fusion protein was monitored by SDS-PAGE analysis. We
detected cleaved proinsulin in the extracts isolated in 6M
guanidine hydrochloride buffer as shown in FIGS. 13A and B.
Conditions are noweing optimized for complete coverage.
The Xa protease has been successfully used previously to
cleave (GVGVP) 20 (SEQ ID NO. 25)-GST fusion (McPherson et al. 1992).
Evaluation of chloroplast gene expression: (1577-P-OO) A
systematic approach to identify and overcome potential limitations of foreign gene expression in chloroplasts of transgenie plants is essential. Information gained herein increases
the utility of choloroplast transformation system by scientists
interested in expressing other foreign proteins. Therefore, it is
important to systematically analyze transcription, RNA abundance, RNA stability, rate of protein synthesis and degradation, proper folding and biological activity. For example, the
rate of transcription of the introduced insulin gene may be
compared with the highly expressing endogenous chloroplast
genes (rbcL, psbA, 16S rRNA), using run on transcription
assays to determine if the 16SrRNA promoter is operating as
expected. Transgenic chloroplast containing each of the three
constructs with different 5' regions is investigated to test their
transcription efficiency. Similarly, trasgene RNA levels is
monitored by northerns, dot blots and primer extension relative to endogenous rbcL, 16S rRNA, or psbA. These results
along with run on transcription assays should provide valuable information of RNA stability, processing, etc. With out
past experience in expression of several foreign genes, foreign transcripts appear to be extremely stable based on north-
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em blot analysis. However, a systematic study is valuable to
advance utility of his system by other scientists.
Importantly, the efficiency of translation may be tested in
isolated chloroplasts and compared with the highly translated
chloroplast protein (psbA). Pulse chase experiments help
assess if translational pausing, premature termination occurs.
Evaluation of percent RNA loaded on polysomes or in constructs with or without 5'UTRs helps determine the efficiency
of the ribosome binding site and 5' stem-loop translational
enhancers. Codon optimized genes are also compared with
unmodified genes to investigate the rate of translation, pausing and termination. In our recent experience, we observed a
200-fold difference in accumulation of foreign proteins due
to decreases in proteolysis conferred by a putative chaperonin
(De Casa et al. 2001). Therefore, proteins from constructs
expressing or not expressing the putative chaperonin (with or
without ORF1+2) provide valuable information on protein
stability. Thus, all of this information may be used to improve
the next generation of chloroplast vectors.
Vector for CTB expression in chloroplasts: The leaser
sequence ( 63 bp) of the native CTB gene (3 72 bp) was deleted
and a start codon (ATG) introduced at the 5' end of the
remaining CTB gene (309 bp). Primers were designed to
introduce a rbs site 5 bases upstream of the start codon. The 5'
primer (3 8 mer) was designed to an on the start codon and the
5'-end of the CTB gene. This primer had an Xbal site at the
5'-end, therbs site [GGAGG], a 5 bp breathing space followed
by the first 20 bp of the CTB gene. The 3' primer (32 mer) was
designed to land on the 3' end of the CTB gene and it introduced restriction sites at the 3' end to facilitate subcloning.
The 347 bp rCTB PCT product was subcloned into pCR2.1
resulting in pcCR2.l-rCTB. The final step was insertion of
rCTB into the Xbal site of the universal or tobacco vector
(pLB-CtV2) that allows the expression of the construct in E.
coli and chloroplasts. Restriction enzyme digestion of the
pLD-LH-rCTB vector with BamHI was performed to confirm
the correct orientation of the inserted fragment in the vector.
Because of similarity of protein synthetic machinery,
expression of the chloroplast vector was test in E. coli before
its use in tobacco transformation. For Escherichia coli
expression the XL-1 Blue MRF ro strain was used. E. coli was
transformed by standard CaC1 2 transformation procedures.
Transformed E. coli (24 hrs culture and 48 hrs culture in 100
ml TB with 100 mg/ml ampicillin) and untransformed E. coli
(24 hrs culture and 48 hrs culture in 100 ml TB with 12.5
mg/ml tetracycline) was then centrifuged at 1OOOOxg in a
Beckman G-15R centrifuge for 15 min. The pellet was
washed with 200 mM Tris-Cl twice and resuspended in 500 µl
extraction buffer 200 mMTris-Cl, pH 8.0, 100 mM NaCal; 10
mM EDTA, 2 mM PMSF) and then sonicated using Autotune
Series High Intensity Ultrasonic Processor. Then, 100 µl aliquots of the sonicated transformed and untransformed cells
[containing 50-100 µg of crude protein extract as determined
by Bradford protein assay (Bio-Rad Inc)] and purified CTB
(Sigma C-9903) were boiled with 2xSDS sample buffer and
separated on a 15% SDS-PAGE gel in Tris-glycine buffer (25
mM Tris, 250 mM glycine, pH 8.3, 0.1 % SDS). The separated
protein was then transferred to a nitrocellulose membrane by
electro blotting using the Trans-Blot Electrophoretic Transfer
Cell (Bio-Rad Inc.).
Imunoblot detection of CTB expression in E. coli: Nonspecific antibody reactions were blocked by incubation of the
membrane in 25 ml of 5% non-fat dry milk in TBS buffer for
1-3 hrs on a rotary shaker (40 rpm), followed by washing in
TBS buffer for 5 min. The membrane was then incubated for
an hour with gentle agitation in 30 ml of a 1:5000 dilution of
rabbit anti-cholera antiserum (Sigma C-3062) in TBS with

Tween-20 [TBST] (containing 1%non-fatdrymilk)followed
by washing 3 times in TBST buffer. The membrane was
incubated for an hour at room temperature with gentle agitation in 30 ml ofa 1:10000 dilution of mouse anti-rabbit 1 gG
conjugated with alkaline phosphate in TBST. It was then
washed thrice with TBST and once with TBS followed by
incubation in the Alkaline Phosphate Color Development
Reagents, BCIP/NBT in AP color development Buffer (BioRad, Inc.) for an hour. Immunoblot analysis snows the presence of 11.5 kDa polypeptide for purified bacterial CTB and
transformed 24 h/48 h cultures (FIG. 3A, lanes 2, 3 and 5).
The 48'h culture appears to express more CTB than that of the
24 h culture indicating the accumulation of the CTB protein
over time. The purified bacterial CTB (45 Kda) dissociated
into monomers (11.5 KDa each) due to boiling prior to SDS
PAGE. These results indicate that the pLD-LH-CTB vector is
expressed in E. coli. Because of the similarity of the E. coli
protein synthetic machinery to that of chloroplasts, chloroplast expression of the above vector should be possible.
CTB expression in chloroplasts: As described below, pLDLH-CTB was integrated into the tobacco chloroplast genome
via particle bombardment (Daniell, 1997). PCR analysis was
performed to confirm chloroplast integration. FIG. 3B shows
primer landing sites and size of expected products. PCR
analysis of clones obtained after the first round of selection
was carried out as described below. PCR products were examined on 0.8% agarose gels. The PCR results (FIG. 3C) show
that clones 1 and 5 that do not show any product are mutants
while clones 2, 3, 4, 6, 7, 8, 9, 10 and 11 that gave a 1.65 kbp
product are transgenic. As expected lanes 13-15 did not give
any PCR product, confirming that the PCR reaction was not
contaminated. Because primers 3P & 3M land on the aadA
gene and on the chloroplast genome, all clones that show PCR
products have integrated the CTB gene and the selectable
marker into the chloroplast genome. Clones that showed
chloroplast integration of the CTB gene were moved to the
second round of selection to increase copy number. PCR
analysis of clones obtained afterthe second round of selection
was also carried out. PCR results shown in FIG. 3D indicate
that clone 5 does not give a 3 kbp product indicating that it is
a mutant as observed earlier. Other clones give strong 3 kbp
product and a faint 1.3 kbp (similar to the 1.3 kbp untransformed plant product), indicating that they are transgenic but
not yet homoplasmic. Complete homoplasmy can be accomplished by several more rounds of selection or by germinating
seeds from transgenic plants on 500 µg/ml of spectinomycin.
Vector constructions: pLD vector is used for all the constructs. This vector was developed for chloroplast transformation. It contains the 16S rRNA promoter (Prm) driving the
selectable marker gene aadA (aminoglycoside adenyl transferase conferring resistance to spectinomycin) followed by
multiple cloning site and then the psbA 3' region (the terminator from a gene coding for photosystem II reaction center
components) from the tobacco chloroplast genome. The pLD
vector is a universal chloroplast expression/integration vector
and can be used to transform chloroplast genomes of several
other plant species (Daniell et al. 1998, Daniell 1999) because
these flanking sequences are highly conserved among higher
plants. The universal vector uses tmA and trnl genes (chloroplast transfer RNAs coding for Alanine and Isoleucine)
from the inverted repeat region of the tobacco chloroplast
genome as flanking sequences for homologous recombination. Because the universal vector integrates foreign genes
within the Inverted Repeat region of the chloroplast genome,
it should double the copy number of the trans gene (from 5000
to 10,000 copies per cell in tobacco). Furthermore, it has been
demonstrated that homoplasmy is achieved even in the first
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round of selection in tobacco probably because of the presence of a chloroplast origin of replication within the flanking
sequence in the universal vector (thereby providing more
templates for integration). These, and several other reasons,
foreign gene expression was shown to be much higher when
the universal vector was used instead of the tobacco specific
vector (Guda et al. 2000).
CTB-Proinsulin Vector Construction: The chloroplast
expression vector pLD-CTB-Proins was constructed as follows. First, both proinsulin and cholera toxin B-subunit genes
were amplified from suitable DNA using primer sequences.
Primer 1 contains the GGAGG chloroplast preferred ribosome binding site five nucleotides upstream of the start codon
(ATG) for the CTB gene and a suitable restriction enzyme site
(Spel) for insertion into the chloroplast vector. Primer 2 eliminates the stop codon and adds the first two amino acids of a
flexible hinge tetrapeptide GPGP as reported by Begerot et al.
(1997), in order to facilitate folding of the CTB-proinsulin
fusion protein. Primer 3 adds the remaining two amino acids
for the hinge tetrapeptide and eliminates the presequence of
the pre-proinsulin. Primer 4 adds a suitable restriction site
(Spel) for subcloning into the chloroplast vector. Amplified
PCR products were inserted into the TA cloning vector. Both
the CTB and proinsulin PCR fragments were excised at the
Smal andXbal restriction sites. Eluted fragments were ligated
into the TA cloning vector. Interestingly, all white colonies
showed the wrong orientation for CTB insert while three of
the five blue colonies examined showed the right orientation
of the CTB insert. The CTB-proinsulin fragment was excised
at the EcoRl sites and inserted into EcoRl digested dephosphorolated pLD vector. Resultant onicroplast integration
expression vector, pLD-CTB-Prions will be tested for expression in E. coli by western blots. After confirmation of expression of CTB-proinsulin fusion in E. coli, pLD-CTB-Prions
will be bombarded into tobacco cells as described below.
The following vectors may be designed to optimize protein
expression, purification and production of proteins with the
same amino acid composition as in human insulin.
a) Using tobacco plants, Eibl (1999) demonstrated, in vivo,
the differences in translation efficiency and mRNA stability of a GUS reporter gene due to various S' and 3'
untranslated regions (UTR's). This already described
systematic transcription and translation analysis can be
used in a practical endeavor of insulin production. Consistent with Eibl's (1999) data for increased translation
efficiency and mRNA stability, the psbA S' UTR can be
used in addition with the psbA 3' UTR already in use.
The 200 bp tobacco chloroplast DNA fragment containing S' psbA UTR may be amplified by PCR using
tobacco chloroplast DNA as template. This fragment
may be cloned directly in the pLD vector multiple cloning site downstream of the promoter and the aadA gene.
The cloned sequence may be exactly the same as in the
psbA gene. (Update "Human Insulin") We have cloned
the S' untranslated region of the tobacco psbA gene
including the promoter (S'UTR), shown in FIG. 32. We
performed PCR using the primers CCGTCGACGTA(SEQ ID N0:4) and
GAGAAGTCCGTATT
GCCCATGGTAAAATCTTGGTTTATTTA (SEQ ID
NO:S), which resulted in a 200 base pair product, as
expected. We inserted this PCR product into a TA cloning vector. Since restriction enzyme sites were not available to subclone the S'UTR immediately upstream of the
gene coding for the CTB-proinsulin fusion protein, we
used the "SOEing" PCR technique to create the DNA
sequence with the S'UTR immediately upstream of the
CTB-proinsulin gene (FIG. 25). The products of this
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PCR include both the S'UTR (200bp) and the gene for
CTB-proinsulin (SCP) at 800 bp. SCP was eluted and
then inserted into the TA cloning vector where DNA
sequencing was performed to confirm accuracy of
nucleotide sequence before it was subcloned into the
pLD vector.
b) Another approach of protein production in chloroplasts
involves potential insulin crystallization for facilitating
purification. The cry2Aa2 Bacillus thuringiensis operon
derived putative chaperonin may be used. Expression of
the cry2Aa2 operon in chloroplasts provides a model
system for hyper-expression of foreign proteins (46% of
total soluble protein) in a folded configuration enhancing their stability and facilitating purification (De Casa
et al. 2001 ). This justifies inclusion of the putative chaperonin from the cry2Aa2 operon in one of the newly
designed constructs. In this region there are two open
reading frames (ORF 1 and ORF2) and a ribosomal
binding site (rbs). This sequence contains elements necessary for Cry2Aa2 crystallization, which help to crystallize insulin and aid in subsequent purification. Successful crystallization of other proteins using this
putative chaperonin has been demonstrated (Ge et al.
1998). The ORF 1 AND ORF2 of the Bt Cry2Aa2
operon may be amplified by PCR using the complete
operon as a template. Subsequent cloning, using a novel
PCR technique, allows for direct fusion of this sequence
immediately upstream of the proinsulin fusion protein
without altering the nucleotide sequence, which is normally necessary to provide a restriction enzyme site
(Horton et al. 1988).
(Update "Human Insulin") Another parameter of foreign
protein production to be investigated is post-translational. The DNA for the putative chaperonin in the
Bacillus thuringiensis Cry 2A2 operon encodes a protein that could potentially fold and crystallize CTBProinsulin, which would allow it to accumulate in
large quantities protected from chloroplast proteases
and facilitate in subsequent purification. Standard
molecular biology techniques were used to insert this
DNA fragment immediately upstream of the S'UTR
of the construct containing the chloroplast optimized
proinsulin. Additionally, another vector was constructed to contain only Shine-Dalgarno sequence
(GGAGG) followed by the sequence encoding forthe
Cholera toxin B subunit and synthetic chloroplast
optimized proinsulin fusion (CTB-PTpris). This construct will allow us to determine the value of the
proinsulin sequence modification both with and without the S'UTR.
c) To address codon optimization the proinsulin gene may
be subjected to certain modifications in subsequent constructs. The plastid modified proinsulin (PtPris) can
have its nucleotide sequence modified such that the
codons are optimized for plastid expression, yet its
amino acid sequence remains identical to human proinsulin. PtPris is an ideal substitute for human proinsulin
in the CTB fusion peptide. The expression of the construct can be compared to the native human proinsulin to
determine the affects to codon optimization, which serve
to address one relevant mechanistic parameter of translation. Analysis of human proinsulin gene showed that
48 of its 87 codons were the lowest frequency codons in
the chloroplast for the amino acid for which they encode.
For example, there are six different codes for leucine,
Their frequency within the chloroplast genome ranges
from 7 .3 to 30.8 thousand codons. There are 12 leucines
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in proinsulin, 8 have the lowest frequency codons (7.3),
and none code for the highest frequency codons (30.8).
In the plastid, optimized proinsulin gene all the codons
code for the most frequent, whereas in human proinsulin
over half of the codas are the least frequent. Human
proinsulin nucleotide sequence contains 62% C+G,
whereas plastid optimized proinsulin gene contain 24%
C+G. Generally, lower C+G content of foreign genes
correlates with higher levels of expression (Table 2).
(Update "Human Insulin") Chloroplast foreign gene
expression correlates well with % AT of the gene
coding sequence. The native human proinsulin
sequence is 38% AT, while the newly synthesized
chloroplast optimized proinsulinis 64%AT. We determined the optimal chloroplast coding sequence for
the proinsulin (PTpris) gene by using a codon composition that is equivalent to the highest translated
chloroplast gene, psbA. The preferred codon composition of the psbA in tobacco is conserved within 20
vascular plant species. We have compared it to the
native human proinsulin DNA sequence (FIG. 27).
Since there are too many changes for conventional
mutagenesis, we employed the Recursive PCR
method for total gene synthesis. FIG. 28 shows the
product of this gene synthesis corresponding to the
280 bp expected size. This product, PTpris, was then
used as a template with CTB and 5'UTR to create a
fusion of these sequences using the SOEing PCR
technique. The products of this reaction can be seen in
FIG. 29. These include 5'UTR (200 bp), CTB (320
bp ), Proinsulin (280 bp ), and CTB-Proinsulin (600
bp) as side products, and also the desired 5'UTR CTBPTpris (5CPTP) AT 800 BP. This was then inserted
into the TA cloning vector where the sequence was
verified before being subcloned into the pLD vector.
d) Another version of the proinsulin gene, mini-proinsulin
(Mpris ), may also have its codons optimized for plastid
expression, and its amino aid sequence does not differ
from human proinsulin (Pris). Pris' sequence is B ChainRR-C Chain-KR-A Chain, whereas Mpris' sequence is
B Chain-KR-A Chain. The MPris sequence excludes the
RR-C Chain, which is normally excised in proinsulin
maturation to insulin. The C chain of proinsulin is an
unnecessary part of in vitro production of insulin. Proinsulin folds properly and forms of the appropriate disulfide bonds in the absence of the C chain. The remaining KR motif that exists between the B chain and the A
chain in MPris allows for mature insulin production
upon cleavage with trypsin and carboxypeptidase B.
This construct may be used for out biopolymer fusion
protein. It=s codon optimization and amino acid
sequence is ideal for mature insulin production.
e) Our current human proinsulin-biopolymer fusion protein contains a facor Xa proteolytic cut site, which serves
as a cleavage point between the biopolymer and the
proinsulin. Currently, cleavage of the polymer-proinsulin fusion protein with the factor Xa has been inefficient
in out hands. Therefore, we replace this cut site with a
trypsin cut site. This eliminates the need for the expensive factor Xa in processing proinsulin. Since proinsulin
is currently processed by trypsin in the formation of
mature insulin, insulin maturation and fusion peptide
cleavage can be achieved in a single step with trypsin
and carboxypeptidase B.
f) We observed incomplete translation products in plastids
when we expressed the 120 mer gene (Guda et al. 2000).
Therefore, while expressing the polymer-proinsulin
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fusion protein, we decreased the length of the polymer
protein to 40 mer, without losing the thermal responsive
property. In addition, optimal codons for glycine (GGT)
and valine (GTA), which constitute 80% of the total
amino acids of the polymer, have been used. In all
nuclear encoded genes, glycine makes up 147/1000
amino acids while in tobacco chloroplsts it is 129/1000.
Highly expressing genes like psbA and rbcL of tobacco
make up 192 and 190 gly/1000. Therefore, glycine may
not be a limiting factor. Nuclear genes use 52/1000 praline as opposed to 42/1000 in chloroplasts. However,
currently used codon for praline (CCG) can be modified
to CCA or CCT to further enhance translation. It is
known that pathways forproline and valine are compartmentalized in chloroplasts (Guda et al. 2000). Also,
praline is known to accumulate in chloroplasts as an
osmoprotectant (Daniell et al. 1994).
g) Codon comparison of the CTB gene with the psbA,
showed 47% homology with the most frequent codons
of the psbA gene. Codon analysis showed that 34% of
the codons of CTB are complimentary to the tRNA
population in the chloroplasts in comparison with 51 %
of psbA codons that are complimentary to the chloroplast tRNA population. Because of the high levels of
CTB expression in transgenic chloroplasts (Henriques
and Daniell, 2000), there will be no need to modify the
CTB gene.
DNA sequence of all constructs may be determined to
confirm the correct orientation of genes, in frame fusion, and
accurate sequences in the recombinant DNA constructs. DNA
sequencing may be performed using a Perkin Elmer ABI
prism 373 DNA sequencing system using ABI Prism Dye
Termination Cycle Sequencing kit. Insertion sites at both
ends may be sequenced by using primers for each strand.
Expression of all chloroplast vectors are first tested in E.
coli before their use in tobacco transformation because of the
similarity of protein synthetic machinery (Brixley et al.
1997). For Escherichia coli expressionXL-1 Blue strain was
used. E. coli may be transformed by a standard CaC1 2 method.
(Update "Human Insulin") All of the resulting vectors,
containing the desired constructs, were used to transform
both the tobacco cultivars, Petit Havana and LAMD 605
(edible tobacco). Transformation was performed using the
particle bombardment method, as described. Bombarded
leaves are currently being regenerated into transgenic plants
under spectinomycin selection. Several clones have begun to
form shoots. The clones of Petit Havana bombarded with the
initial CTB-human proinsulin construct have regenerated
large enough for us to extract DNA. Extracted DNA was used
as a template in PCT reaction to confirm integration of the
cassette into the chloroplast genome by homologous recombination. We used two primers in this reaction, 3P and 3M. 3P
anneals with the native chloroplast genome, while 3M
anneals with the gene for spectinomycin resistance, aadA.
The 1600 bp product of this reaction is indicative of integration of the construct into the genome (FIG. 30). This experiment demonstrated that 7 of the 11 analyzed clones were the
desired chloroplast transgenic plants. Western blots are currently underway to confirm expression of various CTB-proinsulin fusion proteins in E. coli. Because of the similarity of
chloroplast and E. coli protein synthetic machinery, chloroplast vectors are routinely tested in our lab before bombardment. Membranes have been immunoblotted with antibodies
to both CTB and Proinsulin. Results demonstrate the presence of the desired fusion
Optimization of fusion gene expression: It has been
reported that foreign genes are expressed between 5% (cry-
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!AC, cryllA) and 30% (uldA) in transgenic chloroplasts
(Daniell, 1999). Ifthe expression levels ifthe CTB-Proinsulin
or polymer-proinsulin fusion proteins are low, several
approaches will be used to enhance translation of these proteins. In chloroplast, transcriptional regulation of gene
expression is less important, although some modulations by
light and developmental conditions are observed (Cohen and
Mayfield, 1997). RNA and protein stability appear to be less
important because of observation of large accumulation of
foreign proteins (e.g. GUS up to 30% of total protein) and tps
1 transcripts 16,966-fold higher than the highly expressing
nuclear transgenic plants. Chloroplast gene expression is
regulated to a large extent at the post transcriptional level. For
example, 5'UTRs are used for optional translation of chloroplast mRNAs. Shine-Delgarno (GGAGG) sequences as well
as a stem-loop structure located 5' adjacent to the SD
sequence are used for efficient translation. A recent study has
shown that insertion of the psbA 5' UTR downstream of the
16S r RNA promoter enhanced translation of a foreign gene
(GUS) hundred-fold (Eibl et al. 1999). Therefore, the 85-bp
tobacco chloroplast DNA fragment (1595-1680) containing
5' psbA UTR will be amplified using the following primers
(SEQ ID NOs: 6 and 7, respectively): cctttaaaaagccttccattttctattt, gccatggtaaaat cttggtttatta. This PCR product will be
inserted downstream of the 16S rRNA promoter to enhance
translation of the proinsulin fusion proteins.
Yet another approach for enhancement of translation is to
optimize codon compositions of these fusion proteins. Since
both fusion proteins are expressed well inE. coli, we expected
efficient expression in chloroplasts. However, optimizing
codon compositions of proinsulin and CTB genes to march
the psbA gene could further enhance the level of translation.
Although rbcL (RuBisCO) is the most abundant protein on
earth, it is translated as frequently as the psbA gene due to the
extremely high turnover rate of the psbA gene product. The
psbA gene is under stronger selection for increased translation efficiency and is the most abundant thylakoid protein. In
addition, codon usage in higher plant chloroplasts is biased
towards the NNC codon of2-fold degenerate groups (i.e. TTC
over TTT, GAC over GAT, CAC over CAT, AAC over AAT,
ATC over ATT, ATA etc.). This is in addition to a strong bias
towards Tat a third position of 4-fold groups. There is also a
context effect that should be taken into consideration while
modifying specific codons. The 2-fold degenerate sites
immediately upstream from a GNN codon do not show this
Bias towards NNC, (TTT GGA is preferred to TTC GGA
while TTC CGT is preferred to TTT CGT TTC AGT to TTT
AGT and TTC TCT to TTT TCT) (SEQ ID N0:8). In addition, highly expressed chloroplast genes use GNN more frequently than other genes. Codn preference tables known to
one of ordinary skill in the art may be used optimize codon
composition by comparing different species. Abundance of
amino acids in chloroplasts can be taken into consideration
(pathways compartmentalized in plastids as opposed to those
that are imported into plastids ).
As far as the biopolymer gene is concerned, we observed
incomplete translation products in plastids when we
expressed the 120 mer gene (Guda et al. 2000). Therefore,
while expressing the polymer-proinsulin fusion protein, we
decreased the length of the polymer protein to 40 mer, without
losing the thermal responsive property. In addition, optimal
codons for glycine (GGT) and valine (GTA), which constitute
80% of the total amino acids of the polymer, have been used.
In all nuclear encoded genes glycine make up 147/1000
amino acids while in tobacco chloroplasts it is 129/1000.
Highly expressing genes like psbA and rbcL of tobacco make
up 192 and 190 gly/1000. Therefore, glycine may not be a

limiting factor. Nuclear genes use 5211000 pro line as opposed
to 42/1000 in chloroplasts. However, currently used codon for
praline (CCG) can be modified to CCA or CCT to further
enhance translation. It is known that pathways for praline and
valine are compartmentalized in chloroplasts (Guda et al.
2000). Also praline is known to accumulate in chloroplasts as
an osmoprotectant (Daniell et al 1994).
We have reported that foreign genes are expressed between
3% (cry2Aa2) and 46% (cry2Aa2 operon) in transgenic chloroplasts (Kata et al. 1999; De Casa et al. 2001). Several
approaches may be used to enhance translation of the recombinant proteins. In chloroplasts, transcriptional regulation as
a bottle-neck in gene expression has been overcome by utilizing the strong constituitive promoter of the 16s rRNA
(Prrn). One advantage of Prrn is that it is recognized by both
the chloroplast encoded RNA polymerase and the nuclear
encoded chloroplast RNA polymerase in tobacco (Allison et
al. 1996). Several investigators have utilized Prrn in their
studies to overcome the initial hurdle of gene expression,
transcription (DeCosa eta!. 2001, Eibl eta!. 1999, Staub et al.
2000). RNA stability appears to be one among the least problems because of observation of excessive accumulation of
foreign transcripts, at times 16,966-fold higher than the
highly expressing nuclear transgenic plants (Lee et al. 2000).
Also, other investigations regarding RNA stability in chloroplasts suggest that efforts for optimizing gene expression
need to be addressed atthe post-transcriptional level (Higgs et
al. 1999, Eibl et al. 1999). Our work focuses o addressing
protein expression post-transcriptionally. For example, 5' and
3' UTRs are needed for optimal translation and mRNA stability of chloroplast mRNAs (Zerges 2000). Optimal ribosomal binding sites (RBS's) as well as a stem-loop structure
located 5=adjacent to the RBS are needed for efficient translation. A recent study has shown that replacement of the
Shine-Delgarno (GGAGG) with the psbA 5' UTR downstream of the 16S rRNA promoter enhanced translation of a
foreign gene (GUS) hundred-fold (Eibl et al. 1999). Therefore, the 200-bp tobacco chloroplast DNA fragment (16801480) containing 5' psbA UTR may be used. This PCR product is inserted downstream of the 16S rRNA promoter to
enhance translation of the recombinant proteins.
(60/263,668) Yet another approach for enhancement of
translation is to optimize codon compositions. We have compared A+ T % content of all foreign genes that had been
expressed in transgenic chloroplasts with the percentage of
chloroplast expression. We found that higher levels of A+T
always correlated with high expression levels (see Table 2). It
is also potentially possible to modify chloroplast protease
recognition sites while modifying codons, without affecting
their biological functions. Therefore, optimizing codon compositions of insulin and polymer genes to match the psbA
gene should enhance the level of translation. Although rbcL
(RuBisCO) is the most abundant protein on earth, it is not
translated as highly as the psbA gene due to the extremely
high turnover of the psbA gene product. The psbA gene is
under stronger selection for increased translation efficiency
and is the most abundant thylakoid protein. In addition, the
codon usage in higher plant chloroplasts is biased towards the
NNC codon of 2-fold degenerate groups (i.e. TTC over TTT,
GAC over GAT, CAC over CAT, AAC over AAT, ATC over
ATT, ATA etc.). This is in addition to a strong bias towards T
at the third position of the 4-fold degenerate groups. There is
also a context effect that should be taken into consideration
while modifying specific codons. The 2-fold degerate sites
immediately upstream from a GNN codon do not show this
bias towards NNC. (TTT GGA is preferred to TTC GGA
while TTC CGT is preferred to TTT CGT, TTC AGT to TTT
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AGT and TTC TCT to TTT TCT, Morton, 1993; Morton and
Bernadette, 2000). In addition, highly expressed chloroplast
genes use GNN more frequently that other genes. The disclosure of web site http://www.kazusa.or.jp/codon and http://
www.ncbi.nlm.nih.gov may be used to optimize codon composition by comparing codon usage of different plant species'
genomes and PsbA=s genes. Abundance of amino acids in
chloroplasts and tRNA anti codons present in chloroplast may
be taken into consideration. Optimization of polymer and
proinsulin may be performed using a novel PCR approach
(Prodromou and Pearl, 1992; Casimiro et al. 1997), which has
been successfully used in our laboratory to optimize codon
composition of other human proteins.
Bombardment and Regeneration of Chloroplast Transgenic Plants: Tobacco (Nicotiana tabacum var. Petit Havana)
and nicotine free edible tobacco (LAMD 665, gift from Dr.
Keith Wycoff. Planet Biotechnology) plants are grown aseptically by germination of seeds on MSO medium. This
medium contains MS salts (4.3 g/liter), BS vitamin mixture
(myoinositol, 100 mg/liter; thiamine-RC!. 10 mg/liter nicotinic acid. 1 mg/liter/pyridoxine-HCI. 1 mg/liter, sucrose (30
g/liter) and phytagar (6 g/liter) at pH 5.8. Fully expanded,
dark green leaves of about two month old plants are used for
bombardment.
Leaves are placed abaxial side up on a Whatman No. 1 filter
paper laying on the RMOP medium (Daniell, 1993) in standard petri plates ( 1OOx15 mm) for bombardment. Tungsten ( 1
µm) or Gold (0.6 µm) microprojectiles are coated with plasmid DNA (chloroplast vectors) and bombardments carried
out with the biolistic device PDSlOOO/He (Bio-Rad) as
described by Daniell (1997). Following bombardment, petri
plates are sealed with parafilm and incubated at 24 ° C. under
12 h photoperiod. Two days after bombardment, leaves are
chopped into small pieces of-5 mm2 in size and placed on the
selection medium (RMOP containing 500 µg/ml of spectinomycin dihydrochloride) with abaxial side touching the
medium in deep (100x25 mm) petri plates (-10 pieces per
plate). The regenerated spectinomycin resistant shoots are
chopped into small pieces (-2 mm 2 ) and subcloned into fresh
deep petri plates (-5 pieces per plate) containing the same
selection medium. Resistant shoots from the second culture
cycle arbe transferred to the rooting medium (MSO medium
supplemented with IBA. 1 mg/liter and spectinomycin dihydrochloride, 500 mg/liter). Rooted plants are transferred to
soil and grown at 26° C. under continuous lighting conditions
for further analysis.
Polymerase Chain Reaction: PCR is performed using DNA
solated from control and transgenic plants to distinguish a)
true chloroplast transformants from mutants and b) chloroplast transformants from nuclear transformants. Primers for
testing the presence of the aadA gene (that confers spectinomycin resistance) in transgenic pants are landed on the aadA
coding sequence and 16S rRNA gene (primers lP&lM.). To
test chloroplast integration of the insulin gene, one primer
lands on the aadA gene, while another lands on the native
chloroplast genome (primers 3P&3M) as shown in FIGS. 2A
and 3B. No PCR product is obtained with nuclear transgenic
plants using this set of primers. The primer set (2P & 2M, in
FIGS. 2A and 3B) is used to test integration of the entire gene
cassette without internal deletion or looping out during
homologous recombination. A similar strategy has been used
successfully to confirm chloroplast integration of foreign
genes (Daniell et al., 1998; Kata et al, 1999; Guda et al.,
1999). This screening is essential to eliminate mutants and
nuclear transformants.
Total DNA from unbombarded and transgenic plants is
isolated as described by Edwards et al., (1991) to conduct

PCR analyses in transgenic plants. PCR reactions are performed in a total volume of 50 µl containing approximately 10
ng of template DNA and 1 OM of each primer in a mixture of
300 µM of each deoxynucleotide (dNTPs ), 200 mM Tris (pH
8.8), lOOmMKCl, 100mM(NH4 ) 2 S04 ,20mMMgS04 , 1%
Triton X-100, 1 mg/ml nuclease-free BSA and 1 or 2 units of
Taq Plus polymerase (Stratagene, La Jolla, Calif.). PCR is
carried out in the Perkin Elmer's GeneAmp PCR system
2400, by subjecting the samples to 94° C. for 5 min and 30
cycles of94° C. for 1 min, 55° C. for 1.5 min, 72° C. for 1.5
or 2 min followed by a 72° C. step for 7 min. PCR products are
analyzed by electrophoresis on 0.8% agarose gels. Chloroplasat transgenic plants containing the proinsulin gene are
then moved to second round of selection to achieve
homoplasmy.
Southern Blot Analysis: Southern blots are performed to
determine the copy number of the introduced foreign gene per
cell as well as to test homoplasmy. There are several thousand
copies of the chloroplast genome at present in each plant cell.
Therefore, when foreign genes are inserted into the chloroplast genome, it is possible that some of the chloroplast
genomes have foreign genes integrated while others remain
as the wild type (heteroplasmy). Therefore, to ensure that
only the transformed genome exists in cells of transgenic
plants (homoplasmy), the selection process is continued. To
confirm that the wild type genome does not exist at the end of
the selection cycle, total DNA from transgenic plants should
be probed with the chloroplast border (flanking) sequences
(the trnl-tmA fragment FIGS. 2A and 3B). If wild type
genomes are present (heteroplasmy ), the native fragment size
is observed along with transformed genomes. Presence of a
large fragment (due to insertion of foreign genes within the
flanking sequences) and the absence of the native small fragment confirms homoplasmy (Daniell et al., Kata et al., 1999;
Guda et al., 1999).
The copy number of the integrated gene is determined by
establishing homoplasmy form the transgenic chloroplast
genome. Tobacco chloroplasts contain 500-10,000 copies of
their genome per cell (Daniell et al, 1998). If only a fraction
of the genomes are actually transformed, the copy number, by
default, must be less than 10,000. By establishing that in the
transgenics the insulin inserted transformed genome is the
only one present, one can establish that the copy number is
5000-10,000 per cell. This is usually achieved by digesting
the total DNA with a suitable restriction enzyme and probing
with the flanking sequences that enable homologous recombination into the chloroplast genome. The native fragment
present in the control should be absent in the transgenics. The
absence of native fragment proves that only the transgenic
chloroplast genome is present in the cell and there is no
native, untransformed, chloroplast genome, without the insulin gene present. This established the homoplasmic nature of
the transformants, simultaneously, thereby providing an estimate of 5000-10,000 copies of the foreign genes per cell.
Total DNA is extracted from leaves of transformed and
wild type plants using the CTAB procedure outlined in Rogers and Bendich (1988). Total DNA is digested with suitable
restriction enzymes, electrophoresed on 0.7% aragose gels
and transferred to nylon membranes (Micron Separation Inc.,
Westboro, Mass.). Probes are labeled with 32 P-dCTP using
the random-pried procedure (Promega). Prehybridizationand
hybridization steps are carried out at 42° C. for 2 hand 16 h,
respectively. Blots are soaked in a solution containing 2xSSC
and 0.5% SDS for 5 min followed by transfer to 2xSSC and
0.1 % SDS solution for 15 min at room temperature. Then,
blots are incubated in hybridization bottles containing O.lx
SSC and 0.5% SDS solution for 30 min at 37° C. followed by
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another step at 68 C for 30 min, with gentle agitation. Finally
blots are briefly rinsed in O.lxSSC solutions, dried and
exposed to X-ray film in the dark.
Northern Blot Analysis: Northern blots are performed to
test the efficiency of transcription of the proinsulin gene fused
with CTB or polymer genes. Total RNA is isolated from 150
mg of frozen leaves by using the "Rneasy Plant Total RNA
Isolation Kit" (Qaigen Inc., Chatsworth, Calif.). RNA (10-40
mg) is denatured by formaldehyde treatment, separated on a
1.2% agarose gel in the presence of formaldehyde and transferred into a nitrocellulose membrane (MSI) as described in
Sambrook et al. (1989). Probe DNA (proinsulin gene coding
region) is labeled by the random-primed method (Promega)
with 32 P-dCT isotope. The blot is prehybridized, hybridized
and washed as described above for southern blot analysis.
Transcript levels are quantified by the Molecular Analyst
Program using th GS-700 Imaging Densitometer (Bio-Rad,
Hercules, Calif.).
Polymer-insulin fusion purification, quantitation and characterization:

lowered by increasing salt concentration (McPherson et al.,
1996). The pellet containing the insulin-polymer fusion protein is resuspended in the extraction buffer and incubated on
ice for 10 minutes. The mixtures is centrifuged at 12,000 g for
10 minutes (4° C.). The supernatant is then collected and
stored at-20° C. The purified polymer insulin-fusion protein
is electrophoresed in a SDS-PAGE gel according to Leammli
(1970) and visualized by either staining with 0.3 M CuCl 2
(Lee et al. 1987) or transferred to nitrocellulose membrane
and probed with antiserum raised against the polymer or
insulin protein as described below. Quantification of purified
polymer proteins may be carried out by ELISA in addition to
densitometry.
After electrophoresis, proteins are transferred to a nitrocellulose membrane electrophoretically in 25 mM Tris, 192 mM
glycine, 5% methanol (pH 8.3). The filter is blocked with 2%
dry milk in Tris-buffered saline for two hours at room temperature and stained with antiserum raised against the polymer AVGVP (SEQ ID N0:9) (kindly provided by the University of Alabama at Birmingham, monoclonal facility)
overnight in 2% dry milk/Tris buffered saline. The protein
bands reacting to the antibodies are visualized using alkaline
phosphatase-linked secondary antibody and the substrates
nitroblue tetrazolium and 5-bromo-4-chloro-3-indolyl-phosphate (Bio-Rad). Alternatively, for insulin-polymer fusion
proteins, a Mouse anti-human proinsulin (IgGI) monoclonal
antibody is used as a primary antibody. To detect the binding
of the primary antibody to the recombinant proinsulin, a Goat
anti-mouse IgG Horseradish Peroxidase Labeled monoclonal
antibody (HPR) is used. The substrate used for conjugation
with HPR is 3,3',5,5'-Tetramethylbenzidine. All products are
available for American Qualex Antibodies, San Clement,
Calif. As a positive control, human recombinant proinsulin
from Sigma may be used. This human recombinant proinsulin
was expressed inE. coli by a synthetic proinsulingene. Quantification of purified polymer fusion proteins is carried out by
densitometry using Scanning Analysis software (Biosoft,
Ferguson, Mo.) installed on a Macintosh LC III computer
(Apple Computer, Cupertino, USA) with a 160 Mb hard disk
operating on a System 7.1, connected by SCSI interface to a
Relisys RELI 2412 Scanner (Relisys, Milpitas, Calif.).total
proein contents is then determined by the dye-binding assay
using reagents supplied in kit for Bio-Rad, with bovine serum
albumin as a standard.
Characterization ofCTB expression: CTB protein levels in
transgenic plants are determined using quantitative ELISA
assays. A standard curve is generated using known concentrations of bacterial CTB/a 96-well microtiter plate padded
with 100 ml/well of bacterial CTB (concentrations in the
range of 10-1000 ng) is incubated over night at 4 ° C. The plate
is washed thrice with PBST (phosphate buffered saline containing 0.05% Tween-20) the background is blocked b incubation in 1% bovine serum albumin (BSA) in PBS (300
I/well) at 37° C. for 2 h followed by washing 3 times with
PBST. The plate is incubated in a 1:8,000 dilution of rabbit
anti-cholera toxin antibody (Sigma C-3062) (100 ml/well) for
2 hat 37° C., followed by washing the wells three times with
PBST. The plate is incubated with a 1:80,000 dilution of the
anti-rabbit IgG conjugated with alkaline phosphatase (100
ml/well) for 2 hat 3 7° C. and washed thrice with PBST. Then,
100 ml alkaline phosphatase substrate (sigma Fast) pnitrophenyl phosphate tablet in 5 ml of water is added and the
reaction stopped with IM NaOH (50 ml/well) when absorbencies in the mid-range of the titration reach about 2.0, or
after 1 hour, whichever comes first. The plate is then read at
405 nm. These results are used to generate a standard curve
from which concentrations of plant protein can be extrapo-

Because polymer insulin fusion proteins exhibit inverse temperature transition properties as shown in FIGS. lA and B,
they are purified from transgenic plants essentially following
the same method for polymer purification from transgenic
tobacco plants (Zhang et al., 1996). However, an additional
step is introduced to take advantage of the compartmentalization of insulin polymer fusion protein within chloroplasts.
Chloroplasts are first isolated from crude homogenate of
leaves by a simple centrifugation step at 1500xg. This eliminates most of the cellular organelles and proteins (Daniell et
al., 1986). Then, chloroplasts are burst open by resuspending
them in a hypotonic buffer (osmotic shock). This is a significant advantage because there are fewer soluble proteins
inside chloroplasts when compared to hundreds of soluble
proteins in the cytosol. Polymer extraction buffer contains 50
mM Tris-HCI, pH 7.5, 1% 2-mecaptoethanol, 5 mM EDTA
and 2 mM PMSF and 0.8 M NaCl. The homogenate is then
centrifuged at 10,000 g for 10 min (4° C.), and the pellet
discarded. The supernatant is incubated at 42° C. for 30
minutes and then centrifuged immediately for 3 minutes at
5,000 g (room temperature). If insulin is found to be sensitive
to this temperature, T 1 is lowered by increasing salt concentration (McPherson et al., 1996). The pellet containing the
insulin-polymer fusion protein is resuspended in the extracti on buffer and incubated on ice for 10 minutes. The mixture
is centrifuged at 10,000 g for 10 minute (4° C.). The supernatant is then collected and stored at -20° C. The purified
polymer insulin fusion-protein is electrophoresed in a SDSPAGE gel according to Laemml (1970) and visualized by
either staining with 0.3 M CuCl 2 (Lee et al., 1987) or transferred to nitrocellulose membrane and probed with antiserum
raised against the polymer or insulin protein as described
below. Quantification of purified polymer proteins may then
be carried out by densitometry.
Because polymer insulin fusion proteins exhibit inverse
temperature transition properties as shown in FIGS. 12 and
13, they may be purified from transgenic plants essentially
following the same method described for polymer purification from transgenic tobacco plants (Zhang et al., 1996).
Polymer extraction buffer contains 50 mM Tris-HCI, pH, 7 .5,
1%2 mecaptoethanol, 5 mM EDTA and 2 mM PMSF and 0.8
M NaCl. The homogenate is then centrifuged at 10,000 g for
10 minutes (4° C.), and the pellet is discarded. The supernatant is incubated at 42° C. for 30 minute and then centrifuged
immediately for 3 minutes at 5,000 g (room temperature). If
insulin is found to be sensitive to this temperature, T, is

5

10

15

20

25

30

35

40

45

50

55

60

65

US 7,741,536 B2
33

34

lated. Thus, total soluble plant protein (concentration previously determined using the Bradford assay) in bicarbonate
buffer, pH 9.6 (15 nM NaC 03 , 35 nM NaHC0 3 ) is loaded at
100 plant nl/well and the same procedure as above can be
repeated. The absorbance values are used to determine the
ratio of CTB protein to total soluble pant protein, using the
standard curve generated previously and the Bradford assay
results.
Inheritance oflntroduced Foreign Genes: In initial tobacco
transformants, some are allowed to self-pollinate, whereas
others are used in reciprocal crosses with control tobacco
(transgenics as female acceptors and pollen donors: testing
for maternal inheritance). Harvested seeds (Tl) are germinated on media containing spectinomycin. Achievement of
homoplasmy and mode of inheritance can be classified by
looking at germination results. Homoplasmy is indicated by
totally green seedlings (Daniell et al., 199S) while heteroplasmy is displayed by variegated leaves (lack of pigmentation, Svab & Maliga, 1993). Lack of variation in chlorophyll
pigmentation among progeny also underscores the absence of
position effect, an artifact of nuclear transformation. Maternal inheritance may be demonstrated by scie transmission of
introduced genes via seed generated on transgenic plants,
regardless of pollen source (green seedlings on selective
media). When transgenic pollen is used for pollination of
control plants, resultant progeny does not contain resistance
to chemical in selective media (will appear bleached; Svab
and Maliga, 1993). Molecular analyses confirms transmission and expression of introduced genes, and T2 seed is
generated from those confirmed plants by the analyses
described above.
Comparison of Current Purification with Polymer-based
Purification Methods: It is important to compare purification
methods to test yield and purity of insulin produced in E. coli
and tobacco. (60/263,66S) Three methods may be compared:
a standard fusion protein in E. coli, polymer proinsulin fusion
protein in E. coli, and polymer proinsulin fusion in tobacco.
Polymer proinsulin fusion peptide from transgenic tobacco
may be purified by methodology described in section c) and
Daniell (1997). E. coli purification is performed as follows.
One liter of each pLD containing bacteria is grown in
LB/ampicillin (100 µg/ml) overnight and the fusion protein,
eitherpolymer-proinsulin or the control fusion protein (Cowley and Mackin 1997), expressed. (60/1S5,9S7) One liter of
pSBL containing bacteria is grown in LB/ampicillin (100
µg/ml) overnight and the fusion protein expressed. Cells are
harvested by centrifugation at 5000xg for 10 min at 4 ° C., and
the bacterial pellets resuspended in 5 ml/g (wet wt. Bacteria)
of 100 mM Tris-HCI, pH 7.3. Lysozyme is added at a concentration of 1 mg/ml and placed on a rotating shaker at room
temperature for 15 min. The lysate is subjected to probe
sonication for two cycles of 30 s on/30 s off at 4° C. Cellular
debris is removed by centrifugation at 1OOOxg for 5 min at 4°
C. Insulin polymer fusion protein is purified by inverse temperature transition properties (Daniell et al., 1997). The
supernatant is retained and centrifuged again at 27000xg for
15 min at 4 ° C. to pellet the inclusion bodies. The supernatant
is discarded and the pellet resuspended in 1 ml/g (original wt.
Bacteria) of dH 2 0, aliquoted into microcentrifuge tubes as 1
ml fractions, and then centrifuged at 16000xg for 5 min at 4°
C. The pellets are individually washed with 1 ml of 100 mM
Tris-HCI, pH S.5, IM urea, 1-1 Triton X-100 and again
washed with 100 mM Tris HCI pH S.5, 2 M urea, 2% Trinton
X-100. The pellets are resuspended in 1 ml of dH 2 0 and
transferred to a pre-weighted 30 ml Corex centrifuge tube.
The sample is centrifuged at 15000xg for 5 min at 4 ° C., and
the pellet resuspended in 10 ml/g (wet wt. pellet) of 70%

formic acid. Cyanogen bromide is added to a final concentration of 400 mM and the sample incubated at room temperature in the dark for 16 h. The reaction is stopped by transferring the sample to a round bottom flask and removing the
solvent by rotary evaporation at 50° C. The residue is resuspended in 20 ml/g (wet wt. pellet) of dH 2 0, shell frozen in a
dry ice ethanol bath, and then lyophilized. The lyophilized
protein is dissolved in 20 ml/g (wet wt. pellet) of 500 mM
Tris-HCI, pH S.2, 7 M urea. Oixdative sulfitolysis is performed by adding sodium sulfite and sodium tetrahionate to
final concentrations 100 and 10 mM, respectively, and incubating at room temperature for 3 h. This reaction is ten
stopped by freezing on dry ice.
Purification and folding of Human Proinsulin: The S-sulfonated material is applied to a 2 ml bed of Sephadex G-25
equilibrated in 20 mM Tris-HCI, pH S.2, 7 M urea, and then
washed with 9 vols of7 M urea. The collected fraction is then
applied to a Pharmacia Mono Q HR 5/5 column equilibrated
in 20 mM Tris-HCI, pH S.2, 7 M urea at a flow rate of 1
ml/min. A linear gradient leading to a final concentration of
0.5 M NaCl is used to elute the bound material. 2 min (ml)
factions are collected during the gradient, and protein concentration in each fraction determined. Purity and molecular
mass of fractions are estimated by Tricine SDS-PAGE (as
shown in FIG. 2), where Tricine is used as the trailing ion to
allow better resolution of peptides in the range of 1-1000 kDa.
Appropriate fractions are pooled and applied to a 1.6x20 cm
column of Sephadex G-25 (superfine) equilibrated in 5 mM
ammonium acetate pH 6.S. The sample is collected based on
UV absorbance and freeze-dried. The partially purified S-sulfonated material is resuspended in 50 mM glycine/NaOH, pH
10.5 at a final concentration of 2 mg/ml. ~-mer-captoethanol
is added at a ratio ofl .5 mo! per mo! of cysteine of S-sulfonate
and the sample stirred at 4 ° C. in an open container for 16 h.
The sample is then analyzed by reversed-phase high-performance liquid chromatography (RP-HPLC) using a Vydac C4
column (2.2x150 mm) equilibrated in 4% acetonirile and
0.1 % TFA. Adsorbed peptides are eluted with a linear gradient of increasing acetonitrite concentration (O.SS% per min
up to a maximum of 4S% ). The remaining refolded proinsulin
are centrifuged at 16000xg to remove insoluble material, and
loaded onto a semi-preparative Vydad C4 column (10x250
mm). The bound material is then eluted as described above,
and the proinsulin collected and lyophilized.
Analysis and characterization of insulin expressed in E.
coli and Tobacco: The purified expressed proinsulin is subjected to matrix-assisted laser desorption-ionization-time of
flight (MALDI-TCF) analysis (as described by Cowley and
Mackin, 1997), using proinsulin from Eli Lilly as both an
internal and external standard. A proteolytic digestion is performed using Staphylococcus aureus protease VS to determine if the disulfide bridges have formed naturally inside
chloroplasts or by in vitro processing. Five µg of both the
expressed proinsulin and Eli Lilly's proinsulin are lyophilized and resuspended in 50 µI of 250 mM NaP04 pH 7 .S.
Protease VS is added at a ratio of 1:50 (w/w) in experimental
samples and no enzyme added to the controls.All samples are
then incubated overnight at 37° C., the reactions stopped by
freezing on dry ice, and samples stored at -20° C. until
analyzed. The samples are analyzed by RP-HPLC using
Vydac C4 column (2.2x150mm) equilibrated in 4% acetonitrite and 0.1 % TFA. Bound material is then eluted using a
linear gradient of increasing acetonitrile concentration
(O.SS% per min up to a maximum of 4S%).
CTB-GMl ganglioside binding assay: A GMl-ELISA
assay is performed as described by Arakawa et al. (1997) to
determine ifthe affinity of plant-derived CTB for GMl-gan-
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glioside. The microtiter plate is coated with monosialogangliosice-GMl (Sigma G-7641) by incubating the plate with
100 µI/well ofGMl (3.0 µg/ml) in bicarbonate buffer, pH 9.6
at 4 ° C. overnight. Alternatively, the wells are coated with 100
µI/well of BSA (3.0 µg/ml) as control. The plates are incubated with transformed plant total soluble protein and bacterial CTB (Sigma C-9903) in PBS (100 µI/well) overnight at 4°
C. The remainder of the procedure is then identical to the
ELISA described above.
Mouse feeding assays for CTB: This is performed as
described by Haq et al. (1995). BALB/c mice, divided into
groups of five males each, are fasted overnight before feeding
them transformed edible tobacco (that tastes like spinach)
expressing CTB, untransformed edible tobacco and purified
bacterial CTB. Feedings are performed at weekly intervals (0,
7, 14 days) forthree weeks. Animals are observed to confirm
complete consumption of material. On day 20, fecal and
serum samples are collected from each animal for analysis of
anti-CTB antibodies. Mice are bled retro-orbitally and the
samples stored at -20° C. until assayed. Fecal samples are
collected and frozen overnight at - 70° C., lyophilized, resuspended in 0.8 ml PBS (pH 7.2) containing 0.05% sodium
azide per 15 fecal pellets, centrifuged at 1400xg for 5 min and
the supernatant stored at -20° C. until assayed. Samples are
then serially diluted in PBS containing 0.05% Tween-20
(PBST) and assayed for anti-CTB IgG in serum and anti-CTB
IgA in fecal pellets by the ELISA method, as described earlier.
Assessment of diabetic symptoms in NOD mice: The incidence of diabetic symptoms is compared among mice fed
with control nicotine free edible tobacco and those that
express the CTB-proinsulin fusion protein. Four week old
female NOD mile are divided into two groups, each consisting often mice. Each group is fed with control or transgenic
edible tobacco (nicotine free) expressing the CTB-proinsulin
fusion gene. The feeding dosage is determined based on the
level of expression. Starting at 10 weeks of age, the mice are
monitored on a biweekly basis with urinary glucose test strips
(Clinistix and Diastix, Bayer) for development of diabetes.
Glycosuric mice are bled from the tail vein to check for
glycemia using a glucose analyzer (Accu-Check, Boehringer
Mannheim). Diabetes is confirmed by hyperglycemia (>250
mg/di) for two consecutive weeks (Ma et al., 1997).
Induction of oral tolerance: (60/263,668) Four week old
female NOD mice may, for example, be purchased from
Jackson Laboratory (Bar Harbor, Me.) and housed at an animal care facility. The mice are divided into three groups, each
group consisting of ten mice. Each group is fed one of the
following nicotine free edible tobacco: untransformed,
expressing CTB, or expressing CTB-proinsulin fursion protein. Beginning at 5 weeks of age, each mouse is fed 3 g of
nicotine free edible tobacco once per week until reaching 9
weeks of age (a total of five feedings).
Antibody titer: (60/263,668) At ten weeks of age, the
serum and fecal material are assayed for anti-CTB and antiproinsulin antibody isotypes using the ELISA method
described above.
Assessment of diabetic symptoms in NOD mice: (60/263,
668) The incidence of diabetic symptoms can be compared
among mice fed with control nicotine free edible tobacco that
expresses CTB and those that express the CTB-proinsulin
fusion protein. Starting at 10 weeks of age, the mice are
monitored on a biweekly basis with uninary glucose test
strips (Clinistix and Diastix, Bayer) for development of diabetes. Glycosuric mice are bled from the tail vein to check for
glycemia using a glucose analyzer (ACCU-Check, Boe-

hringer Mannheim). Diabetes is confirmed by hyper glycemia (>250 mg/di) for two consecutive weeks (Ma et al., 1997)
Human Serum Albumin
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HSA is a monomeric globular protein and consists of a
single, generally nonglycosylated, polypeptide chain of 585
amino acids (66.5 KDa and 17 disulfid bonds) with no posttranslational modifications. It is composed of three structurally similar globular domains and the disulfides are positioned in repeated searies of nine loop-link-loop structures
centered around eight sequential Cys-Cys pairs. HSA is initially synthesized as pre-pro-albumin by the liver and
released from endoplasmatic reticulum after removal of the
aminoterminal prepeptide of 18 amino acids. The pro-albumin is further processed in the Golgi complex where the other
6 aminoterminal residues of the proeptide are cleaved by a
serine proteinase (12). This results in the secretion ofthemature polypeptide of 585 amino acids. HAS is encoded by two
codominant autosomic allelic genes. HSA belongs to the
multigene family ofproteinase (12). This results in the secretion of the mature polypeptide of 585 amino acids. HSA is
encoded by two codominant autosomic allelic genes. HSA
belongs to the multigene family of proteins that include
alpha-fetoprotein and human group-specific component (Ge)
or vitamin D-binding family. HSA facilitates transfer of many
lgand across organ circulatory interfaces such as in the liver,
intestine, kidney and brain. In addition to blood plasma,
serum albumin is also found in tissues. HSA accounts for
about 60% of the total protein in blood serum. In the serum of
human adults, the concentration of labumin is 40 mg/ml.
Medical applications of HSA: The primary function of
HSA is the maintenance of colloid osmotic pressue (COP)
within the blood vessels. Its abundance makes it an important
determinant of the pharmacokinetic behavior of many drugs.
Reduced synthesis of HSA can be due to advanced liver
disease, impaired intestinal absorption of nutrients or poor
nutritional intake. Increased albumin losses can be due to
kidney diseases (increased glomerular permeability to macromolecules in the nephritic syndrome), intestinal diseases
(protein-losing enteropathies) or exudative skin disorders
(burns). Catabolic states such as chronic infections, sepsis,
surgery, intestinal resection, trauma or extensive bums can
also cause hypoalbuminemia. HSA is used in therapy of
blood volume disorders, for example posthaemorrhagic acute
hypovolaemia or extensive burns, treatment of dhydration
states, and also for cirrhotic and hepatic illnesses. It is also
used as an additive in perfusion liquid for extracorporeal
circulation. HSA is used clinically for replacing blood volume, but also has a variety of non-therapeutic uses, including
its role as a stabilizer in formulations for other therapeutic
proteins. HSA is a stabilizer ofr biological materials in nature
and is used for preparing biological standards and referenced
materials. Furthermore, HSA is frequently used as an experimental antigen, a cell-culture constituent and a standard in
clinical-chemistry tests.
Expression systems for HSA: The expression and purification of recombinant HSA from various microorganisms has
been reported previously (13-17). Saccharomyces cerevisiae
has been used to produce HSA both intracellularly, requiring
denaturation and refolding prior to analysis (18), and by
secretion (19). Secreted HSA was equivalent structurally, but
the recombinant product had lower levels of expression (recovery) and structural heterogeneity compared to the blood
derived protein (20). HSA was also expressed in Kluyveromyces lactis, a yeast with good secretary properties achieving
1 g/liter in fed batch cultures (21 ). Ohtani et al. (22) developed
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a HSA expression system using Pichia patoris and established a purification method obtaining recombinant protein
with similar levels of purity and properties as the human
protein. In Bacillus subtilis, HSA could be secreted using
baterial signal peptides (15). HSA production in E. coli was
successful but required additional in vitro processing with
trypsin to yield the mature protein (14). Sijmons et al. (23)
expressed HSA in transgenic potato and tobacco plants.
Fusion of HSA to the plant PR-S presequence resulted in
cleavage of the presequence at its natural site and secretion of
correctly processed HSA, that was indistinguishable form the
authentic human protein. The expression was 0.014% of the
total soluble protein. However, none of these methods have
been exploited commercially.
Challenges in commercial production ofHSA: Albumin is
currently obtained by protein fractionation from plasma and
is the world's most used intravenous protein, estimated at
around 500 metric tons per year. Albumin is administered by
intravenous injection of solutions containing 20% of albumin. The average dosage of albumin for each patient varies
between 20-40 grams/day. The consumption of albumin is
around 700 kilograms per million habitants per year. In addition to the high cost, HSA has the risk of transmitting disease
as with other blood-deriviative products. The price of alumin
is about $3.7/g. Thus, the market of this protein approximately amounts to $2,600,000 per million people per year
(0.7 billion dollars per year in USA). Because of the high cost
of albumin, synthetic macromolecules (like dextrans) are
used to increase plasma colloidosmotic pressure.
Commercial HSA is mainly prepared from human plasma.
This source, hardly meets the requirements of the world market. The availability of human plasma is limited and careful
heat treatment of the product prepared must be performed to
avoid potential contamination of the product hepatitis, HIV
and other viruses. The costs ofHSA extaction from blood are
very high. In order to meet the demands of the large albumin
market with a safe product at a low cost, innovative production systems are needed. Plant biotechnology offers promise
of obtaining safe and cheap proteins to be used to treat human
diseases.

IFN-a5 has, at least, the same antiviral activity as IFN-a2 and
in vitro experiments (unpublished data in Dr. Prieto's lab). It
has been shown recently that IFN-a5 is the sole IFN-a subtype expressed in normal liver tissue (34 ). IFN-a expression
in patients with chronic hepatitis C is reduced in the liver (34)
and induced in mononuclear cells (35).
Interferons are mainly known for their antiviral activities
against a wide spectrum of viruses but also for their protective
role against some non-viral pathogens. They are potent imunomodulators, possess direct antiproliferative activities and
are cytotoxic or cytostatic for a number of different tumour
cell types. IFN-a is mainly employed as a standard therapy
for hairy cell leukemia, metastasizing carcinoma and AIDSassociated angiogenic tumors of mixed cellularity known as
Kaposi sarcomas. It is also active against a number of other
tumours and viral infections. For example, it is the current
approved therapy for chronic viral hepatitis B (CHB) and C
(CHC). The IFN-a subtype used for chronic viral hepatitis is
IFN-a2. About 40% of patients with CHB and about 25% of
patients with CHC respond to this therapy with sustained viral
clearance. The usual doses ofIFN-a are 5-10 MU (subcutaneous injection) three days per week for CHB and 3 MU three
days per week for 12 months ofCHC. Three MU ofIFN-a2
represent approximately 15 µg of recombinant protein. The
response rate in patients with chronic hepatitis C can be
increased by combining IFN-a2 and ribavirin. This combination therapy, which considerably increases the cost of the
therapy and causes some additional side effects, results in
sustained biochemical and virological remission in about
40-50% of cases. Recent data suggest that pegilated interferon in weekly doses of 180 .mu.g can also increase the
sustained response rate to about 40%. IFN-a5 is the only
IFN-a subtype expressed in liver; this expression is reduced
in patients with CHC and IFN-a6 seems to have one of the
highest antiviral activity in liver tumour cells (see above). An
international patent to use IFN-a5 has been filed by Prieto's
group to facilitate commercial development (36).
Human interferons are currently prepared in microbial systems via recombinant DNA technology in amounts which
cannot be isolated from natural sources (leukocytes, fibroblasts, lymphocytes). Different recombinant interferon-a
genes have been cloned and expressed in E. coli (3 7 a, b) or
yeast (38) by several groups. Generally, the synthesized protein is not correctly folded due to the lack of disulfide bridges
and therefore, it remains insoluble in inclusion bodies that
need to be solubilized and refolded to obtain the active interferon (39, 40). One of the most efficient methods of interferon-a expression has been published recently by Babu et al.
(41 ). In this method, E. coli cells transformed with interferon
vectors (regulated by temperature inducible promoters) were
grown in high cell density cultures; this resulted in the production of 4 g interferon-a/liter of culture. Expression
resulted exclusively in the form of insoluble inclusion bodies
which were solubilized under denaturing conditions, refolded
and purified to near homogeneity. The yield of purified interferon-a was approximately 300 mg/I of culture. Expression in
plants via the nuclear genome has not been very successful.
Smirnov et al. (42) obtained transformed tobacco plants with
Agrobacterium tumefaciens using the interferon-.quadrature.gene under 35S CaMV promoter but the expression level
was very low. Eldelbaum et al. (43) showed tobacco nuclear
transformation with Interferon-.quadrature. and the expression level detected was 0.000017% of fresh weight.
The number of subjects infected with hepatitis C virus
(HCV) is estimated to be 120 million ( 5 million in Europe and
4 million in USA). Seventy per cent of the infected people
have abnormal liver function and about one third of these have

10

15

20

25

30

35

40

Interferon Alpha
Interferons (IFNs) constitute a heterogeneous family of
cytokines with antiviral, antigrowth, and immunomodulatory
properties (24-26). Type I IFNs are acid-stable and constitute
the first line of defense against viruses, both by displaying
direct antiviral effects and by interacting with the cytokine
cascade and the immune system. Their function is to induce
regulation of growth and differentiation ofT cells. The human
IFN-a family consists of at least 22 intronless genes, 9 of
which are pseudogenes and 13 expressed genes (subtypes)
(27). Human IFN-a genes encode proteins of 188 or 189
amino acids. The first 23 amino acids constitute a signal
peptide, and the other 165 or 166 amino acids form the mature
protein. IFN-a subtypes show 78-94% homology at the
nucleotide level. Presence of two disulfide bonds between
Cys-l:Cys-99 and Cys-29:Cys139 is conserved among all
IFN-a species (28). Human IFN-a genes are expressed constitutively in organs of normal individuals (29, 30). Individual
IFN-a genes are differently expressed depending on the
stimulus and they show restricted cell type expression (31 ).
Although all IFN-a subtypes bind to a common receptor (32),
several reports suggest that they show quantitatively distinct
patterns of antiviral, growth inhibitory and immunomodulatory activities (33). IFN-a8 and IFN-a5 seem to have the
greatest antiviral activity in liver tumour cells HuH7 (33).
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severe viral hepatitis or cirrhosis. It might be estimated however that there are about 10,000-15,000 cases of chronic
infection with hepatitis B virus (HBV) in Europe, a slightly
lower number of cases in USA. In Asia the prevalence of
chronic HCV and HBV infection is very high (about 110
million of people are infected by HCV and about 150 millions
are infected by HBV). In Africa HCV infection is very prevalent. Since unremitting chronic viral hepatitis leads to liver
cirrhosis and eventually to liver cancer, the high prevalence of
HBV and HCV infection in Asia and Africa accounts fortheir
very high incidence of hepatocellular carcinoma. Based on
these data, the need for IFN-a is large. IFN-a2 is currently
produced in microorganisms by a number of companies and
the price of 3 MU (15 .mu.g) of recombinant protein in the
western market is about $25. Thus, the cost of one year
IFN-a2 therapy is about$ 4,000 per patient. This price makes
this product unavailable for most of the patients in the world
suffering from chronic viral hepatitis. Clearly methods to
produce less expensive recombinant proteins via plant biotechnology innovations would be crucial to make antiviral
therapy widely available. Besides, ifIFN-a5 is more efficient
than IFN-a2, lower doses may be required.

physiological functions. Thus liver cirrhosis should be
viewed as a disease accompanied by a hormone deficiency
syndrome for which replacement therapy with IGF-I is warranted. Clinical studies are in progress to ascertain the role of
IGF-I in the management of cirrhotic patients. IGF-I is also
being currently used for Laron dwarfism treatment. These
patients lack liver GH receptor so IGF-I is not expressed (59).
Also IGF-I, acting as a hypoglycemiant, is given together
with insulin in diabetes mellitus (60, 61 ). Anabolic effects of
IGF-I are used in osteoporosis treatment (62, 63) hypercatabolism and starvation due to burning and HIV infection (64,
65). Unpublished studies indicate that IGF-I could also be
used in patients with articular degenerative disease (osteoarthritis).
The potency of IGF-I has encouraged a great number of
scientists to try IGF-I expression in various microorganisms
due to the small amount present in human plasma. Production
ofIGF-I in yeast was shown to have several disadvantages
like low fermentation yields and risks of obtaining undesirable glycosylation in these molecules (66). Expression in
bacteria has been the most successful approach, either as a
secreted form fused to protein leader sequences ( 67) or fused
to a solubilized affinity fusion protein (68). In addition, IGF-I
has been produced as insoluble inclusion bodies fused to
protective polypeptides (69). Sun-Ok Kim and Young Lee
(70a) expressed IGF-I as a truncated beta-galactosidase
fusion protein. The final purification yielded approximately 5
mg ofIGF-I having native conformation per liter of bacterial
culture. IGF-I has also been expressed in animals. Zinovieva
et al. (70b) reported an expression of 0.543 mg/ml in rabbit
milk.
IGF-I circulates in plasma in a fairly high concentration
varying between 120-400 ng/ml. In cirrhotic patients the values ofIGF-I fall to 20 ng/ml and frequently to undetectable
levels. Replacement therapy with IGF-I in liver cirrhosis
requires administration of 1.5-2 mg per day for each patient.
Thus, every cirrhotic patient will consume about 600 mg per
year. IGF-I is currently produced in bacteria (71). The high
amount of recombinant protein needed for IGF-I replacement
therapy in patients with liver cirrhosis will make this treatment exceedingly expensive if new methods for cheap production of recombinant proteins are not developed. Besides,
as described above, IGF-I is used in treatment of dwarfism,
diabetes, osteoporosis, starvation and hypercatabolism.
IGF-I use in osteoarthritis is currently being investigated.
Again, plant biotechnology could provide a solution to make
economically feasible the application ofIGF-I therapy to all
these patients.

10

15

20

Insulin-Like Growth Factor-I (IGF-I)
25

The Insulin-like Growth Factor protein, IGF-I, is an anabolic hormone with a complex maturation process. A single
IGF-I gene is transcribed into several mRNAs by alternative
splicing and use of different transcription initiation sites (4446). Depending on the choice of splicing, two immature proteins are produced: IGF-IA, expressed in several tissues and
IGF-IB, mostly expressed in liver (45). Both pre-proteins
produce the same mature protein. A and B immature forms
have different lengths and composition, as their termini are
modified post-translationally by glycosylation. However,
these ends are processed in the last step of maturation. Mature
IGF-I protein is secreted, not glycosylated and has three
disulfide bonds, 70 amino acids and a molecular weight of7 .6
kD (47-49). Physiologically, IGF-I expression is induced by
growth hormone (GH). Actually, the knock out of IGF-I in
mice has shown that several functions attributed originally to
GH are in fact mediated by IGF-I. GH production by adenohypofisis is repressed by feed-back inhibition ofIGF-I. GH
induces IGF-I synthesis in different tissues, but mostly in
liver, where 90% ofIGF-I is produced (48). The IGF-I receptor is expressed in different tissues. It is formed by two
polypeptides: alpha that interacts with IGF-I and beta
involved in signal transduction and also present in the insulin
receptor (50, 51). Thus, IGF-I and insulin activation are similar.
IGF-I is a potent multifunctional anabolic hormone produced in the liverupon stimulation by growth hormone (GH).
In liver cirrhosis the reduction of receptors for GH in hepatocytes and the diminished synthesis of the liver parenchyma
cause a progressive fall of serum IGF-I levels. Patients with
liver cirrhosis have a number of systemic derangements such
as muscle atrophy, osteopenia, hypogonadism, protein-calorie malnutrition which could be related to reduced levels of
circulating IGF-I. Recent studies from Prieto's laboratory
have demonstrated that treatments with low doses of IGF-I
induce significant improvements in nutritional status (52),
intestinal absorption (53-55), osteopenia (56), hypogonadism
(57) and liver function (58) in rats with experimental liver
cirrhosis. These data support that IGF-I deficiency plays a
pathogenic role in several systemic complications occurring
in liver cirrhosis. The liver can be considered as an endocrine
gland synthesising a hormone such as IGF-I with important
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SUMMARY OF THE INVENTION
The present invention develops recombinant DNA vectors
for enhanced expression of human serum albumin, insulinlike growth factor I, and interferon-a2 and 5, via chloroplast
genomes of tobacco, optimizes processing and purification of
pharmaceutical proteins using chloroplast vectors in E. coli,
and obtains transgenic tobacco plants.
The transgenic expression of proteins or fusion proteins is
characterized using molecular and biochemical methods in
chloroplasts.
Existing or modified methods of purification are employed
on transgenic leaves.
Mendelian or maternal inheritance of transgenic plants is
analyzed.
Large scale purification of therapeutic proteins from transgenic tobacco and comparison of current purification meth-
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ods in E. coli or yeast is performed, and natural refolding in
chloroplasts is compared with existing in vitro processing
methods;
Comparison/characterization (yield and purity) of therapeutic proteins produced in yeast or E. coli with transgenic
tobacco chloroplasts is performed, as are In vitro and in vivo
(pre-clinical trials) studies of protein biofunctionality.
The invention further provides transformed plants comprising a gene provided by an expression cassette, preferably
by a universal vector, which codes for a variety of desired
products, especially biologically active molecules like peptides (polypeptides), proteins, insulin, human serum albumin
(HSA) and other molecules further described hereinafter. The
plants are allowed or caused to grow, and the desired products
are isolated from the transformed crop, like tobacco, maize,
etc., and if desirable, harvested first and if necessary, purified.
Preferably, the expression cassette codes for Serum Human
Albumin (HSA) or a Serum Human Albumin (HSA) fusion
protein.
Typical pharmaceutical peptides or proteins produced in
transgenic plants include hepatitis B surface antigen, norwalk
virus capsid protein, foot-and-mouth disease virus, human
rhinovirus 14, human immunodeficiency virus, S. mutans
surface protein, E. coli enterotoxin, B subunit, malarial circumsporozoite epitopes, mouse ZP3 protein epitope (vaccine); mouse catalytic antibody 6D4, mouse mAB Guy's 13,
mAB Bl-8, anti-phytochrome Fv protein, anti-substance P
(antibody); human serum albumin (HSA), human protein C
(serum protein); a-trichosanthin, ricin (cytotoxin); human
epidermal growth factor (growth factor); leu-enkephalin
(neuropeptide) and human acid-glucosidase (hGC) (enzyme). Many of these molecules have been expressed in
tobacco, potato tubers, etc.
Of particular interest, in accordance with the present invention, is the production of human serum albumin (HSA) with
the universal integration and expression vector or with any
plastid expression vector. The HSA has already been produced in transgenic (nuclear) potato and tobacco plants. Sijmons et al, 1990. The aforementioned products can be produced via chloroplast transformation in accordance with the
present invention.
Recombinant Human Serum Albumin in Plants. In nuclear
transgenic tobacco and potato plants, recombinant human
serum albumin (rHSA) that is indistinguishable from the
authentic human protein has been produced (Sijmons et al.,
1990). This showed the expression of a valuable protein in
transgenic plants, but also that it was possible to achieve
proper processing by fusion ofHSA to a plant pro-sequence
that resulted in cleavage and secretion of the correct protein.
The chloroplast genome of a selected plant like tobacco can
be readily transformed with a universal vector as describedherein and made to express HSA.

accomplished in several phases. Transient expression of foreign genes in plastids of dicots (80, 81) was followed by such
studies in monocots (82). Unique to the chloroplast genetic
engineering is the development of a foreign gene expression
system using autonomously replicating chloroplast expression vectors (80). Stable integration of a selectable marker
gene into the tobacco chloroplast genome (83) was also
accomplished using the gene gun. However, useful genes
conferring valuable traits via chloroplast genetic engineering
have been demonstrated only recently. For example, plants
resistant to B.t. sensitive insects were obtained by integrating
the cryIAc gene into the tobacco chloroplast genome (84).
Plants resistant to B.t. resistant insects (up to 40,000 fold)
were obtained by hyper-expression of the cry2A gene within
the tobacco chloroplast genome (85). Plants have also been
genetically engineered via the chloroplast genome to confer
herbicide resistance and the introduced foreign genes were
maternally inherited, overcoming the problem of out-cross
with weeds (86). Chloroplast genetic engineering technology
is currently being applied to other useful crops (73, 87).
A remarkable feature of chloroplast genetic engineering is
the observation of exceptionally large accumulation of foreign proteins in transgenic plants, as much as 46% of CRY
protein in total soluble protein, even in bleached old leaves
(3). Stable expression of a pharmaceutical protein in chloroplasts was first reported for GVGVP (SEQ ID NO. 20), a
protein based polymer with varied medical applications (such
as the prevention of post-surgical adhesions and scars, wound
coverings, artificial pericardia, tissue reconstruction and programmed drug delivery (88)).
Engineering novel pathways via the chloroplast: In plant
and animal cells, nuclear mRNAs are translated monocistronically. This poses a serious problem when engineering
multiple genes in plants (91). Therefore, in order to express
the polyhydroxybutyrate polymer or Guy's 13 antibody,
single genes were first introduced into individual transgenic
plants, then these plants were back-crossed to reconstitute the
entire pathway or the complete protein (92, 93). Similarly, in
a seven year long effort, Ye et al. (81) recently introduced a set
of three genes for a short biosynthetic pathway that resulted
in .beta.carotene expression in rice. In contrast, most chloroplast genes of higher plants are cotranscribed (91 ). Expression of polycistrons via the chloroplast genome provides a
unique opportunity to express entire pathways in a single
transformation event. The Bacillus thuringiensis (Bt)
cry2Aa2 operon has recently been used as a model system to
demonstrate operon expression and crystal formation via the
chloroplast genome (3). Cry2Aa2 is the distal gene ofa threegene operon. The orf immediately upstream of cry2Aa2
codes for a putative chaperonin that facilitates the folding of
cry2Aa2 (and other proteins) to form proteolytically stable
cuboidal crystals (94).
Therefore, the cry2Aa2 bacterial operon was expressed in
tobacco chloroplasts to test the resultant transgenic plants for
increased expression and improved persistence of the accumulated insecticidal protein(s). Stable foreign gene integration was confirmed by PCR and Southern blot analysis in
T.sub.O and T.sub.1 transgenic plants. Cry2Aa2 operon
derived protein accumulated at 45.3% of the total soluble
protein in mature leaves and remained stable even in old
bleached leaves (46.1 % ) (FIG. 4). This is the highest level of
foreign gene expression ever reported in transgenic plants.
Exceedingly difficult to control insects (10-day old cotton
bollworm, beetarmy worm) were killed 100% after consuming transgenic leaves. Electron micrographs showed the presence of the insecticidal protein folded into cuboidal crystals
similar in shape to Cry2Aa2 crystals observed in Bacillus
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Chloroplast genetic engineering: When the concept of
chloroplast genetic engineering was developed (72, 73), it
was possible to introduce isolated intact chloroplasts into
protoplasts and regenerate transgenic plants (74). Therefore,
early investigations on chloroplast transformation focused on
the development of in organelle systems using intact chloroplasts capable of efficient and prolonged transcription and
translation (75-77) and expression of foreign genes in isolated chloroplasts (78). However, after the discovery of the
gene gun as a transformation device (79), it was possible to
transform plant chloroplasts without the use of isolated plastids and protoplasts. Chloroplast genetic engineering was
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thuringiensis (FIG. 5). In contrast to currently marketed
transgenic plants with soluble CRY proteins, folded protoxin
crystals will be processed only by target insects that have
alkaline gut pH; this approach should improve safety of Bt
transgenic plants. Absence of insecticidal proteins in transgenic pollen eliminates toxicity to non-target insects via pollen. In addition to these environmentally friendly approaches,
this observation should serve as a model system for largescale production of foreign proteins within chloroplasts in a
folded configuration enhancing their stability and facilitating
single step purification. This is the first demonstration of
expression of a bacterial operon in transgenic plants and
opens the door to engineer novel pathways in plants in a single
transformation event.
Engineering small peptides via the chloroplast genome: It
is common knowledge that the medical community has been
fighting a vigorous battle against drug resistant pathogenic
bacteria for years. Cationic antibacterial peptides from mammals, amphibians and insects have gained more attention over
the last decade (95). Key features of these cationic peptides
are a net positive charge, an affinity for negatively-charged
prokaryotic membrane phospholipids over neutral-charged
eukaryotic membranes and the ability to form aggregates that
disrupt the bacterial membrane (96).
There are three major peptides with a-helical structures,
cecropin fromHyalophora cecropia (giant silk moth), magainins from Xenopus laevis (African frog) and defensins from
mammalian neutrophils. Magainin and its analogues have
been studied as a broad-spectrum topical agent, a systemic
antibiotic; a wound-healing stimulant; and an anticancer
agent (97). We have recently observed that a synthetic lytic
peptide (MSI-99, 22 amino acids) can be successfully
expressed in tobacco chloroplast (98). The peptide retained
its lytic activity against the phytopathogenic bacteria
Pseudomonas syringae and multi drug resistant human pathogen, Pseudomonas aeruginosa. The anti-microbial peptide
(AMP) used in this study was an amphipathic alpha-helix
molecule that has an affinity for negatively charged phospholipids commonly found in the outer-membrane of bacteria.
Upon contact with these membranes, individual peptides
aggregate to form pores in the membrane, resulting in bacterial lysis. Because of the concentration dependent action of
the AMP, it was expressed via the chloroplast genome to
accomplish high dose delivery at the point of infection. PCR
products and Southern blots confirmed chloroplast integrati on of the foreign genes and homoplasmy. Growth and development of the transgenic plants was unaffected by hyperexpression of the AMP within chloroplasts. In vitro assays
with T.sub.O and T.sub.1 plants confirmed that the AMP was
expressed at high levels (21.5 to 43% of the total soluble
protein) and retained biological activity against Pseudomonas syringae, a major plant pathogen. In situ assays resulted
in intense areas of necrosis around the point of infection in
control leaves, while transformed leaves showed no signs of
necrosis (200-800 .mu.g ofAMP atthe site ofinfection) (FIG.
6). T.sub.1 in vitro assays against Pseudomonas aeruginosa
(a multi-drug resistant human pathogen) displayed a 96%
inhibition of growth (FIG. 7). These results give a new option
in the battle against phytopathogenic and drug-resistant
human pathogenic bacteria. Small peptides (like insulin) are
degraded in most organisms. However, stability of this AMP
in chloroplasts opens up this compartment for expression of
hormones and other small peptides.
Expression of cholera toxin .beta. subunit oligomers as a
vaccine in chloroplasts: Vibrio cholerae, which causes acute
watery diarrhea by colonizing the small intestine and producing the enterotoxin, cholera toxin (CT). Cholera toxin is a

hexamericAB.sub.5 protein consisting of one toxic 27 kDaA
subunit having ADP ribosyl transferase activity and a nontoxic pentamerofl 1.6 kDa B subunits (CTB) that binds to the
A subunit and facilitates its entry into the intestinal epithelial
cells. CTB when administered orally (99) is a potent mucosa!
immunogen which can neutralize the toxicity of the CT holotoxin by preventing it from binding to the intestinal cells
(100). This is believed to be a result ofit binding to eukaryotic
cell surfaces via the G.sub.Ml gangliosides, receptors present
on the intestinal epithelial surface, thus eliciting a mucosa!
immune response to pathogens (101) and enhancing the
immune response when chemically coupled to other antigens
(102-105).
Cholera toxin (CTB) has previously been expressed in
nuclear transgenic plants at levels of 0.01 (leaves) to 0.3%
(tubers) of the total soluble protein. To increase expression
levels, we engineered the chloroplast genome to express the
CTB gene (10). We observed expression of oligomeric CTB
at levels of 4-5% of total soluble plant protein (FIG. SA). PCR
and Southern Blot analyses confirmed stable integration of
the CTB gene into the chloroplast genome. Western blot
analysis showed that transgenic chloroplast expressed CTB
was antigenically identical to commercially available purified
CTB antigen (FIG. 9). Also, G.sub.Ml-ganglioside binding
assays confirm that chloroplast synthesized CTB binds to the
intestinal membrane receptor of cholera toxin (FIG. SB).
Transgenic tobacco plants were morphologically indistinguishable from untransformed plants and the introduced gene
was found to be stably inherited in the subsequent generation
as confirmed by PCR and Southern Blot analyses. The
increased production of an efficient transmucosal carrier molecule and delivery system, like CTB, in chloroplasts of plants
makes plant based oral vaccines and fusion proteins with
CTB needing oral administration, a much more feasible
approach. This also establishes unequivocally that chloroplasts are capable of forming disulfide bridges to assemble
foreign proteins.
Expression and Assembly of Monoclonals in Transgenic
Chloroplasts: Dental caries (cavities) is probably the most
prevalent disease of humankind. Colonization of teeth by S.
mutants is the single most important risk factor in the development of dental caries. S. mutants is a non-motile, gram
positive coccus. It colonizes tooth surfaces and synthesizes
glucans (insoluble polysaccharide) and fructans from sucrose
using the enzymes glucosyltransferase and fructosyltransferase respectively (106a ). The glucans play an important role
by allowing the bacterium to adhere to the smooth tooth
surfaces. After its adherence, the bacterium ferments sucrose
and produces lactic acid. Lactic acid dissolves the minerals of
the tooth, producing a cavity.
A topical monoclonal antibody therapy to prevent adherence of S. mutans to teeth has recently been developed. The
incidence of cariogenic bacteria (in humans and animals) and
dental caries (in animals) was dramatically reduced for periods of up to two years after the cessation of the antibody
therapy. No adverse events were detected either in the
exposed animals or in human volunteers (106b ). The annual
requirement for this antibody in the US alone may eventually
exceed 1 metric ton. Therefore, this antibody was expressed
via the chloroplast genome to achieve higher levels of expression and proper folding (11 ). The integration of antibody
genes into the chloroplast genome was confirmed by PCR and
Southern blot analysis. The expression of both heavy and
light chains was confirmed by western blot analysis under
reducing conditions (FIG. lOA,B). The expression of fully
assembled antibody was confirmed by western blot analysis
under non-reducing conditions (FIG. lOC). This is the first
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report of successful assembly of a multi-subunit human protein in transgenic chloroplasts. Production of monoclonal
antibodies at agricultural level should reduce their cost and
create new applications of monoclonal antibodies.

BtORF1+2-ATG-HSA: ORF 1 and ORF2 of the Bt
Cry2Aa2 operon were amplified in a PCR using the complete
operon as a template. The fragment was cloned into PCR 2.1
vector, excised as an EcoRI-EcoRV fragment, inserted at
EcoRV site with theATG-HSA sequence and introduced into
the pLD vector as an EcoRI-NotI fragment. The ORF! and
ORF2 were fused upstream of the ATG-HSA. (Update
"Human Therapeutic Proteins") This introduced the putative
chaperonin (ORF2) of the B.t. cry2Aa2 operon upstream of
the HSA gene, which has been shown to fould foreign proteins and form crystals, aiding in protein stability and purification.
BtORF1+2-5'UTRpsbA-ATG-HSA: The 5'UTRpsbA was
introduced in the above vector upstream of the HSA at the
EcoRV-Ncol site.
Because of the similarity of protein synthetic machinery
(109), expression of all chloroplast vectors was first tested in
E. coli before their use in tobacco transformation. Different
levels of expression were obtained inE. coli depending on the
construct (FIG. 18). Using the psbA 5' UTR and the ORF!
and ORF2 of the cry2Aa2 operon, we obtained higher levels
of expression than using only the RBS. We have observed in
previous experiments that HSA in E. coli is completely
insoluble (as is shown in ref14), probably due to an improper
folding resulting from the absence of disulfide bonds. This is
the reason why the protein is precipitated in the gel (FIG. 18).
Different polypeptide sizes were observed, probably due to
incomplete translation. Assuming that E. coli and chloroplast
have similar protein synthesis machinery, one could expect
different levels of expression in transgenic tobacco chloroplasts depending on the regulatory sequences, with the advantage that disulfide bonds are formed in chloroplasts (9). These
three vectors were bombarded into tobacco leaves via particle
bombardment (10) and after 4 weeks small shoots appeared
as a result of independent transformation events. They all
were tested by PCR to check integration in the chloroplast
genome as shown in FIGS. lOA and B. The positive clones
were transferred to pots. Transgenic leaves analyzed by westem blots showed different levels of expression depending on
the 5' region used in the transformation vector. Maximum
levels were observed in the plants transformed with the HSA
preceded by the 5' UTR of the psbA gene. Quantification of
the HSA and molecular analysis of these transformants are in
progress. (Update "Human Therapeutic Proteins") All chloroplast vectors were bombarded into tobacco leaves via particle bombardment and after 4 weeks shoots appeared as a
result of independent transformation events. All shoots were
tested by PCR to verify integration into the chloroplast
genome. The positive clones were passed through a second
round of selection to achieve homoplasmy and transferred to
pots. The phenotype of these plants was completely normal.
Transgenic leaves analyzed by western blots showed consistently the same pattern of expression depending on the 5'
region used in the transformation vector (see FIG. 19). Maximum levels of expression were observed in the plants transformed with the HSA preceded by the psbA 5' UTR and
promoter. Molecular characterization of the first generation is
in progress. Southern blots of several clones showed
homoplasmy in all transgenic lines except one (see clone #6,
FIG. SA). Northern blots showed different length of transcripts depending on the 5' regulatory region that was inserted
upstream of the HSA gene (see FIG. 25). The most abundant
transcript was the monocistron in plants with the 5'psbA
promoter up stream of the HSA gene. Polycistrons of different
length were observed based on the number of promoters used
in each construct and differential processing.

5

Human Serum Albumin
Nuclear Transformation: The human HSA CDNA was
cloned from human liver cells and the patatin promoter
(whose expression is tuber specific (107)) fused along with
the leader sequence of PIN II (proteinase II inhibitor potato
transit peptide that directs HSA to the apoplast (108)). Leaf
discs of Desiree and Kennebec potato plants were transformed using Agro bacterium tumefaciens. A total of98 transgenic Desiree clones and 30 Kennebec clones were tested by
PCR and western blots. Western blots showed that the recombinant albumin (rHSA) had been properly cleaved by the
proteinase 11 inhibitor transit peptide (FIG. 16). Expression
levels of both cultivars were very different among all transgenic clones as expected (FIG. 17), probably because of
position effects and gene silencing (89,90). The population
distribution was similar in both cultivars: majority of transgenic clones showed expression levels between 0.04 and
0.06% of rHSA in the total soluble protein. The maximum
recombinant HSA amount expressed was 0.2%. Between one
and five T-DNA insertions per tetraploid genome were
observed in these clones. Plants with higher protein expression were always clones with several copies of the HSA gene.
Levels of mRNA were analyzed by Northern blots. There was
a correlation between transcript levels and recombinant albumin accumulation in transgenic tubers. The N-terminal
sequence showed proper cleavage of the transit peptide and
the amino terminal sequence between recombinant and
human HSA was identical. Inhibition of patatin expression
using the antisense technology did not improve the amount of
rHSA. Average expression level among 29 transgenic plants
was 0.032% of total soluble protein, with a maximum expression of0.1 %.
Transformation of the tobacco chloroplast genome was
initiated for hyperexpression of HSA. The codon composition is ideal for chloroplast expression and no changes in
nucleotide sequences were necessary. For all the constructs
pLD vector was used. Several vectors were designed to optimize HSA expression. All these contained ATG as the first
amino acid of the mature protein.
RBS-ATG-HSA The first vector included the gene that
codes for the mature HSA plus an additional ATG as a translation initiation codon. We included the ATG in one of the
primers of the PCR, 5 nucleotides downstream of the chloroplast preferred RBS sequence GGAGG. The cDNA sequence
of the mature HSA (cloned in Dr. Mingo-Castel' s laboratory)
was used as a template. The PCR product was cloned into
PCR2.1 vector, excised as anEcoRI-NotI fragment and introduced into the pLD vector. (Update "Human Therapeutic
Proteins") The vector includes the chloroplast preferred
Ribosome Binding Site (RBS) sequence GGAGG.
5'UTRpsbA-ATG-HSA: The 200 bp tobacco chloroplast
DNA fragment containing the 5' psbA UTR was amplified
using PCR and tobacco DNA as template. The fragment was
cloned into PCR 2.1 vector, excised EcoRI-Ncol fragment
was inserted at the Neal site of the ATG-HSA and finally
inserted into the pLD vector as an EcoRI-NotI fragment
downstream of the 16S rRNA promoter to enhance translation of the protein. (Update "Human Therapeutic Proteins")
HSA was cloned downstream of the psbA 5' UTR including
the promoter and untranslated region, which has been shown
to enhance translation.
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We have observed different levels of HSA m ELISA
depending on the extraction buffer used and further optimization of this procedure is in progress. With incomplete
extraction procedures, the highest HSA level of expression in
plants transformed with pLD-S'psbA-HSA was up to 11.1 %
of total soluble protein; this is more than 100 fold the expression observed with other two constructs (see FIG. 26).
Because we have routinely observed high levels of foreign
gene expression with other two vectors, we anticipate that the
actual level of HSA expression in pLD-S'psbA-HSA may
exceed SO% of total soluble protein. Since the expression of
HSA under the S'psbA control is light dependent, the time of
the tissue harvest for expression studies is important. Such
changes in HSA accumulation are currently being investigated using ELISA and Northerns.
Characterization of HSA from transgenic chloroplasts for
proper folding, disulfide bond formation and functionality is
in progress. The stromal pH within chloroplasts and the presence of both thioredoxin and disulfide isomerase systems
provide optimal conditions for proper folding and disulfide
bond formation within folded HSA.

To demonstrate expression, purification and proper cleavage of the fusion protein we also cloned the full length IGF-I
(including the pre-sequence) in an alphavirus vector and
expressed the protein in human cultured cells. Alphavirus
system has been used because it expresses adequate amounts
of protein to induce a very good immune response in test
animals. We observed that the protein had the predicted size,
is properly cleaved in cells to produce the mature protein and
is exported into the growth medium. This secreted protein
could be immunoprecipitated using anti-IGF-I antibody. The
zz-tev-IGF-I was also cloned in an alphavirus vector,
expressed and labeled in human cultured cells. This has
allowed us to see that the protein had the predicted size and as
expected, is not secreted. To cleave zz tag after purification
from chloroplasts, TEV protease is necessary. Therefore, we
have expressed and purified TEV protease in bacteria. After
purification we could obtain approximately O.S mg. This TEV
protease cleaved the labeled zz-tev-IGF-I producing two
fragments, zz-tev and mature IGF -I. We are currently labeling
more fusion protein to optimize conditions for TEV cleavage.
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Interferon-as
EXPERIMENTAL
Interferon-as has not been expressed yet as a commercial
recombinant protein. The first attempt has been made
recently. The IFN-aS gene was cloned and the sequence of the
mature protein was inserted into the pET28 vector, that
included the ATG, histidine tag for purification and thrombin
cleavage sequences. The tagged IFN-aS was purified first by
binding to a nickel column and biotinylated thrombin was
then used to eliminate the tag on IFN-aS. Biotinylated thrombin was removed from the preparation using streptavidin
agarose. The expression level was S .6 micrograms per liter of
broth culture and the recombinant protein was active in antiviral activity similar or higher than commercial IFN-a2 (IntronA, Schering Plouth).
(Update "Human Therapeutic Proteins") As proposed, we
have cloned human IFNaS, fused with a Histidine tag and
introduced the gene into the chloroplast transformation vector (pLD). Western blots demonstrated expression of the
IFNaS protein in E. coli using pLD vectors, and the maximum level was observed with the S'psbA UTR and promoter.
IFNaS gene was cloned into the pLD using both sequences
and bombarded into tobacco leaves. Shoots appeared after S
weeks and the second round of selection is in progress.
Insulin-Like Growth Factor-I (IGF-I) Recent studies have
demonstrated that treatment with low doses ofIGF-I induced
significant improvements in nutritional status (S2), intestinal
absorption (S3-SS), osteopenia (S6), hypogonadism (S7) and
liver function (SS) in rats with experimental liver cirrhosis.
These data support that IGF-I deficiency plays a pathogenic
role in several systemic complications occurring in liver cirrhosis. Clinical studies are in progress to ascertain the role of
IGF-I in the management of cirrhotic patients. Unpublished
studies indicate that IGF-I could also be used in patients with
articular degenerative disease (osteoarthritis).
(Update "Human Therapeutic Proteins") From previous
studies we observed that IGF-I gene coding sequence is not
suitable for high levels of expression in chloroplasts. Therefore, we have determined the optimal chloroplast sequence
and employed a recursive PCR method for total gene synthesis (see FIG. 27). The newly synthesized gene was cloned into
a PCR 2.1 vector. Insertion of zz-tev sequence upstream of
IGFl coding sequence for facilitating subsequent purification
is in progress.
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Evaluation of Chloroplast Gene Expression: A systematic
approach is used to identify and overcome potential limitations of foreign gene expression in chloroplasts of transgenic
plants. This experiment increases the utility of chloroplast
transformation system by scientists interested in expressing
other foreign proteins. Therefore, it is important to systematically analyze transcription, RNA abundance, RNA stability, rate of protein synthesis and degradation, proper folding
and biological activity. The rate of transcription of the introduced HSA gene is compared with the highly expressing
endogenous chloroplast genes (rbcL, psbA, 16S rRNA),
using run on transcription assays to determine if the
16SrRNA promoter is operating as expected. The transcription efficiency of transgenic chloroplast containing each of
the three constructs with different S' regions is tested. Similarly, transgene RNA levels are monitored by northerns, dot
blots and primer extension relative to endogenous rbcL, 16S
rRNA or psbA. These results, along with run on transcription
assays, provide valuable information of RNA stability, processing, etc. RNA appears to be extremely stable based on
northern blot analysis. This systematic study is valuable to
advance utility of this system by other scientists. Most importantly, the efficiency of translation is tested in isolated chloroplasts and compared with the highly translated chloroplast
protein (psbA). Pulse chase experiments help assess iftranslational pausing, premature termination occurs. Evaluation of
percent RNA loaded on polysomes or in constructs with or
without S'UTRs helps to determine the efficiency of the ribosome binding site and S' stem-loop translational enhancers.
Codon optimized genes (IGF-I, IFN) are compared with
unmodified genes to investigate the rate of translation, pausing and termination. A 200-fold difference in accumulation of
foreign proteins due to decreases in proteolysis conferred by
a putative chaperonin (3) was observed. Therefore, proteins
from constructs expressing or not expressing the putative
chaperonin (with or without ORF! +2) provide valuable information on protein stability.
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Example 2

have been investigated for this purpose (120). Chemical
cleavage methods have low specificity and the relatively
harsh cleavage conditions can result in chemical modifications of the released products (120). Some of the enzymatic
methods offer significantly higher cleavage specificities
together with high efficiency, e.g. H64A subtilisin, IgA protease and factor Xa (119,120), but these enzymes have the
drawback of being quite expensive.
Trypsin, which cleaves C-terminal of basic amino-acid
residues, has been used for a long time to cleave fusion
proteins (14,121). Despite expected low specificity, trypsin
has been shown to be useful for specific cleavage of fusion
proteins, leaving basic residues within folded protein
domains uncleavaged (121). The use of trypsin only requires
that the N-terminus of the mature protein be accessible to the
protease and that the potential internal sites are protected in
the native conformation. Trypsin has the additional advantage
of being inexpensive and readily available. In the case of
HSA, when it was expressed in E. coli with 6 additional
codons coding for a trypsin cleavage site, HSA was processed
successfully into the mature protein after treatment with the
protease. In addition, the N-terminal sequence was found to
be unique and identical to the sequence of natural HSA, the
conversion was complete and no degradation products were
observed (14). This in vitro maturation is selective because
correctly folded albumin is highly resistant to trypsin cleavage at inner sites (14). This system could be tested for chloroplasts HSA vectors using protein expressed in E. coli.
Staub et al. (9) demonstrated that the chloroplast methionine aminopeptidase is active and they found 95% of removal
of the first methionine of an ATG-somatotropin protein that
was expressed via the chloroplast genome. There are several
investigations that have shown a very strict pattern of cleavage by this peptidase (122). Methionine is only removed
when second residues are glycine, alanine, serine, cysteine,
threonine, praline or valine, but if the third amino acid is
pro line the cleavage is inhibited. In the expression of our three
proteins we use this approach to obtain the mature protein in
the case of Interferon because the penultimate aminoacid is
cystein followed by aspartic acid. For HSA the second aminoacid is aspartic acidandforIGF-I glycine but it is followed
by praline, so the cleavage is not dependable.
For IGF-I expression, the use of the TEV protease (Gibco
cat n 10127-017) would be ideal. The cleavage site that is
recognized for this protease is Glu-Asn-Leu-Tyr-Phe-GlnGly (SEQ ID NO. 10) and it cuts between Gln-Gly. This
strategy allows the release of the mature protein by incubation
with TEV protease leaving a glycine as the first amino acid
consistent with human mature IGF-I protein.
The purification system of the E. coli Interferon-.alpha.5
expression method was based on 6 Histidine-tags that bind to
a nickel colunm and biotinylated thrombin to eliminate the
tag on IFN-a5. Thrombin recognizes Leu-Val-Pro-Arg-GlySer (SEQ ID NO. 11) and cuts between Arg and Gly. This
leaves two extra amino acids in the mature protein, but antiviral activity studies have shown that this protein is at least as
active as commercial IFN-a2.

Expression of the Mature Protein
HSA, Interferon and IGF-I are pre-proteins that need to be
cleaved to secrete mature proteins. The codon for translation
initiation is in the presequence. In chloroplasts, the necessity
of expressing the mature protein forces introduction of this
additional amino acid in coding sequences. In order to optimize expression levels, we first subclone the sequence of the
mature proteins beginning with an ATG. Subsequent immunological assays in mice demonstrates the extra-methionine
causes immunogenic response and low bioactivity. Alternatively, systems may also produce the mature protein. These
systems can include the synthesis of a protein fused to a
peptide that is cleaved intracellularly (processed) by chloroplast enzymes or the use of chemical or enzymatic cleavage
after partial purification of proteins from plant cells.
Use of Peptides that are Cleaved in Chloroplast: Staub et al.
(9) reported chloroplast expression of human somatotropin
similar to the native human protein by using ubiquitin fusions
that were cleaved in the stroma by an ubiquitin protease.
However, the processing efficiency ranged from 30-80% and
the cleavage site was not accurate. In order to process chloroplast expressed proteins a peptide which is cleaved in the
stroma is essential. The transit peptide sequence of the
RuBisCo (ribulose 1,5-bisphosphate carboxylase) small subunit is an ideal choice. This transit peptide has been studied in
depth (111 ). RuBisCo is one of the proteins that is synthesized in cytoplasm and transported postranslationally into the
chloroplast in an energy dependent process. The transit peptide is proteolytically removed upon transport in the stroma
by the stromal processing peptidase (112). There are several
sequences described for different species (113). A transit
peptide consensus sequence for the RuBisCo small subunit of
vascular plants is published by Keegstra et al. (114). The
amino acids that are proximal to the C-terminal (41-59) are
highly conserved in the higher plant transit sequences and
belong to the domain which is involved in enzymatic cleavage
(111 ). The RuBisCo small subunit transit peptide has been
fused with various marker proteins (114, 115), even with animal proteins (116, 117), to target proteins to the chloroplast.
Prior to transformation studies, the cleavage efficiency and
accuracy are tested by in vitro translation of the fusion proteins and in organello import studies using intact chloroplasts.
Thereafter, knowing the correct fusion sequence for producing the mature protein, such sequence encoding the amino
terminal portion of tobacco chloroplast transit peptide is
linked with the mature sequence of each protein. Codon composition of the tobacco RuBisCo small subunit transit peptide
is compatible with chloroplast optimal translation (see section d3 and table 1 on page 30). Additional transit peptide
sequences for targeting and cleavage in the chloroplast have
been described (111). The lumen ofthylakoids could also be
a good target because thylakoids are readily purified. Lumenal proteins can be freed either by sonication or with a very
low triton XlOO concentration, although this requires insertion of additional amino acid sequences for efficient import
(111 ).
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Example 3
Use of Chemical or Enzymatic Cleavage: The strategy of
fusing a protein to a tag with affinity for a certain ligand has
been used extensively for more than a decade to enable affinity purification of recombinant products (118-120). A vast
number of cleavage methods, both chemical and enzymatic,

65

Optimization of Gene Expression: Foreign genes are
expressed between 3% (cry2Aa2) and 47% (cry2Aa2
operon) in transgenic chloroplasts (3,85). Based on the outcome of the evaluation ofHSA chloroplast transgenic plants,
several approaches can be used to enhance translation of the
recombinant proteins. In chloroplasts, transcriptional regulation of gene expression is less important, although some
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modulations by light and developmental conditions are
observed (123). RNA stability appears to be one among the
least problems because of observation of excessive accumulation of foreign transcripts, at times 16,966-fold higher than
the highly expressing nuclear transgenic plants (124). Chloroplast gene expression is regulated to a large extent at the
post-transcriptional level. For example, 5' UTRs are necessary for optimal translation of chloroplast mRNAs. ShineDalgarno (GGAGG) sequences, as well as a stem-loop structure located 5' adjacent to the SD sequence, are required for
efficient translation. A recent study has shown that insertion
of the psbA 5' UTR downstream of the 16S rRNA promoter
enhanced translation of a foreign gene (GUS) hundred-fold
(125a). Therefore, the 200-bp tobacco chloroplast DNA fragment (1680-1480) containing 5' psbA UTR should be used.
This PCR product is inserted downstream of the 16S rRNA
promoter to enhance translation of the recombinant proteins.
Yet another approach for enhancement of translation is to
optimize codon compositions. Since all the three proteins are
translated in E. coli (see section b ), it would be reasonable to
expect efficient expression in chloroplasts. However, optimizing codon compositions to match the psbA gene could
further enhance the level of translation. Although rbcL
(RuBisCO) is the most abundant protein on earth, it is not
translated as highly as the psbA gene due to the extremely
high turnover of the psbA gene product. The psbA gene is
under stronger selection for increased translation efficiency
and is the most abundant thylakoid protein. In addition, the
codon usage in higher plant chloroplasts is biased towards the
NNC codon of 2-fold degenerate groups (i.e. TTC over TTT,
GAC over GAT, CAC over CAT, AAC over AAT, ATC over
ATT, ATA etc.). This is in addition to a strong bias towards T
at third position of 4-fold degenerate groups. There is also a
context effect that should be taken into consideration while
modifying specific codons. The 2-fold degenerate sites
immediately upstream from a GNN codon do not show this
bias towards NNC. (TTT GGA is preferred to TTC GGA
while TTC CGT is preferred to TTT CGT, TTC AGT to TTT
AGT and TTC TCT to TTT TCT)(125b,126). In addition,
highly expressed chloroplast genes use GNN more frequently
that other genes. Codon composition was optimized by comparing different species. Abundance of amino acids in chloroplasts and tRNA anticodons present in chloroplast must be
taken into consideration. We also comparedA+ T % content of
all foreign genes that had been expressed in transgenic chloroplasts in our laboratory with the percentage of chloroplast
expression. We found that higher levels of A+ T always correlated with high expression levels (see table 1). It is also
possible to modify chloroplast protease recognition sites
while modifying codons, without affecting their biological
functions.
The study of the sequences of HSA, IGF-I and Interferon-.quadrature.5 was done. The HSA sequence showed
57% of A+ T content and 40% of the total codons matched
with the psbA most translated codons. According to the data
of table 1, we expected good chloroplast expression of the
HSA gene without any modifications in its codon composition. IFN-.quadrature.5 has 54% of A+ T content and 40% of
matching with psbA codons. The composition seems to be
good but this protein is small (166 amino acids) and the
sequence was optimized to achieve A+ T levels close to 65%.
Finally, the analysis of the IGF-I sequence showed that the
A+ T content was 40% and only 20% of the codons are the
most translated in psbA. Therefore, this gene needed to be
optimized. Optimization of these two genes is done using a
novel PCR approach (127,128) which has been successfully
used to optimize codon composition of other human proteins.

Example 5
Vector Constructions
5
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For all the constructs pLD vector is used. This vector was
developed in this laboratory for chloroplast transformation. It
contains the 16S rRNA promoter (Prrn) driving the selectable
marker gene aadA (aminoglycoside adenyl transferase conferring resistance to spectinomycin) followed by the psbA 3'
region (the terminator from a gene coding for photo system II
reaction center components) from the tobacco chloroplast
genome. The pLD vector is a universal chloroplast expression/integration vector and can be used to transform chloroplast genomes of several other plant species (73,86) because
these flanking sequences are highly conserved among higher
plants. The universal vector uses trnA and trnl genes (chloroplast transfer RNAs coding for Alanine and Isoleucine)
from the inverted repeat region of the tobacco chloroplast
genome as flanking sequences for homologous recombination. Because the universal vector integrates foreign genes
within the Inverted Repeat region of the chloroplast genome,
it should double the copy number of the trans gene (from 5000
to 10,000 copies per cell in tobacco). Furthermore, it has been
demonstrated that homoplasmy is achieved even in the first
round of selection in tobacco probably because of the presence of a chloroplast origin of replication within the flanking
sequence in the universal vector (thereby providing more
templates for integration). Because of these and several other
reasons, foreign gene expression was shown to be much
higher when the universal vector was used instead of the
tobacco specific vector (88).
The following vectors are used to optimize protein expression, purification and production of proteins with the same
amino acid composition as in human proteins.
a) In order to optimize expression, translation is increased
using the psbA 5'UTR and optimizing the codon composition for protein expression in chloroplasts according
to criteria discussed previously. The 200 bp tobacco
chloroplast DNA fragment containing 5' psbA UTR is
amplified by PCR using tobacco chloroplast DNA as
template. This fragment is cloned directly in the pLD
vector multiple cloning site (EcoRI-NcoI) downstream
of the promoter and the aadA gene. The cloned sequence
is exactly the same as in the psbA gene.
b) For enhancing protein stability and facilitating purification, the cry2Aa2 Bacillus thuringiensis operon derived
putative chaperonin is used. Expression of the cry2Aa2
operon in chloroplasts provides a model system for
hyper-expression of foreign proteins (46% of total
soluble protein) in a folded configuration enhancing
their stability and facilitating purification (3). This justifies inclusion of the putative chaperonin from the
cry2Aa2 operon in one of the newly designed constructs.
In this region there are two open reading frames (ORF!
and ORF2) and a ribosomal binding site (rbs). This
sequence contains elements necessary for Cry2Aa2
crystallization which help to crystallize the HSA, IFG-I
and IFN-a proteins aiding in the subsequent purification. Successful crystallization of other proteins using
this putative chaperoninhas been demonstrated (94). We
amplify the ORF! and ORF2 of the Bt Cry2Aa2 operon
by PCR using the complete operon as template. The
fragment is cloned into a PCR 2.1 vector and excised as
an EcoRI-EcoRV product. This fragment is then cloned
directly into the pLD vector multiple cloning site
(EcoRI-EcoRV) downstream of the promoter and the
aadAgene.
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c) To obtain proteins with the same amino acid composition as mature human proteins, we first fuse all three
genes (codon optimized and native sequence) with the
RuBisCo small subunit transit peptide. Also other constructions are done to allow cleavage of the protein after
isolation from chloroplast. These strategies also allow
affinity purification of the proteins.
The first set of constructs includes the sequence of each
protein beginning with an ATG, introduced by PCR using
primers. Processing to get the mature protein may be performed where the ATG is shown to be a problem (determined
by mice immunological assays). First, we use the RuBisCo
small subunit transit peptide. This transit peptide is amplified
by PCR using tobacco DNA as template and cloned into the
PCR 2.1 vector. All genes are fused with the transit peptide
using a Mlul restriction site that is introduced in the PCR
primers for amplification of the transit peptide and genes
coding for three proteins. The gene fusions are inserted into
the pLD vectors downstream of the 5'UTR or ORF1+2 using
the restriction sites Neal and EcoRV respectively. If use of
tags or protease sequences is necessary, such sequences can
be introduced by designing primers including these
sequences and amplifying the gene with PCR. After completing vector constructions, all the vectors are sequenced to
confirm correct nucleotide sequence and in frame fusion.
DNA sequencing is done using a Perkin Elmer ABI prism 3 73
DNA sequencing system.
Because of the similarity of protein synthetic machinery
(109), expression ofall chloroplast vectors is first tested inE.
coli before their use in tobacco transformation. For Escherichia coli expression XL-1 Blue strain is used. E. coli can be
transformed by standard CaC1 2 transformation procedures
and grown in TB culture media. Purification, biological and
immunogenic assays are done using E. coli expressed proteins.

1 mg/liter and spectinomycin dihydrochloride, 500 mg/liter).
Rooted plants are transferred to soil and grown at 26° C. under
16 hour photoperiod conditions for further analysis.

10

15

20

25

30

35

Example 6
Bombardment, Regeneration and Characterization of
Chloroplast Transgenic Plants
Tobacco (Nicotiana tabacum var. Petit Havana) plants are
grown aseptically by germination of seeds on MSO medium.
This medium contains MS salts (4.3 g/liter), BS vitamin mixture (myo-inositol, 100 mg/liter; thiamine-RC!, 10 mg/liter;
nicotinic acid, 1 mg/liter; pyridoxine-HCl, 1 mg/liter),
sucrose (30 g/liter) and phytagar (6 g/liter) at pH 5.8. Fully
expanded, dark green leaves of about two month old plants
are used for bombardment.
Leaves are placed abaxial side up on a Whatman No. 1 filter
paper laying on the RMOP medium (79) in standard petri
plates (1OOxl5 mm) for bombardment. Gold (0.6 µm) microprojectiles are coated with plasmid DNA (chloroplast vectors) and bombardments are carried out with the biolistic
device PDS 1000/He (Bio-Rad) as described by Daniell (110).
Following bombardment, petri plates are sealed with parafilm
and incubated at 24° C. under 12 h photoperiod. Two days
after bombardment, leaves are chopped into small pieces of
-5 mm 2 in size and placed on the selection medium (RMOP
containing 500 µg/ml of spectinomycin dihydrochloride)
with abaxial side touching the medium in deep (100x25 mm)
petri plates (-10 pieces per plate). The regenerated spectinomycin resistant shoots are chopped into small pieces (-2
mm2 ) and subcloned into fresh deep petri plates (-5 pieces
per plate) containing the same selection medium. Resistant
shoots from the second culture cycle are then transferred to
the rooting medium (MSO medium supplemented with IBA,
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PCR Analysis of Putative Transformants
PCR is done using DNA isolated from control and transgenic plants in order to distinguish a) true chloroplast transformants from mutants and b) chloroplast transformants from
nuclear transformants. Primers for testing the presence of the
aadA gene (that confers spectinomycin resistance) in transgenic plants are landed on the aadA coding sequence and 16S
rRNA gene. In order to test chloroplast integration of the
genes, one primer lands on the aadA gene while another lands
on the native chloroplast genome. No PCR product is
obtained with nuclear transgenic plants using this set of primers. The primer set is used to test integration of the entire gene
cassette without any internal deletion or looping out during
homologous recombination. Similar strategy was used successfully to confirm chloroplast integration of foreign genes
(3,85-88). This screening is essential to eliminate mutants
and nuclear transformants. In order to conduct PCR analyses
in transgenic plants, total DNA from unbombarded and transgenic plants is isolated as described by Edwards et al. (129).
Chloroplast transgenic plants containing the desired gene are
then moved to second round of selection in order to achieve
homoplasmy.
Southern Analysis for Homoplasmy and Copy Number
Southern blots are done to determine the copy number of
the introduced foreign gene per cell as well as to test
homoplasmy. There are several thousand copies of the chloroplast genome present in each plant cell. Therefore, when
foreign genes are inserted into the chloroplast genome, some
of the chloroplast genomes have foreign genes integrated
while others remain as the wild type (heteroplasmy). Therefore, in order to ensure that only the transformed genome
exists in cells of transgenic plants (homoplasmy), the selection process is continued. In order to confirm that the wild
type genome does not exist at the end of the selection process
is continued. In order to confirm that the wild type genome
does not exist at the end of the selection cycle, total DNA from
transgenic plants are probed with the chloroplast border
(flanking) sequences (the trnI-trnA fragment). When wild
type genomes are present (heteroplasmy), the native fragment
size is observed along with transformed genomes. Presence
of a large fragment (due to insertion of foreign genes within
the flanking sequences) and absence of the native small fragment confirms homoplasmy (85,86,88).
The copy number of the integrated gene is determined by
establishing homoplasmy for the transgenic chloroplast
genome. Tobacco chloroplasts contain 5000-10,000 copies
of their genome per cell (86). Ifonly a fraction of the genomes
are actually transformed, the copy number, by default, must
be less than 10,000. By establishing that in the trans genies the
gene inserted transformed genome is the only one present,
one can establish that the copy number is 5000-10,000 per
cell. This is usually done by digesting the total DNA with a
suitable restriction enzyme and probing with the flanking
sequences that enable homologous recombination into the
chloroplast genome. The native fragment present in the control should be absent in the trans genies. The absence of native
fragment proves that only the transgenic chloroplast genome
is present in the cell and there is no native, untransformed,
chloroplast genome, without the foreign gene present. This
establishes the homoplasmic nature of our transformants,
simultaneously providing us with an estimate of 5000-10,
000 copies of the foreign genes per cell.
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Northern Analysis for Transcript Stability
Northern blots are done to test the efficiency of transcription of the genes. Total RNA is isolated from 150 mg of frozen
leaves by using the "Rneasy Plant Total RNA Isolation Kit"
(Qiagen Inc., Chatsworth, Calif.). RNA (10-40 µg) is denatured by formaldehyde treatment, separated on a 1.2% agarose gel in the presence of formaldehyde and transferred to a
nitrocellulose membrane (MSI) as described in Sambrook et
al. (130). Probe DNA (proinsulin gene coding region) is
labeled by the random-primed method (Promega) with 32 PdCTP isotope. The blot is pre-hybridized, hybridized and
washed as described above for southern blot analysis. Transcript levels are quantified by the Molecular Analyst Program
using the GS-700 Imaging Densitometer (Bio-Rad, Hercules,
Calif.).

there is no crystal formation, other purification methods must
be used (classical biochemistry techniques and affinity colunms with protease cleavage).

Expression and Quantification of the Total Protein Expressed
in Chloroplast
Chloroplast expression assays are done for each protein by
Western Blot. Recombinant protein levels in transgenic
plants are determined using quantitative ELISA assays. A
standard curve is generated using known concentrations and
serial dilutions of recombinant and native proteins. Different
tissues are analyzed using young, mature and old leaves
against these primary antibodies: goat anti-HAS (Nordic
Immunology), anti-IGF-I and anti-Interferon alpha (Sigma).
Bound IgG is measured using horseradish peroxidase-labelled anti-goat IgG.
Inheritance oflntroduced Foreign Genes
While it is unlikely that introduced DNA would move from
the chloroplast genome to nuclear genome, it is possible that
the gene could get integrated in the nuclear genome during
bombardment and remain undetected in Southern analysis.
Therefore, in initial tobacco transformants, some are allowed
to self-pollinate, whereas others are used in reciprocal crosses
with control tobacco (transgenics as female accepters and
pollen donors; testing for maternal inheritance). Harvested
seeds (Tl) will be germinated on media containing spectinomycin. Achievement ofhomoplasmy and mode ofinheritance
can be classified by looking at germination results.
Homoplasmy is indicated by totally green seedlings (86)
while heteroplasmy is displayed by variegated leaves (lack of
pigmentation, 83). Lack of variation in chlorophyll pigmentation among progeny also underscores the absence of position effect, an artifact of nuclear transformation. Maternal
inheritance is be demonstrated by sole transmission of introduced genes via seed generated on transgenic plants, regardless of pollen source (green seedlings on selective media).
When transgenic pollen is used for pollination of control
plants, resultant progeny do not contain resistance to chemical in selective media (will appear bleached; 83). Molecular
analyses confirm transmission and expression of introduced
genes, and T2 seed is generated from those confirmed plants
by the analyses described above.
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Example 7
Purification Methods
The standard method of purification employs classical biochemical techniques with the crystallized proteins inside the
chloroplast. In this case, the homogenates are passed through
miracloth to remove cell debris. Centrifugation at 10,000xg
palletizes all foreign proteins (3). Proteins are solubilized
using pH, temperature gradient, etc. This is possible if the
ORF! and 2 of the cry2Aa2 operon (see section c) can fold
and crystallize the recombinant proteins as expected. Where
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HSA: Albumin is typically administered in tens of gram quantities. At a purity level of 99.999% (a level considered sufficient for other recombinant protein preparations), recombinant HSA (rHSA) impurities on the order of one mg will still
be injected into patients. So impurities from the host organism must be reduced to a minimum. Furthermore, purified
rHSA must be identical to human HSA. Despite these stringent requirements, purification costs must be kept low. To
purify the HSA obtained by gene manipulation, it is not
appropriate to apply the conventional processes for purifying
HSA originating in plasma as such. This is because the impurities to be eliminated from rHSA completely differ from
those contained in the HSA originating in plasma. Namely,
rHSA is contaminated with, for example, coloring matters
characteristic to recombinant HSA, proteins originating in
the host cells, polysaccharides, etc. In particular, it is necessary to sufficiently eliminate components originating in the
host cells, since they are foreign matters for living organisms
including human and can cause the problem of antigenicity.
In plants two different methods of HSA purification have
been done at laboratory scale. Sijmons et al. (23) transformed
potato and tobacco plants with Agrobacterium tumefaciens.
For the extraction and purification of HSA, 1000 g of stem
and leaf tissue was homogenized in 1000 ml cold PBS, 0.6%
PVP, 0.1 mMPMSF and 1 mMEDTA. The homogenate was
clarified by filtration, centrifuged and the supernatant incubated for 4 h with 1.5 ml polyclonal antiHSA coupled to
Reactigel spheres (Pierce Chem) in the presence of 0.5%
Tween 80. The complex HSA-anti HSA-Reactigel was collected and washed with 5 ml 0.5% Tween 80 in PBS. HSA
was desorbed from reactigel complex with 2.5 ml of 0.1 M
glycine pH 2.5, 10% dioxane, immediately followed by a
buffer exchanged with Sephadex G25 to 50 mM Tris pH 8.
The sample was then loaded on a HR5/5 MonoQ anion
exchange colunm (Pharmacia) and eluted with a linear NaCl
gradient (0-350 mM NaCl in 50 mM Tris ph 8 in 20 min at 1
ml/min). Fractions containing the concentrated HSA (at 290
mM NaCl) were lyophilized and applied to a HR 10/30
Sepharose 6 colunm (Pharmacia) in PBS at 0.3 ml/min. However, this method uses affinity columns (polyclonal antiHSA) that are very expensive to scale-up. Also the protein is
released from the colunm with O. lM glycine pH 2.5 that will
most probably, denature the protein. Therefore, this method
can suitably modified to reduce these drawbacks.
The second method is for HSA extraction and purification
from potato tubers (Dr. Mingo-Castel's laboratory). After
grinding the tuber in phosphate buffer pH 7.4 (1 mg/2 ml), the
homogenate is filtered in miracloth and centrifuged at 14.000
rpm 15 minutes. After this step homogenate another filtration
of the supernatant in 0.45 µm filters is necessary. Then, chromatography of ionic exchange in FPLC using a DEAE
Sepharose Fast Flow colunm (Amersham) is required. Fractions recovered are passed though an affinity colunm (Blue
Sepharose fast flow Amersham) resulting in a product of high
purity. HSA purification based on either method is acceptable.
IDF-1: All earlier attempts to produce IGF-I in E. coli or
Saccharomyces cerevisiae have resulted in misfolded proteins. This has made it necessary to perform additional in vitro
refolding or extensive separation techniques in order to
recover the native and biological form of the molecule. In
addition, IFG-I has been demonstrated to possess an intrinsic
thermodynamic folding problem with regard to quantitatively
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folding in to a native disulfide-bonded conformation in vitro
(131). Samuelsson et al. (131) and Joly et al. (132) co-expressed IGF-I with specific proteins of E. coli that significantly improved the relative yields of correctly folded protein
and consequently facilitating purification. Samuelson et al.
(132) fused the protein to affinity tags based on either the
IgG-binding domain (Z) from Staphylococcal protein A or
the two serum albumin domains (ABP) from Streptococcal
protein G (134). The fusion protein concept allows the IGF-I
molecules to be purified by IgG or HSA affinity chromatography. We also use this Z tags for protein purification including the double Z domain from S. aureus protein and a
sequence recognized by TEV protease (see section d.2). The
fusion protein is incubated with an IgG colunm where binding via the Z domain occurs. Z domain-IgG interaction is very
specific and has high affinity, so contaminant proteins can be
easily washed off the colunm. Incubation of the colunm with
TEV protease elutes mature IGF-I from the colunm. TEV
protease is produced in bacteria in large quantities fused to a
6 histidine tag that is used for TEV purification. This tag can
be used to separate IGF-I from contaminant TEV protease.

samples are subjected to tryptic digestion followed by peptide
mass mapping using matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS). Samples are reduced
with dithiothreitol, alkylated with iodoacetamide and then
digested with trypsin comprising three additions of 1: 100
enzyme/substrate over 48 h at 37° C. Subsequently tryptic
peptides are separated by referse-phase HPLC on a Vydac
C18 colunm.

IFN-a: In the E. coli expression method used, the purification
system was based on using 6 Histidine-tags that bind to a
nickel colunm and biotinylated thrombin to eliminate the tag
on IFN-a5.
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Example 8
Characterization of the Recombinant Proteins
30

For the safe use of recombinant proteins as a replacement
in any of the current applications, these proteins must be
structurally equivalent and must not contain abnormal hostderived modifications. To confirm compliance with these criteria we compare human and recombinant proteins using the
currently highly sensitive and highly resolving techniques
expected by the regulatory authorities to characterize recombinant products (135).
Amino Acid Analysis
Amino acid analysis to confirm the correct sequence is
performed following off-line vapour phase hydrolysis using
ABI 420A amino acid derivatizer with an on line 130A phenylthiocarbamyl-amino acid analyzer (Applied Biosystems/
ABI). N-terminal sequence analysis is performed by Edman
degradation using ABI 477 A protein sequencer with an online 120A phenylthiohydantoin-amino acid analyzer. Automated C-terminal sequence analysis uses a Hewlett-Packard
G1009A protein sequencer. To confirm the C-terminal
sequence to a greater number of residues, the C-terminal
tryptic peptide is isolated from tryptic digests by reversephase HPLC.
Protein Folding and Disulfide Bridges Formation
Western blots with reducing and non-reducing gels are
done to check protein folding. PAGE to visualize small proteins will be done in the presence oftricine. Protein standards
(Sigma) are loaded to compare the mobility of the recombinant proteins. PAGE is performed on PhastGels (Pharmacia
Biotech). Proteins are blotted and then probed with goat
anti-HSA, interferon alpha and IGF-I polyclonal antibodies.
Bound IgG is detected with horseradish peroxidase-labelled
anti goat IgG and visualized on X-ray film using ECL detection reagents (Amersham).
Tryptic Mapping
To confirm the presence of chloroplast expressed proteins
with disulfide linkages identical to native human proteins, the
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Mass Analysis
Electrospray mass spectrometry (ESMS) is performed
using a VG Quattro electrospray mass spectrometer. Samples
are desalted prior to analysis by reverse-phase HPLC using an
acetonitrile gradient containing trifluoroacetic acid. Spectra
are measured in a nitrogen atmosphere using a Jasco 1600
spectropolarimeter.
Chromatographic Techniques
For HSA, analytical gel-permeation HPLC is performed
using a TSK G3000 SWxl column. Preparative gel permeation chromatography of HSA is S200 HR colunm. The
monomer fraction, identified by absorbance at 280 nm, is
dialyzed and reconcentrated to its starting concentration. For
IGF-I, the reversed-phase chromatrography the SMART system (Pharmacia Biotech) is used withmPRC C2/18 SC 2.1/10
colurmi.
Viscosity
This is a classical assay for recombinant HSA. Viscosity is
a characteristic of proteins related directly to their size, shape,
and conformation. The viscosities of HSA and recombinant
HSAcan be measured at lOOmg. Ml-1 in0.15 MNaCl using
a U-tube viscosimeter (M2 type, Poulton, Selfe and Lee Ltd.
Essex, UK) at 25° C.
Glycosy lati on
Chloroplast proteins are not known to be glycosylated.
However there are no publications to confirm or refute this
assumption. Therefore glycosylation should be measured
using a scaled-up version of the method of Ahmed and Further (136).
Example 9
Biological Assays

45

50

55

60

65

Since HSA does not have enzymatic activity, 1t 1s not
possible to run biological assays. However, three different
techniques can be used to check IGF-I functionally. All of
them are based on the proliferation ofIFG-I responding cells.
First, radioactive thymidine uptake can be measured in 3T3
fibroblasts, that express IFG-I receptor, as an estimate of
DNA synthesis. Also, a human megakaryoblastic cell line,
HU-3, can be used.As HU-3 grows in suspension, changes in
cell number and stimulation of glucose uptake induced by
IGF-I are assayed usingAlamarB!ue or glucose consumption,
respectively. AlmarB!ue (Accumed International, Westlake,
Ohio) is reduced by mitochondrial enzyme activity. The
reduced form of the reagent is fluorescent and can be quantitatively detected, with an excitation of 530 nm and an emission of 590 nm. AlamarB!ue is added to the cells for 24 hours
after 2 days induction with different doses ofIGF-I and in the
absence of serum. Glucose consumption by HU-3 cells is then
measured using a colorimetric glucose oxidase procedure
provided by Signma. HU-3 cells are incubated in the absence
of serum with different doses ofIGF-I. Glucose is added for
8 hours and glucose concentration is then measured in the
supernatant. All three methods to measure IFG-I functionally
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are precise, accurate and does dependent, with a linear range
between 0.5 and 50 ng/ml (137).
The method to determine IFN activity is based on their
anti-viral properties. This procedure measures the ability of
IFN to protect HeLa cells against the cytopathic effect of
encephalomyocarditis virus (EMC). This assay is performed
in 96-well microtitre plate. First, HeLa cells are seeded in the
wells and allowed to grow to confluency. Then, the medium is
removed, replaced with medium containing IFN dilutions,
and incubated for 24 hours. EMC virus is added and 24 hours
later the cytopathic effect is measured. For that, the medium
is removed and wells are rinsed two times with PBS and
stained with methyl violet dye solution. The optical density is
read at 540 nm. The values of optical density are proportional
to the antiviral activity of IFN (138). Specific activity is
determined with reference to standard IFN-a (code 82/576)
obtained from NIBSC.

effects in increasing bone and muscle mass, improving liver
function and correcting hypogonadism. Briefly, the induction
protocol is as follows: Liver cirrhosis is induced in rats by
inhalation of carbon tetrachloride twice a week for 11 weeks,
with a progressively increasing exposure time from 1 to 5
minutes per gassing session. After the 11th week, animals
continue receiving CCl4 once a week (3 minutes per inhalation) to complete 30 weeks of CCl 4 administration. During
the whole induction period, Phenobarbital (400 mg/L) is
added to drinking water. To test the therapeutic efficacy of
tobacco-derived IGF-I, cirrhotic rats receive 2 µg/100 g body
weight/day of this compound in two divided doses, during the
last 21 days of the induction protocol (weeks 28, 29, and 30).
On day 22, animals are sacrificed and liver and blood samples
collected. The results are compared to those obtained in cirrhotic animals receiving placebo instead of tobacco-derived
IGF-I, and to healthy control rats.
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Animal Testing and Pre-Clinical Trials
Once albumin is produced at adequate levels in tobacco
and the physicochemical properties of the product correspond
to those of the natural protein, toxicology studies need to be
done in mice. To avoid mice response to the human protein,
transgenic mice carrying HSA genomic sequences are used
(139). After injection ofnone, 1, 10, 50 and 100 mg of purified
recombinant protein, classical toxicology studies are carried
out (body weigh and food intake, animal behavior, piloerection, etc). Albumin can be tested for blood volume replacement after paracentesis to eliminate the fluid from the peritoneal cavity in patients with liver cirrhosis. It has been shown
that albumin infusion after this maneuver is essential to preserve effective circulatory volume and renal function (140).
IGF-I and IFN-a are tested for biological effects in vivo in
animal models. Specifically, woodchucks (marmota monax)
infected with the woodchuck hepatitis virus (WHY), are
widely considered as the best animal model of hepatitis B
virus infection (141). Preliminary studies have shown a significant increase in 5' oligoadenylate synthase RNA levels by
real time polymerase chain reaction (PCR) in woodchuck
peripheral blood mononuclear cells upon incubation with
human IFN-a5, a proof of the biological activity of the human
IFN-a5 in woodchuck cells. For in vivo studies, a total of 7
woodchucks chronically infected with WHY (WHY surface
antigen and WHY-DNA positive in serum) are used: 5 animals are injected subcutaneously with 500,000 units of
human IFN-a5 (the activity of human IFN-a5 is determined
as described previously) three times a week for 4 months; the
remaining two woodchucks are injected with placebo and
used as controls. Follow-up includes weekly serological
(WHY surface antigen and anti-WHY surface antibodies by
ELISA) and viorological (WHY DNA in serum by real time
quantitative PCR) as well as monthly immunological
(T-helper responses against WHY surface and WHY core
antigens measured by interleukin 2 production from PBMC
incubated with those proteins) studies. Finally, basal and end
of treatment liver biopsies should be performed to score liver
inflammation and intrahepatic WHY-DNA levels. The final
goal of treatment is decrease of viral replication by WHYDNA in serum, with secondary end points being histological
improvement and decrease in intrahepatic WHY-DNA levels.
For IFG-1, the in vivo therapeutic efficacy is tested in
animals in situations ofIGF-I deficiency such as liver cirrhosis in rats. Several reports (56-58) have been published showing that recombinant human IGF-I has marked beneficial

25

30

35

40

45

50

55

60

65

Expression of the Native Cholera Toxin B Subunit Gene as
Oligomers
Bacterial antigens like the B subunit proteins, CTB and
LTB, which are two chemically, structurally and immunologically similar candidate vaccine antigens of prokaryotic
enterotoxins, have been expressed in plants. CTB is a candidate oral subunit vaccine for cholera that causes acute watery
diarrhea by colonizing the small intestine and producing the
enterotoxin, cholera toxin (CT). Cholera toxin is a hexameric
AB 5 protein consisting of one toxic 27 kDa A subunit having
ADP ribosyl transferase activity and a nontoxic pentamer of
11.6 kDa B subunits (CTB) that binds to the A subunit and
facilitates its entry into the intestinal epithelial cells. CTB
when administered orally is a potent mucosa! immunogen,
which can neutralize the toxicity of the CT holotoxin by
preventing it from binding to the intestinal cells (4). This is
believed to be a result of it binding to eukaryotic cell surfaces
via GM1 gangliosides, receptors present on the intestinal epithelial surface, eliciting a mucosa! immune response to pathogens and enhancing the immune response when chemically
coupled to other antigens (5,6).
Native CTB and LTB genes have been expressed at low
levels via the plant nucleus. Since, both CTB and LTB are
AT-rich compared to plant nuclear genes, low expression was
probably due to a number of factors such as a aberrant mRNA
splicing, mRNA instability or inefficient codon usage. To
avoid these undesirable features synthetic "plant optimized"
genes encoding LTB were created and expressed in potato,
resulting in potato tubers expressing up to 10-20 µg of LTB
per gram of fresh weight (7). However, extensive codon
modification of genes is laborious, expensive and often not
available due to patent restrictions. One of the consequences
of these constitutively expressed high LTB levels, was the
stunted growth of transgenic plants that was eventually overcome by tissue specific expression in potato tubers. The maximum amount of CTB protein detected in auxin induced,
nuclear transgenic potato leaf tissues was approximately
0.3% of the total soluble leaf protein when the native CTB
gene was fused to an endoplasmic reticulum retention signal,
thus targeting the protein to the endoplasmic reticulum for
accumulation and assembly (8).
Increased expression of levels of several proteins have
been attained by expressing foreign proteins in chloroplasts
of higher plans (9-11 ). Human somatotropin has been
expressed in chloroplasts with yields of 7% of the total
soluble protein (12). The accumulation levels of the Bt
Cry2Aa2 operon in tobacco chloroplasts are as high as 46.1 %
of the total soluble plant protein (1 3). This high level of
expression is attributed to the putative chaperoning, orfl and
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orf2, upstream of Cry2Aa2 in the operon that may help to fold
the protein into a crystalline form that is stable and resistant to
proteolytic degradation. Besides the ability to express polycistrons, yet another advantage of chloroplast transformation
I, is the lack of recombinant protein expression in pollen of
chloroplast transgenic plants. As there is no chloroplast DNA
in pollen of most crops, pollen mediated outcross of recombinant genes into the environment is minimized (10-15).
Since the transcriptional and translational machinery of
plastids is prokaryotic in origin and the N. tabaccum chloroplast genome has 62.2% AT content, it was likely that native
CTB genes would be efficiently expressed in this organelle
without the need for codon modification. Also, codon comparison of the CTB gene with psbA, the major translation
product of the chloroplast, showed 47% homology with the
most frequent codons of the psbA gene. Highly expressed
plastid genes display a codon adaptation, which is defined as
a bias towards a set of codons which are complimentary to
abundanttRNAs (16). Codon analysis showed that 34% of the
codons ofCTB are complimentary to the tRNA population in
the chloroplasts in comparison with 51 % of psbA codons that
are complimentary to the chloroplast tRNA population.
Also, stable incorporation of the CTB gene into the precise
location between the trnA and trnI genes of the chloroplast
genome by homologous recombination, should eliminate the
'position effect' frequently observed in nuclear transgenic
plants. This should allow uniform expression levels in different transgenic lines. Amplification of the trans gene, should
result in a high level ofCTB gene expression since each plant
cell contains up to 50,000 copies of the plastid genome (17).
Another significant advantage of the production of CTB in
chloroplasts, is the ability of chloroplasts to form disulfide
bridges (12, 18,19) which are necessary forthe correct folding
assembly of the CTB pentamer (20).
In this study, we report the integration of the CTB gene into
the inverted repeat region of the tobacco chloroplast genome,
allowing 2 copies/chloroplast genome of the CTB gene per
cell, resulting in chloroplasts accumulating high levels of
CTB. This eliminates the need to modify the CTB gene for
optimal expression in plants.

Tris, 250 mM glycine, pH 8.3, 0.1 % SDS). The separated
protein was transferred to a nitrocellulose membrane by electro blotting at 70 v for 90 min.

Construction of the Chloroplast Expression Vector pLDCTB: The leader sequence (63 bp) of the native CTB gene
was deleted and a start codon was introduced at the 5' end.
Primers were designed to introduce an rbs site 5 bases
upstream of the start codon. The CTB PCR product was then
cloned into the multiple cloning site of the pCR2. 1 vector
(Invitrogen) and subsequently into the chloroplast expression
vector pLD-CtV2 using suitable restriction sites. Restriction
enzyme digestions of the pLD-LH-CTM vector were done to
confirm the correct orientation of the inserted fragment.
Expression of the pLD-LH-CTB vector was tested in E.
coli XL-1 Blue MRF re strain before tobacco transformation.
E. coli was transformed by standard CaC1 2 transformation
procedures. Transformed E. coli (24 and 28 hrs culture in 100
ml TB with 100 µg/ml ampicillin) and untransformedE. coli
(24 and 48 hrs culture in 100 ml TB with 12.5 µg/ml tetracycline) were centrifuged for 15 min. The pellet obtained was
washed with 200 mM Tris-Cl twice, resuspended in 500 µl
extraction buffer (200 mM Tris-Cl, pH 8.0, 100 mM NaCl, 10
mM EDTA, 2 mM PMSF) and sonicated. To aliquots of 100
µl transformed and untransformed sonicates [containing
50-100 µg of crude protein extract as determined by Bradford
protein assay (Bio-rad)] and purified CTB (100 ng, Sigma),
2xSDS sample buffer was added. These sample mixtures
were loaded on a 15% sodium SDS-PAGE gel and electrophoresed at 200 v for 45 min. in Tris-glycine buffer (25 mM
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ImmunoblotAnalysis ofCTB Production inE. coli: Nonspecific antibody reactions were blocked by incubation of the
membrane in 25 ml of 5% non-fat dry milk in TBS buffer for
2 hon a rotary shaker (40 rpm) followed by washing in TBS
buffer for 5 min. The membrane was incubated for 1 h in 30
ml of a 1:5000 dilution of rabbit anti-chloera antiserum
(Sigma) in TBST (TBS with 0.5% Tween-20), containing 1%
non-fat dry milk, followed by washing thrice in TBST. Incubation for an hour at room temperature in 30 ml of a 1: 10,000
dilution of alkaline phoshphatase conjugated mouse antirabbit IgG. (Sigma) in TBST, washing thrice in TBST and
once with TBS was followed by incubation in the Alkaline
Phosphatase Color Development Reagents, BCIP/NBT in AP
color development buffer (Bio-Rad) for an hour.
Bombardment and Regeneration of Chloroplast Transgenic
Plants: Fully expanded, dark green leaves of about two-month
old Nicotiana tabcum var. Petit Havana plants were placed
abaxial side up on filter papers in RMOP (21) petridish plates.
Microprojectiles coated with pLD-LH-CTB DNA were bombarded into the leaves using the biolistic device PDSIOOO/
He (Bio-Rad), as described by Daniell (21). Following incubation at 24 ° C. in the dark for two days, the bombarded
leaves were cut into small (-5 mm2 ) pieces and placed abaxial
side up (5 pieces/plate) on selection medium (RMOP containing 500 mg/L spectinomycin dihydrochloride ). Spectinomycin resistant shoots obtained after about 1-2 months were
cut into small pieces (-2 mm 2 ) and placed on the same selection medium.
PCR Analysis: Total plant DNA from putative transgenic
and untransformed plants was isolated using the DNeasy kit
(Qiagen). PCR primers 3P (5AAAACCCGTCCTCAGTTCGGATTGC-3') (SEQ ID NO. 13) and 3M (5'-CCGCGTTGTTTCATCAAGCCTTACTG-3') (SEQ ID NO. 14) were
used for PCR on putative transgenic and untransformed plant
total DNA. Samples were carried though 30 cycles using the
following temperature sequence: 94° C. for 1 min, 62° C. for
1.5 min and 72° C. for 2 min. Cycles were preceded by
denaturation for 5 min at 94.degree. C. PCR confirmed shoots
from the second selection were transferred to rooting medium
(MSO medium containing 500 mg/L spectinomycin).
Southern Blot Analysis: Ten micrograms of total plant DNA
(isolated using DNeasy kit) per sample were digested with
Bg!II, separated on a 0.7% agarose gel and transferred to a
nylon membrane. A 0.8 kb fragment probe, homologous to
the chloroplast border sequences, was generated when vector
DNA was digested with Bg!II and BamHI. Hybridization was
performed using the Ready To Go protocol (Pharmacia).
Southern blot confirmed plants were transferred to pots. On
flowering, seeds obtained from T 0 lines were germinated on
spectinomycin dihydrochloride-MSO media and T 1 seedlings were grown in bottles containing MSO with spectinomycin (500 mg/L) for 2 weeks. The plants were later transferred to pots.
Western Blot Analysis of Plant Protein: Transformed and
untransformed leaves (100 mg) were ground in liquid nitrogen and resuspended in 500 µl of extraction buffer (200 mM
Tris-Cl,pH8.0, lOOmMNaCl, 10mMEDTA,2mMPMSF).
Leaf extracts (100-120 µg as determined by Lowry assay)
were boiled (4 min) and unboiled in reducing sample buffer
(BioRad) and electrophoresed in 12% polyacrylamide gels
using the buffer system ofLaemmli (22). The separated proteins were transferred to a nitrocellulose membrane by elec-
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troblotting at 85 v for 1 h. The innnunoblot detection procedure was similar to that done for E.coli blots described above.
For the chemiluminescent detection, the S. Tag™ AP
Lumiblot kit (Novagen) was used.
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Determination of Chloroplast Integration and Homoplasmy:
PCR and Southern hybridization were used to determine integration of the CTB gene into the chloroplast genome. Primers, 3P and 3M, designed to confirm incorporation of the gene
5 cassette into the chloroplast genome were used to screen
ELISA Quantification ofCTB: Different concentrations (100
putative transgenics initially. The primer, 3P, landed on the
µI/well) of 100 mg leaves (transformed and untransformed
chloroplast genome outside of the chloroplast flanking
plants) ground with liquid nitrogen and resuspended in bicarsequence used for homologous recombination as shown in
bonate buffer, pH 9.6 (15 mM Na 2 C0 3 , 35 mM NaHC0 3 )
FIG. 21A. The primer, 3M, landed on the aadA gene. No PCR
were bound to a 96 well polyvinyl chloride microliter plate 1o product should be obtained if foreign genes are integrated into
(Costar) overnight at 4° C. The background was blocked with
the nuclear genome or in mutants lacking the aadA gene. The
1% Bovine serum albumin (BSA) in O.OlM phosphate buffpresence of the 1.6 kb PCR product in 9 of the 10 putative
transgenics screened, confirmed the site-specific integration
ered saline (PBS) for 2 hat 37° C., washed thrice with washof the gene cassette into the chloroplast genome. Database
ing buffer, PBST (PBS and 0.05% Tween 20) and rabbit
anti-cholera serum diluted 1:8,000 in PBST containing 0.5% 15 searches showed that no random priming took place as both
the 3P and 3M primers showed no homology with other gene
BSA was added and incubated for 2 hat 3 7° C. The wells were
sequences. This is confirmed by the absence of PCR product
washed and incubated with 1:50,000 mouse anti rabbit IgGin untransformed plants (FIG. 21B). Similar strategy has been
alkaline phosphatase conjugate in PBST containing 0.5%
used successfully by us in order to confirm chloroplast inteBSA for 2 hat 37° C. The plate was developed with Sigma
20 gration of foreign genes (13,14,24,25). This screening is
FastpNPP substrate (Sigma) for 30 minutes at room temperaessential to eliminate mutants and nuclear transformants and
ture and the reaction was ended by addition of3N NaOH and
saves space and labor of maintaining hundreds of transgenic
plates were read at 405 nm.
lines.
GM 1 Ganglioside Binding Assay: To determine the affinity of
Southern blot analysis of three of the PCR positive transchloroplast derived CTB for GM 1 -gangliosides, microliter 25 genie lines was done to further confirm site specific integraplates were coated with monosialoganglioside-GM 1 (Sigma)
tion and to establish copy number. In the chloroplast genome,
(3.0 µg/ml in bicarb buffer) and incubated at 4° C. overnight.
BgIII sites flank the chloroplast border sequences 5' of 16S
As a control, BSA (3.0 µg/ml in bicarb buffer) was coated on
rRNA and 3' of the trnA region as shown in FIG. 23A. A 6.17
some wells. The wells were blocked with 1% BSA in PBS for
kb fragment from a transformed plant and a 4.47 kb fragment
2 hat 37° C., washed thrice with washing buffer, PBST and 30 from an untransformed plant were obtained when total plant
incubated with dilutions of transformed plant protein,
DNA from transformed and untransformed plants was
untransformed plant protein and bacterial CTB in PBS. Incudigested with Bg!II. The blot of the digested products was
bation of plates with primary and secondary antibody diluprobed with a 32 P random primer-labeled 0.81 kb trnI-trnA
tions and detection was similar to the CTB ELISA procedure
fragment. The probe hybridized with the control giving a 4.47
described above.
35 kb fragment as expected, while for the transgenic lines a 6.17
kb fragment was observed, indicating that all plastid genomes
pLD-LH-CTB vector construction and E. coli expression:
had the gene cassette inserted between the tml and trnA
The pLD-LH-CTB vector integrates the genes ofinterest into
regions. The absence of a 4.47 kb fragment in transgenic lines
the inverted repeat regions of the chloroplast genome
indicates that homoplasmy has been achieved, to the detecbetween the trnI and trnA genes. Integration occurs through
40 tion level of a Southern blot. These results explain the high
homologous recombination events between the trnl and trnA
levels ofCTB observed in transgenic tobacco plants. Southchloroplast genome as shown in FIG. 21A. The chimeric
ern
blot confirmed plants transferred to pots were seen to have
aminoglycoside 3' adenyltransferase (aadA) gene that confers
no adverse pleiotropic effects when compared to untransresistance to spectinomycin-streptomycin and the CTB gene
formed plants as shown in FIG. 4A. Southern blot analysis of
downstream of it are driven by the constitutive promoter of
45 T plants in FIG. 3C shows that all 4 gransgenic lines ana1
the rRNA operon (Prrn) and transcription is terminated by the
lyzed maintained homoplasmy.
psbA3' untranslated region. Since the protein synthetic
machinery of chloroplasts is similar to that of E. coli (23),
ImmunoblotAnalysis of Chloroplast Synthesized CTB: AntiCTB expression of the pLD-LH-CTB vector in E. coli was
chloera toxin antibodies did not show significant cross-reactested. Western blot analysis of sonicated E. coli whole cell
50 tion with tobacco plant protein as can be seen in FIG. 22C,
extract showed the presence of 11 kDa CTB monomers, similanes 1 & 2. Boiled and unboiled leaf homogenates were run
lar to that obtained when purified connnercially available
on 12% SDS PAGE gels. Unboiled chloroplast synthesized
CTB was treated in the same manner as shown in FIG. 22A.
CTB protein appeared as compact 45 kDa oligomers as
Oligomeric expression ofCTB was not observed inE. coli, as
shown in FIG. 22C, lane 4 similar to the unboiled, pentameric
expected, due to the absence of a leader peptide sequence
55 bacterial CTB which appeared to have partially dissociated
present in the native CTB gene that directs the CTB monomer
into tetramers, trimers and monomers upon storage at 4° C.
into the periplasmic space allowing for concentration and
over a period of several months from FIG. 22C, lane 7.
oligomeric assembly.
While heat treatment (4 min. boiling) prior to SDS PAGE
Selection and Regeneration ofTransgenic Plants: Bombarded
of pentameric bacterial CTB, gave CTB monomers predomileaf pieces when placed on selection medium continued to 60 nantly, with some protein in the dimeric and trimeric form as
grow but were bleached. Green shoots emerged from the part
shown in FIG. 22C, lane 6, chloroplast synthesized CTB
of the leaf in contact with the medium. Five rounds of bomdissociated into dinnners and trimers only, when subjected to
similar heat treatment as in FIG. 22C, lanes 3 & 5. These
bardment ( 5 leaves each) resulted in 68 independent transforresults are different from the heat induced dissociation of
mation events. Each such transgenic line was subjected to a
second round of antibiotic selection. These putative transfor- 65 potato plant nucleus synthesized CTB; oligomers into monomants were subjected to PCR analysis to distinguish from
mers (8). A probable reason for this stability could be a more
nuclear transformants and mutants.
stable conformation of chloroplast synthesized CTB which
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may be an added advantage in storage and administration of
edible vaccines. Leaf homogenates from four different transgenic plants showed almost similar expression levels of CTB
protein (see FIG. 22B). This suggests very little clonal variation of CTB expression, as was confined later by ELISA
quantification assays. Consistent expression levels of recombinant proteins in plants (as obtained for CTB in this research)
may be essential for production of edible vaccines in plants.

isolation and lysis of CTB producing chloroplasts from chloroplast transformed plants could serve as a cost-effective
means of mass production of purified CTB. If used as an
edible vaccine, a selection scheme eliminating the use of
antibiotic resistant genes should be developed. One such
scheme uses the betaine aldehyde dehydogenase (BADH)
gene, which converts toxic betaine aldehyde to nontoxic glycine betaine, an osmoprotectant (28). Also, several other
strategies have been proposed to eliminate antibiotic-resistant genes from transgenic plants (29.)
Transgenic potato plants that synthesize a CTB-insulin
fusion protein at levels of up to 0.1 % of the total soluble tuber
protein have been found to show a substantial reduction in
pancreatic islet inflammation and a delay in the progression
of clinical diabetes (30). This may prove to be an effective
clinical approach for prevention of spontaneous autoimmune
diabetes. Since, increased CTB expression levels have been
shown to be achievable via the chloroplast genome through
this research, expression of a CTB-proinsulin fusion protein
in the chloroplasts of edible tobacco (LAMD) is currently
being tested in our laboratory. While existing expression levels ofCTB via the chloroplast genome are adequate for commercial exploitation, levels can be increased further (about 1O
fold) by insertion of a putative chaperonin, as in the case ofBt
Cry2aA2 operon, (13) which likely aids in the subsequent
purification ofrecombinant CTB due to crystallization.

ELISA Quantification of CTB Expression: Comparison of
the absorbance at 405 nm of a known amount of bacterial
CTB-antibody complex (linear standard curve) and that of a
known concentration of transformed plant total soluble protein was used to estimate CTB expression levels. Optimal
dilutions of total soluble protein from two transgenic lines
were loaded in wells of the microliter plate. As reported
previously (8), it was necessary to optimize the dilutions of
total soluble protein, as levels of CTB protein detected varied
with the concentration of total soluble protein, resulting in too
high concentrations of total soluble protein inhibiting the
CTB protein from binding to the wells of the plate. Both T
lines yielded CTB protein levels ranging between 3.5% t~
4.1 % of the total soluble protein (40 µg of chloroplast synthesized CTB protein in 1 mg of total soluble protein) as
shown in FIG. SA. Also, estimation of CTB protein expression levels from different stages of leaves-young, mature
and old determined that mature leaves have the highest levels
of CTB protein expression. This is in accordance with the
results obtained when similar experiments were performed
when the Bt Cry2aA2 gene was expressed without the putative chaperonin genes, but contrary to results with the Bt
Cry2aA2 operon, which showed high expression levels in
older leaves, probably due to the stable crystalline structure
(13).
GM 1 Ganglioside ELISA Binding Assays: Both chloroplast
synthesized and bacterial CTB demonstrated a strong affinity
for GM!, -gangliosides (see FIG. SB) indicating that chloroplast synthesized CTB conserved the antigenic sites necessary for binding of the CTB pentamer to the pentasaccharide
GM 1 I. The GM 1 binding ability also suggest proper folding of
CTB molecules resulting in the pentameric structure. Since
oxidation of cysteine residues in the B subunits is a prerequisite for in vivo formation of CTB pentamers (20), proper
folding is a further confirmation of the ability of chloroplasts
to form disulfide bonds.
High levels of expression ofCTB in transgenic tobacco did
not affect growth rates, flowering or seed setting as has been
observed in this laboratory, unlike previously reported for the
synthetic LTB gene, constitutively expressed via the nuclear
genome (7). Transformed plant seedlings were green in color
while untransformed seedlings lacking the aadA gene were
bleached white as shown in FIG. 4B when germinated on
antibiotic medium.
The potential use of this technology is three-fold. While, it
can be used for large scale production of purified CTB, it can
also be used as an edible vaccine if expressed in an edible
plant or as a transmucosal carrier of peptides to which it is
~used to, so as to either enhance mucosa! immunity or to
mduce oral tolerance to the products of these peptides (5).
Large-scale production of purified CTB in bacteria involves
the use of expensive fermentation techniques and stringent
purification protocols (26) making this a prohibitively expensive technology for developing countries. The cost of producing 1 kg of recombinant protein in transgenic crops has been
estimated to be 50 times lower than the cost of producing the
same amount by E. coli fermentation, assuming that recombinant protein is 20% of total E. coli protein (27). Thus,
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Example 11
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Universal Chloroplast Integration and Expression
Vectors Tobacco
Exemplary universal chloroplast vectors were constructed
by first cutting out the tobacco chloroplast DNA BamHI
fragment (130656-140992) containing the 16S and 23S
rRNA genes and subcloning it into a commonly available
bacterial plasmid pUC19. A map of the tobacco chloroplast
genome is shown in FIG. 35. A 2.1 kbp HindIII-EcoRI fragment present within this fragment, containing a universal
border sequence comprising tmI and trnA genes (FIG. 37A),
including the spacer region between the genes, was subcloned
into the pUC19 plasmid at the PvuII site (FIG. 37B). The
resultant plasmid was designated pSBL-Ct Bor (FIG. 37C).
The vector pSBL-RD-EPSPS (FIG. 36) contains a mutant
EPSP synthase gene that codes for the enzyme EPSP synthase. Glyphosate, the active ingredient in Mosanto's
ROUND UP™, binds to the protein EPSP synthase and
blocks the synthesis of essential amino acids, resulting in
death of a plant. The EPSP synthase coded for by the mutant
gene does not bind glyphosate, and therefore confers herbicide resistance to crop plants. In a preferred embodiment of
the present invention, the EPSP synthase coding region can be
spliced out of vector pSBL-RD-EPSPS and replaced with the
coding sequence for HSA or an HSA fusion protein.
Other genes, such as those that confer resistance to adverse
environmental factors such as salt/drought tolerance (osmotolerance genes such as betaine aldehyde dehydrogenase,
(BADH), for the overproduction of glycine betaine) or thermotolerance (genes coding for heat shock proteins) or cold
shock tolerance proteins, or to pathogen resistance, such as
antimicrobial (lytic peptides, chitinase) or antiviral (coat proteins) can be inserted singly or in non-conflicting combinations into the universal chloroplast vector, or into different
cassettes of the same universal chloroplast vector to transform the target plant into one with the desired trait.
Construction of a Universal Chloroplast Integration Vector
Containing a Synthetic Spacer 2 Region: A universal chloro-
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68

plast vector containing only the spacer 2 region of the tobacco
chloroplast genome was constructed by first subcloning a
synthetic oligonucleotide comprising the spacer 2 region into
the bacterial plasmid pUC19. The positive and negative
strands of the 64 base pair spacer sequence were synthesized,
the sequence of the positive strand was as follows: 5'GCTGCGCCAGGGAAAAGAATAGAAGAAGCATCTGACTACTTCATGCATGCTCCAC
TTGGCTCGG-3' The synthetic fragments were mixed and
allowed to anneal, then ligated into pUC19 at the PvuII site.
(FIG. 37B) Insertion of an appropriate selectable marker gene
and a heterologous gene were as described above for pSBLCtBor.
(FIG. 37C) To prepare a longer sequence which includes
the tRNAile and the TRNA la genes, the same methodology is
followed.

(0.6 um) microprojectiles were coated with plasmid DNA, of
interest (e.g. pSBL-RD-EPSPS or pZS-RD-EPSPS) and
bombardments were carried out with the biolistic device
PDSlOOO/He (Bio-Rad) as described by Daniell, 1997. Following bombardment, petri plates were sealed with parafilm
and incubated at 24° C. under 12 h photoperiod. Two days
after bombardment, leaves were chopped into small pieces of
about 5 mm2 in size and placed on the lethal selection
medium (RMOP containing a selectable marker such as about
500 ~g/ml of spectinomycin dihydrochloride) with abaxial
side touching the medium in deep (100x25 mm) petri plates
(about 10 pieces per plate).
Selected from the shoots that died, the regenerated spectinomycin resistant shoots were chopped into small pieces
(about 2 mm2) and subcloned into fresh deep petri plates
(about 5 pieces per plate) containing the same lethal selection
medium. Resistant shoots from the second culture cycle were
transferred to rooting medium (MSO medium supplemented
with IBA, 1 4 liter and an appropriate antibiotic like 500
~g/ml of spectinomycin dihydrochloride,). Rooted plants
were transferred to soil and grown at 26° C. under continuous
lighting conditions for further analysis.
After transfer to the lethal selection medium, the explants
gradually became pale and in about 3-8 weeks, green calli and
shoots developed from the bombarded side of the leaf. Resistant shoots from each callus were considered as a clone.
PCR screening for chloroplast transformants after the first
culture cycle showed that 12 out of 20 resistant clones integrate the foreign genes like the aadA gene linked to the
EG121 gene into the chloroplast genome. These 12 clones
were advanced to further steps of regeneration. The entire
process of regeneration, starting from bombardment until
transfer to soil, takes about 3-5 months.
FIG. 38 shows transformed and untransformed tobacco
plastids growing in the presence of spectinomycin indicating
non-lethal selection on the medium (500 yg/ml).
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Transformation of Different Plants
Example 12

20

Chloroplast Transformation of Tobacco: The following
example describes a classic protocol for transformation of
tobacco chloroplast for which any vector can be used including a vector containing the coding sequence for HSA or an
HSA fusion protein. Two such vectors are identified below.
All new chloroplast vectors were first tested in tobacco as
described in Daniell, (1997). Tobacco (Nicotiana tabacum
var. Petit Havana) plants were grown aseptically by germination of seeds on MSO medium containing MS salts (4.3
g/liter), BS vitamin mixture (myo-inositol, 100 mg/liter; thiamine-HCl, 10 mg/liter; nicotinic acid, 1 mg/liter; pyridoxineHCl, 1 mg/liter), sucrose (30 g/liter) and phytagar (6 g/liter) at
pH 5.8. Fully expanded green leaves of about two month old
plants were selected for bombardment.
Leaves were placed abaxial side up on a Whatman No. 1
filter paper laying on RMOP* medium in standard Petri plates
(100x15 mm) for bombardment. Tungsten (1 um) or Gold

25
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35

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS, 26
<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 1
LENGTH, 1250
TYPE, PRT
ORGANISM, Artificial sequence
FEATURE,
OTHER INFORMATION, Protein-based polymer (PBP) made from synthetic
genes.

<400> SEQUENCE, 1
Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly
1
5
10
15
Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val
20
25
30
Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly
35
40
45
Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val
50
55
60
Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro
65
70
75
80
Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly
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69

70
-continued

85

90

95

Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val
100

105

110

Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly
115

120

125

Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val
130

135

140

Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro
145

150

155

160

Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly
165

170

175

Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val
180

185

190

Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly
195

200

205

Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val
210

215

220

Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro
225

230

235

240

Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly
245

250

255

Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val
260

265

270

Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly
275

280

285

Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val
290

295

300

Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro
305

310

315

320

Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly
325

330

335

Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val
340

345

350

Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly
355

360

365

Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val
370

375

380

Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro
385

390

395

400

Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly
405

410

415

Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val
420

425

430

Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly
435

440

445

Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val
450

455

460

Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro
465

470

475

480

Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly
485

490

495

Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val
500

505

510
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-continued
Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly
515

520

525

Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val
530

535

540

Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro
545

550

555

560

Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly
565

570

575

Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val
580

585

590

Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly
595

600

605

Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val
610

615

620

Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro
625

630

635

640

Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly
645

650

655

Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val
660

665

670

Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly
675

680

685

Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val
690

695

700

Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro
710

705

715

720

Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly
725

730

735

Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val
740

745

750

Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly
755

760

765

Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val
770

775

780

Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro
785

790

795

800

Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly
805

810

815

Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val
820

825

830

Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly
835

840

845

Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val
850

855

860

Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro
865

870

875

880

Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly
885

890

895

Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val
900

905

910

Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly
915

920

925
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-continued
Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val
930
935
940
Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro
945
950
955
960
Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly
965
970
975
Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val
980
985
990
Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly
995
1000
1005
Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly
1010
1015
1020
Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly
1025
1030
1035
Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly
1040
1045
1050
Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly
1055
1060
1065
Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly
1070
1075
1080
Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly
1085
1090
1095
Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly
1100
1105
1110
Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly
1115
1120
1125
Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly
1130
1135
1140
Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly
1145
1150
1155
Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly
1160
1165
1170
Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly
1175
1180
1185
Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly
1190
1195
1200
Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly
1205
1210
1215
Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly
1220
1225
1230
Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly
1235
1240
1245
Val Pro
1250

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 2
LENGTH,
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION: Illustrative endoplasmic reticulum retention
signal

<400> SEQUENCE, 2
Ser Glu Lys Asp Glu Leu
1

5
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76
-continued

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 3
LENGTH, 4
TYPE, PRT
ORGANISM, Artificial sequence
FEATURE,
OTHER INFORMATION, Illustrative peptide

<400> SEQUENCE, 3
Gly Pro Gly Pro
1

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 4
LENGTH, 25
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Primer

<400> SEQUENCE, 4
ccgtcgacgt agagaagtcc gtatt

<210>
<211>
<212>
<213>
<220>
<223>

25

SEQ ID NO 5
LENGTH, 27
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Primer

<400> SEQUENCE, 5
gcccatggta aaatcttggt ttattta

<210>
<211>
<212>
<213>
<220>
<223>

27

SEQ ID NO 6
LENGTH, 28
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Primer

<400> SEQUENCE,
cctttaaaaa gccttccatt ttctattt

<210>
<211>
<212>
<213>
<220>
<223>

28

SEQ ID NO 7
LENGTH, 25
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Primer

<400> SEQUENCE, 7
gccatggtaa aatcttggtt tatta

<210> SEQ ID NO 8
<400> SEQUENCE, 8
000

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 9
LENGTH, 5
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Synthetic peptide

<400> SEQUENCE, 9

25
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78
-continued

Ala Val Gly Val Pro
1

<210>
<211>
<212>
<213>
<220>
<223>

5

SEQ ID NO 10
LENGTH, 7
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Illustrative peptide (cleavage site recognized
for TEV protease)

<400> SEQUENCE, 10
Glu Asn Leu Tyr Phe Gln Gly
1

<210>
<211>
<212>
<213>
<220>
<223>

5

SEQ ID NO 11
LENGTH,
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Cleavage site recognized by Thrombin

<400> SEQUENCE, 11
Leu Val Pro Arg Gly Ser
1

<210>
<211>
<212>
<213>
<220>
<223>

5

SEQ ID NO 12
LENGTH,
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, 6-His tag

<400> SEQUENCE, 12
His His His His His His
1

<210>
<211>
<212>
<213>
<220>
<223>

5

SEQ ID NO 13
LENGTH, 25
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, PCR primer 3P

<400> SEQUENCE, 13
aaaacccgtc ctcagttcgg attgc

<210>
<211>
<212>
<213>
<220>
<223>

25

SEQ ID NO 14
LENGTH, 25
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, PCR primer 3M

<400> SEQUENCE, 14
ccgcgttgtt tcatcaagcc ttacg

<210>
<211>
<212>
<213>

SEQ ID NO 15
LENGTH, 119
TYPE, PRT
ORGANISM, Escherichia coli

<400> SEQUENCE, 15
Gly Ile Val Pro Gly Val Gly Ile Val Pro Gly Val Gly Ile Val Pro
1
5
10
15
Gly Val Gly Ile Val Pro Gly Val Gly Ile Val Pro Gly Val Gly Ile

25
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80

79
-continued
20

25

30

Val Pro Gly Val Gly Ile Val Pro Gly Val Gly Ile Val Pro Gly Val
35
40
45
Gly Ile Val Pro Gly Val Gly Ile Val Pro Gly Val Gly Ile Val Pro
50
55
60
Gly Val Gly Ile Val Pro Gly Val Gly Ile Val Pro Gly Val Gly Ile
65
70
75
80
Val Pro Gly Val Gly Ile Val Pro Gly Val Gly Ile Val Pro Gly Val
85
90
95
Gly Ile Val Pro Gly Val Gly Ile Val Pro Gly Val Gly Ile Val Pro
100
105
110
Gly Val Gly Ile Pro Gly Val
115

<210>
<211>
<212>
<213>

SEQ ID NO 16
LENGTH, 260
TYPE, DNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 16
tttgtgaacc aacacctgtg cggctcacac ctggtggaag ctctctacct agtgtgcggg

60

gaacgaggct tcttctacac acccaagacc cgccgggagg cagaggacct gcaggtgggg

120

caggtggagc tgggcggggg ccctggtgca ggcagcctgc agcccttggc cctggagggg

180

tccctgcaga agcgtggcat tgtggaacaa tgctgtacca gcatctgctc cctctaccag

240

ctggagaact actgcaacta

260

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 17
LENGTH, 260
TYPE, DNA
ORGANISM, Artificial sequence
FEATURE,
OTHER INFORMATION, Chloroplast modified proinsulin sequence

<400> SEQUENCE, 17
ttcgtaaacc aacacttatg tggttctcac ctagtagaag ctttatactt agtatgtggt

60

gaacgtggtt tcttctacac tcctaaaact cgtcgtgaag ctgaagattt acaagtaggt

120

caagtagaat taggtggtgg tcctggtgct ggttctttac aacctttagc tttagaaggt

180

tctttacaaa aacgtggtat tgtagaacaa tgttgtactt ctatttgttc tttataccaa

240

ttagaaaact actgtaacta

260

<210>
<211>
<212>
<213>

SEQ ID NO 18
LENGTH, 210
TYPE, DNA
ORGANISM, Homo sapiens

<400> SEQUENCE, 18
ggaccggaga cgctctgcgg ggctgagctg gtggatgctc ttcagttcgt gtgtggagac

60

aggggctttt atttcaacaa gcccacaggg tatggctcca gcagtcggag ggcgcctcag

120

acaggcatcg tggatgagtg ctgcttccgg agctgtgatc taaggaggct ggagatgtat

180

tgcgcacccc tcaagcctgc caagtcagct

210

<210>
<211>
<212>
<213>

SEQ ID NO 19
LENGTH, 210
TYPE, DNA
ORGANISM, Homo sapiens
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81
-continued
<400> SEQUENCE, 19
ggtcctgaaa ctttatgtgg tgctgaatta gtagatgctt tacaattcgt atgtggtgat

60

cgtggtttct atttcaacaa acctactggt tacggttctt cttctcgtcg tgctcctcaa

120

actggtattg tagatgaatg ttgtttccgt tcttgtgatt tacgtcgttt agaaatgtac

180

tgtgctcctt taaaacctgc taaatctgct

210

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 20
LENGTH, 5
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Protein-based polymer (PBP) made from synthetic
genes

<400> SEQUENCE, 20
Gly Val Gly Val Pro
1

<210>
<211>
<212>
<213>
<220>
<223>

5

SEQ ID NO 21
LENGTH, 605
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Protein-based polymer (PBP) made from synthetic
genes.

<400> SEQUENCE, 21
Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly
1
5
10
15
Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val
20
25
30
Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly
35
40
45
Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val
50
55
60
Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro
65
70
75
80
Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly
85
90
95
Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val
100
105
110
Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly
115
120
125
Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val
130
135
140
Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro
145
150
155
160
Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly
165
170
175
Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val
180
185
190
Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly
195
200
205
Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val
210
215
220
Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro

US 7,741,536 B2
84
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-continued
225

230

235

240

Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly
245

250

255

Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val
260

265

270

Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly
275

280

285

Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val
290

295

300

Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro
305

310

315

320

Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly
325

330

335

Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val
340

345

350

Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly
355

360

365

Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val
370

375

380

Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro
385

390

395

400

Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly
405

410

415

Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val
420

425

430

Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly
435

440

445

Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val
450

455

460

Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro
465

470

475

480

Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly
485

490

495

Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val
500

505

510

Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly
515

520

525

Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val
530

535

540

Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro
545

550

555

560

Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly
565

570

575

Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val
580

585

590

Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro
595

<210>
<211>
<212>
<213>
<220>
<223>

600

SEQ ID NO 22
LENGTH, 250
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Protein-based polymer
genes.

605

(PBP) made from synthetic

US 7,741,536 B2

85

86
-continued

<400> SEQUENCE, 22
Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly
1
5
10
15
Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val
20
25
30
Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly
35
40
45
Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val
50
55
60
Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro
65
70
75
80
Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly
85
90
95
Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val
100
105
110
Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly
115
120
125
Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val
130
135
140
Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro
145
150
155
160
Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly
165
170
175
Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val
180
185
190
Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly
195
200
205
Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val
210
215
220
Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro
225
230
235
240
Gly Val Gly Val Pro Gly Val Gly Val Pro
245
250

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 23
LENGTH, 7
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, RBS sequence

<400> SEQUENCE, 23
Gly Ala Ala Gly Gly Ala Gly
1

<210>
<211>
<212>
<213>
<220>
<223>

5

SEQ ID NO 24
LENGTH, 200
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Protein-based polymer (PBP) made from synthetic
genes.

<400> SEQUENCE, 24
Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly
1
5
10
15
Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val

US 7,741,536 B2
87

88
-continued

20

25

30

Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly
35
40
45
Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val
50
55
60
Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro
65
70
75
80
Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly
85

90

95

Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val
100
105
110
Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly
115
120
125
Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val
130
135
140
Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro
145
150
155
160
Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly
165
170
175
Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val
180

185

190

Gly Val Pro Gly Val Gly Val Pro
195
200

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 25
LENGTH, 100
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Protein-based polymer (PBP) made from synthetic
genes.

<400> SEQUENCE, 25

Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly
1
5
10
15
Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val
20
25
30
Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly
35
40
45
Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val
50
55
60
Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro
65
70
75
80
Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly
85

Val Gly Val Pro
100

<210> SEQ ID NO 26
<211> LENGTH, 5
<212> TYPE, PRT

90

95

US 7,741,536 B2

89

90
-continued

<213> ORGANISM, Artificial Sequence
<220> FEATURE,
<223> OTHER INFORMATION, Chloroplast preferred Ribosome Binding Site
(RBS) Shine-Dalgarno sequence
<400> SEQUENCE, 26
Gly Gly Ala Gly Gly
1

5

I claim:
1. A stable plastid transformation and expression vector
competent for stably transforming a target plastid genome,
wherein said vector comprises an expression cassette comprising as operably linked components, in the 5' to the 3'
direction of translation, a promoter operative in a plastid, a
selectable marker sequence, a heterologous DNA sequence
coding for Human Serum Albumin or anHuman Serum Albumin fusion protein, a transcription termination region functional in said plastid, and, flanking each side of the expression
cassette, flanking DNA sequences which are homologous to a
DNA sequence comprising a transcriptionally active spacer
sequence of the target plastid genome, whereby stable integration of the heterologous DNA sequence into the target
plastid genome is facilitated through homologous recombination of the flanking DNA sequences with the homologous
sequences in the target plastid genome.
2. The vector of claim 1, wherein the heterologous DNA
sequence codes for human serum albumin.
3. The vector of claim 1, wherein said spacer sequence is
conserved in plastid genomes of different plant species,
whereby stable intergration of the expression cassette into the
target plastid genome is facilitated through homolgous
recombination of the flanking sequences with the homologous sequences in the target plastid genome.
4. A stably transformed plant which comprises plastids
stably transformed with the vector of claim 1.
5. The transformed plant of claim 4 which is a tobacco or
alfalfa plant.
6. A stable plastid transformation and expression vector
competent for stably transforming a target plastid genome,
wherein said vector comprises an expression cassette com-

15

20

25

30

35

40

prising, as operably linked components, a heterologous DNA
sequence coding for a human serum albumin protein or
human serum albumin fusion protein, regulatory sequences to
control the expression of said human serum albumin or
human serum albumin fusion protein, and, flanking each side
of the expression cassette, flanking DNA sequences which are
homologous to a DNA sequence comprising a transcriptionally active spacer sequence of the target plastid genome,
whereby stable integration of the heterologous DNA
sequence and regulatory sequences into the plastid genome is
facilitated through homologous recombination of the flanking DNA sequences with the homologous sequences-in the
target plastid genome.
7. The stable vector of claim 6, wherein the regulatory
sequences include a 5' UTR sequence positioned to enhance
the translation of the protein.
8. A method of producing Human Serum Albumin, said
method comprising:
a. growing a plant that contains a transgenic plastid that
comprises an expression cassette comprising a promoter
operative in said plastid, a selectable marker sequence, a
heterologous DNA sequence coding for Human Serum
Albumin or an Human Serum Albumin fusion protein,
and a transcription termination region functional in said
plastid inserted into a transcriptionally active spacer
sequence in the plastid genome of said transgenic plastid
such that it expresses human serum albumin or the
human serum albumin fusion protein in the plastid,
b. harvesting the plant, and
c. purifying the human serum albumin or human serum
albumin fusion protein from said plant.

* * * * *

